



US 20250263760A1

(19) United States

(12) Patent Application Publication

Ding et al.

(10) Pub. No.: US 2025/0263760 A1

(43) Pub. Date: Aug. 21, 2025

(54) MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS

(71) Applicant: University of Florida Research Foundation, Incorporated, Gainesville, FL (US)

(72) Inventors: Yousong Ding, Gainesville, FL (US); Ran Zuo, Gainesville, FL (US)

(73) Assignee: University of Florida Research Foundation, Incorporated, Gainesville, FL (US)

(21) Appl. No.: 19/198,441

(22) Filed: May 5, 2025

Related U.S. Application Data

(60) Continuation of application No. 18/529,216, filed on Dec. 5, 2023, now Pat. No. 12,319,946, which is a division of application No. 18/152,329, filed on Jan. 10, 2023, now Pat. No. 11,879,144, which is a division of application No. 16/982,087, filed on Sep. 18, 2020, filed as application No. PCT/US2019/023370 on Mar. 21, 2019, now Pat. No. 11,591,627.

(60) Provisional application No. 62/818,024, filed on Mar. 13, 2019, provisional application No. 62/645,873, filed on Mar. 21, 2018.

Publication Classification

(51) Int. Cl.

C12P 13/22 (2006.01)

C12N 9/02 (2006.01)

C12N 9/04 (2006.01)

C12N 15/62 (2006.01)

(52) U.S. Cl.


CPC C12P 13/227 (2013.01); C12N 9/0006 (2013.01); C12N 9/0042 (2013.01); C12N 9/0075 (2013.01); C12N 15/62 (2013.01); C12Y 101/9901 (2013.01); C12Y 106/02004 (2013.01); C12Y 114/13039 (2013.01)

(57)

ABSTRACT

The disclosure relates, in some aspects, to compositions and methods useful for production of nitrated aromatic molecules. The disclosure is based, in part, on whole cell systems expressing artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. In some aspects, the disclosure relates to methods of producing nitrated aromatic molecules in whole cell systems having artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes.

Specification includes a Sequence Listing.






Fig. 1




Fig. 2A




Fig. 2B




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8





FIG. 9



FIGs. 10A-10C




FIG. 11

A.




FIG. 12A




FIG. 12B





FIG. 13



FIGs. 14A-14B




FIG. 15




FIG. 16A




FIG. 16B




FIG. 17

MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS

RELATED APPLICATIONS

[0001] This Application claims the benefit under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Ser. No. 62/645,873, filed Mar. 21, 2018, entitled "WHOLE CELL PROCESSES TO PRODUCE NITROAROMATICS", AND 62/818,024, filed Mar. 13, 2019, entitled "DIRECT AROMATIC NITRATION SYSTEM FOR SYNTHESIS OF NITROTRYPTOPHANS IN *ESCHERICHIA COLI*", the entire contents of each of which are incorporated by reference herein.

GOVERNMENT SUPPORT

[0002] This invention was made with government support under FA9550-16-1-0186 awarded by the United States Air Force. The government has certain rights in the invention.

BACKGROUND

[0003] The nitro (—NO₂) group acts as an essential unit in a number of pharmaceuticals, exemplified by anticancer drug nilutamine, anti-Parkinson agent tolcapone, and anti-infective agents chloramphenicol and the recently approved delamanid and nifurtimox-eflornithine combination. Drug candidates bearing the —NO₂ group also commonly appear in drug pipelines for treating a variety of existing and emerging diseases. Additionally, the nitro group in particular is a versatile synthetic handle present in numerous building blocks in the synthesis of complex drug molecules. The fundamental importance of the nitro group in pharmaceutical industry has driven the development of chemical nitration methods. Classical electrophilic nitration methods with nitric acid as the nitrating reagent dominate current industrial processes. The limitations of the electrophilic method, however, is that it is generally non-selective, poorly tolerates other functional groups, potentially raises safety concerns, and generates large quantities of acidic waste.

SUMMARY

[0004] The disclosure relates, in some aspects, to compositions and methods useful for production of nitrated aromatic molecules. The disclosure is based, in part, on whole cell systems expressing artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. In some aspects, the disclosure relates to methods of producing nitrated aromatic molecules in whole cell systems having artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. In some aspects, the disclosure relates to methods of producing nitrated tryptophan molecules in whole cell systems having artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes.

[0005] One significant advantage of whole cell nitration systems described by the disclosure compared to *in vitro* nitration reactions is the *in situ* production of NO from L-Arg. Typically, expensive NO donors are a major barrier for industrial application of nitration biocatalysts (e.g., TxtE fusion proteins, for example TB14). With the help of functional helper genes, such as *Bacillus subtilis* nitric oxide synthase (BsNOS) in whole cell nitration systems described herein, recombinant bacterial cells produce NO from L-Arg, which is synthesized by the *E. coli* cell from cheap carbon

and nitrogen sources, and hence greatly lower the cost of biocatalytic nitration processes.

[0006] Accordingly, in some aspects, the disclosure relates to a recombinant bacterial cell comprising one or more isolated nucleic acids engineered to express: a fusion protein comprising a TxtE enzyme linked to a catalytic domain of a CYP102A1 (P450BM3) reductase enzyme via an amino acid linker sequence that can be varied in terms of identities and length, e.g., between 14 and 27 amino acids in length; and a nitric oxide synthase (NOS) enzyme.

[0007] In some embodiments, a recombinant bacterial cell is a Gram-negative bacterial cell. In some embodiments, a recombinant bacterial cell is an *E. coli* bacterial cell.

[0008] In some embodiments, a fusion protein is a TB14 fusion protein having the sequence set forth in SEQ ID NO: 1. In some embodiments, a fusion protein is a TB14 fusion protein encoded by the sequence set forth in SEQ ID NO: 2.

[0009] In some embodiments, a NOS enzyme is a bacterial NOS enzyme. In some embodiments, a NOS enzyme is a *Bacillus subtilis* NOS enzyme. In some embodiments, a *Bacillus subtilis* NOS enzyme is encoded by the sequence set forth in SEQ ID NO: 3. In some embodiments, a *Bacillus subtilis* NOS enzyme comprises the amino acid sequence set forth in SEQ ID NO: 5.

[0010] In some embodiments, a recombinant bacterial cell further comprises an isolated nucleic acid engineered to express an enzyme that is able to regenerate reducing agent, e.g., NADH and/or NADPH. In some embodiments, this enzyme is a glucose I-dehydrogenase (GDH) enzyme. In some embodiments, a GDH enzyme is a bacterial GDH enzyme. In some embodiments, a bacterial GDH enzyme is a *Bacillus megaterium* GDH enzyme. In some embodiments, a *Bacillus megaterium* GDH enzyme comprises the sequence set forth in SEQ ID NO: 6. In some embodiments, a *Bacillus megaterium* GDH enzyme is encoded by the sequence set forth in SEQ ID NO: 7.

[0011] In some aspects, one or more isolated nucleic acids are located (e.g., situated) on a plasmid, for example a bacterial plasmid. In some embodiments, a bacterial cell comprises one or more plasmids comprising the one or more isolated nucleic acids. In some embodiments, an isolated nucleic acid engineered to express the NOS enzyme and an isolated nucleic acid engineered to express the GDH enzyme are located on the same plasmid. In some embodiments, an isolated nucleic acid engineered to express the fusion protein is located on a plasmid that does not contain an isolated nucleic acid engineered to express the NOS enzyme and/or an isolated nucleic acid engineered to express the GDH enzyme.

[0012] In some embodiments, one or more isolated nucleic acids (e.g., one or more isolated nucleic acids encoding a fusion protein, a NOS enzyme, and/or a GDH enzyme) are integrated into a chromosome of a bacterial cell.

[0013] In some embodiments, one or more isolated nucleic acid is operably linked to a promoter sequence. In some embodiments, an isolated nucleic acid engineered to express a fusion protein is operably linked to a first promoter, an isolated nucleic acid engineered to express a NOS enzyme is operably linked to a second promoter, and an isolated nucleic acid engineered to express a GDH enzyme is operably linked to a third promoter. In some embodiments, a first promoter, a second promoter, and/or a third promoter is a T7 promoter. In some embodiments, a promoter is an inducible promoter.

[0014] In some embodiments, a bacterial cell is genetically modified to lack expression of one or more of the following genes: traA (tryptophanase), trpR (tryptophan repressor), tyrA (T protein), and pheA (P protein), in some embodiments, a bacterial cell comprises the genotype ΔtrpRΔtryrAΔpheA (e.g., is a triple deletion mutant for trpR, tyrA, and pheA).

[0015] In some aspects, the disclosure relates to an isolated nucleic acid comprising the sequence set forth in any one of SEQ ID NOS: 8-13.


[0016] In some aspects, the disclosure relates to a composition comprising one or more of a recombinant bacterial cell as described by the disclosure, and a bacterial culture media. In some embodiments, a composition comprises a plurality of recombinant bacterial cells as described herein.

[0017] In some embodiments, a bacterial culture media is selected from the group consisting of M9, Lysogeny Broth (LB), SOC media, and Terrific Broth (TB).

[0018] In some embodiments, a composition further comprises one or more antibiotic agents. In some embodiments, one or more antibiotic agent is ampicillin or kanamycin.

[0019] In some embodiments, a composition further comprises a tryptophan or tryptophan analogue. In some embodiments, a composition further comprises one or more of the following: L-tryptophan (L-Trp), L-arginine (L-Arg), or an analogue of L-tryptophan. In some embodiments, an analogue of L-tryptophan is selected from the group consisting of α-Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-Trp, 6-F-Trp, and 7-Me-Trp.

[0020] In some embodiments, the tryptophan or tryptophan analogue is a compound of Formula Ia:



[0021] wherein:

[0022] each X¹ is independently halogen, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₂-C₆ alkenyl, substituted or unsubstituted C₂-C₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocycl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{4la}, —N(R^{4la})₂, or —SR^{4la};

[0023] wherein each R^{4la} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocycl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or two instances of R^{4la} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{4la} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;


[0024] each of X² and X³ is, independently, hydrogen, halogen, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₂-C₆ alkenyl, substituted or unsubstituted C₂-C₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocycl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{4la}, —N(R^{4la})₂, or —SR^{4la};

[0025] wherein each R^{4la} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocycl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{4la} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

[0026] R₁ is H or optionally substituted alkyl; and

[0027] R₂ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl. In another aspect, R₁ is H or alkyl. In another aspect, R₁ is H. In another aspect, R₁ is alkyl. In another aspect, R₁ is H methyl. In another aspect, R₂ is H. In another aspect, R₁ and R₂ are each H. In another aspect, R₁ is alkyl and R₂ is H. In another aspect, R₁ is methyl and R₂ is H.

[0028] In some embodiments, the tryptophan or tryptophan analogue is a compound of Formula IVa:



[0029] wherein:

[0030] each of Y¹, Y², and Y³ is, independently, hydrogen, halogen, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₂-C₆ alkenyl, substituted or unsubstituted C₂-C₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocycl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{4la}, —N(R^{4la})₂, or —SR^{4la}; and


[0031] wherein each R^{Ala} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{Ala} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

[0032] R_1 is H or optionally substituted alkyl; and

[0033] R_2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl. In another aspect, R_1 is H or alkyl, in another aspect, R_1 is H. In another aspect, R_1 is alkyl. In another aspect, R_1 is H or methyl. In another aspect, R_2 is H. In another aspect, R_1 and R_2 are each H. In another aspect, R_1 is alkyl and R_2 is H. In another aspect, R_1 is methyl and R_2 is H.

[0034] In some embodiments, a composition further comprises one or more of a nitrated tryptophan or a nitrated tryptophan analogue. In some embodiments, a composition further comprises one or more of the following: 4-NO₂-L-Trp, nitrated 4-NO₂- α -Me-Trp, 4-F-7-NO₂-Trp, 4-Me-7-NO₂-Trp, 5-MeO-4-NO₂-Trp, 5-Me-4-NO₂-Trp, nitrated 5-F-4-NO₂-Trp, 6-F-4-NO₂-Trp, or 7-Me-4-NO₂-Trp.

[0035] In some embodiments, the nitrated tryptophan or nitrated tryptophan analogue is a compound of Formula I, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof:



[0036] wherein:

[0037] X^1 is halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala},

[0038] wherein each R^{Ala} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{Ala} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

tuted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{Ala} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

[0039] each of X^2 and X^3 is, independently, hydrogen, halogen, substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala},

[0040] wherein each R^{Ala} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{Ala} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

[0041] R_1 is H or optionally substituted alkyl;


[0042] R_2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; and

[0043] Y is NO₂. In another aspect, R_1 is H or alkyl. In another aspect, R_1 is H. In another aspect, R_1 is alkyl. In another aspect, R_1 is H or methyl. In another aspect, R_2 is H. In another aspect, R_1 and R_2 are each H. In another aspect, R_1 is alkyl and R_2 is H. In another aspect, R_1 is methyl and R_2 is H.


[0044] In some aspects, the compound disclosure relates to a compound of Formula I, wherein at least one of X^1 , X^2 , or X^3 is a “weakly deactivating group”, a “weakly activating group”, a “moderately activating group”, or a “strongly activating group”, as known in the art and as defined herein. In other aspects, at least one of X^1 , X^2 , or X^3 is H, halogen (e.g., F, Cl, Br, I), substituted or unsubstituted C₁₋₆ alkyl (e.g., methyl, CH₃), substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala}.

[0045] In another aspect, X^1 is halogen (e.g., F, Cl, Br, I), substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, CH_3), substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala}; and X^2 and X^3 are each independently H, halogen (e.g., F, Cl, Br, I), substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, CH_3), substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala}. In another aspect, X^1 is halogen or C_{1-6} alkyl (e.g., methyl, CH_3). In another aspect, X^1 is halogen. In another aspect, X^1 is C_{1-6} alkyl (e.g., methyl, CH_3). In another aspect, X^1 is halogen or C_{1-6} alkyl (e.g., methyl, CH_3) and at least one of X^2 and X^3 is hydrogen. In another aspect, X^1 is halogen and each of X^2 and X^3 is hydrogen. In another aspect, X^1 is fluorine and each of X^2 and X^3 is hydrogen. In another aspect, X^1 is C_{1-6} alkyl and each of X^2 and X^3 is hydrogen. In another aspect, X^1 is methyl and each of X^2 and X^3 is hydrogen.


[0046] In some embodiments, the compound of Formula I is a compound of Formula II:



[0047] In certain embodiments, the compound of Formula I is a compound of Formula III:



[0048] In some embodiments, the nitrated tryptophan or nitrated tryptophan analogue is a compound of Formula IV, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof:



[0049] wherein:

[0050] each of Y^1 , Y^2 , and Y^3 is, independently, hydrogen, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala},

[0051] wherein each R^{Ala} is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R^{Ala} are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;

[0052] R_1 is H or optionally substituted alkyl;

[0053] R_2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; and

[0054] X is NO₂. In another aspect, R_1 is H or alkyl. In another aspect, R_1 is H. In another aspect, R_1 is alkyl. In another aspect, R_1 is H or methyl. In another aspect, R_2 is H. In another aspect, R_1 and R_2 are each H. In another aspect, R_1 is alkyl and R_2 is H. In another aspect, R_1 is methyl and R_2 is H.


[0055] In some aspects, the compound disclosure relates to a compound of Formula IV, wherein at least one of Y^1 , Y^2 , or Y^3 is a “weakly deactivating group”, a “weakly activating group”, a “moderately activating group”, or a “strongly activating group”, as known in the art and as defined herein. In other aspects, at least one of Y^1 , Y^2 , or Y^3 is H, halogen (e.g. F, Cl, Br, I), substituted or unsubstituted C_{1-6} alkyl (e.g. methyl, CH_3), substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{Ala}, —N(R^{Ala})₂, or —SR^{Ala}.

[0056] In embodiments, Y^1 , Y^2 , or Y^3 is halogen and the halogen is fluorine. In embodiments, Y^1 , Y^2 , or Y^3 is


unsubstituted C₁-C₆ alkyl. In embodiments, the unsubstituted C₁-C₆ alkyl is methyl (—CH₃). In embodiments, two of Y¹, Y² and Y³ are hydrogen. In embodiments, Y² and Y³ are hydrogen. In embodiments, Y¹ and Y³ are hydrogen. In embodiments, Y¹ and Y² are hydrogen.

[0057] In some aspects, the disclosure relates to a compound of Formula IV, wherein at least one of Y¹, Y² or Y³ is halogen or C₁₋₆ alkyl (e.g. methyl, CH₃). In another aspect, Y³ is halogen (e.g. F, Cl, Br, I), substituted or unsubstituted C₁₋₆ alkyl (e.g. methyl, CH₃), substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, it monocyclic, 5- to 6-membered heteroaryl, —OR^{4la}, —N(R^{4la})₂, or —SR^{4la}; and Y¹ and Y² are each independently H, halogen (e.g. F, Cl, Br, I), substituted or unsubstituted C₁₋₆alkyl (e.g. methyl, CH₃), substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₂₋₆ alkynyl, substituted or unsubstituted, monocyclic, 3- to 6-membered carbocyclyl, substituted or unsubstituted, monocyclic, 3- to 6-membered heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl, —OR^{4la}, —N(R^{4la})₂, or —SR^{4la}). In another aspect, Y³ is halogen or C₁₋₆ alkyl (e.g. methyl, CH₃). In another aspect, Y³ is halogen or C₁₋₆alkyl (e.g. methyl, CH₃) and at least one of Y¹ and Y² is hydrogen. In another aspect, Y³ is halogen or C₁₋₆ alkyl (e.g. methyl, CH₃) and Y¹ and Y² are each hydrogen. In another aspect, Y³ is halogen. In another aspect, Y³ is halogen and at least one of Y₁ and Y² is hydrogen. In another aspect, Y³ is halogen and Y¹ and Y² are each hydrogen. In certain embodiments, Y³ is fluorine and at least one of Y¹ and Y² is hydrogen. In another aspect, Y³ is fluorine and Y¹ and Y² are each hydrogen. In another aspect, Y³ is C₁₋₆ alkyl. In another aspect, Y³ is C₁₋₆ alkyl and at least one of Y¹ and Y² is hydrogen. In another aspect, Y³ is C₁₋₆ alkyl and Y¹ and Y² are each hydrogen. In certain embodiments, Y³ is methyl and at least one of Y¹ and Y² is hydrogen. In another aspect, Y³ is methyl and Y¹ and Y² are each hydrogen.

[0058] In certain embodiments, the compound of Formula IV is a compound of Formula V:



[0059] In certain embodiments, the compound of Formula IV is a compound of Formula VI:



[0060] In another aspect, the invention is directed to a compound of Formulae I-VI, wherein the compound is:

- [0061] (S)-2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl) propanoic acid;
- [0062] (S)-2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0063] (S)-2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0064] (S)-2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0065] (S)-2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
- [0066] (S)-2-amino-3-(5-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0067] (S)-2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0068] (S)-2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0069] (S)-2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl) propanoic acid;
- [0070] (S)-2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0071] (S)-2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0072] (S)-2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0073] (S)-2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl) propanoic acid;
- [0074] (S)-2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0075] (S)-2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0076] (S)-2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0077] (S)-2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl) propanoic acid;
- [0078] (S)-2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0079] (S)-2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0080] (S)-2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0081] (S)-2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0082] (S)-2-amino-3-(5-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0083] (S)-2-amino-3-(6-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0084] (S)-2-amino-3-(7-amino-4-nitro-1H-indol-3-yl) propanoic acid;

- [0085] (S)-2-amino-3-(4-amino-7-nitro-1H-indol-3-yl) propanoic acid;
- [0086] (S)-2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0087] (S)-2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0088] (S)-2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0089] (S)-2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0090] (S)-2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl) propanoic acid;
- [0091] (S)-2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl) propanoic acid;
- [0092] (S)-2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl) propanoic acid;
- [0093] (S)-2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl) propanoic acid;
- [0094] (S)-2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0095] (S)-2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0096] (S)-2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0097] (S)-2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0098] (S)-2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0099] (S)-2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0100] (S)-2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0101] (S)-2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0102] (S)-2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0103] (S)-2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0104] (S)-2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0105] (S)-2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl) propanoic acid;
- [0106] (S)-2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0107] (S)-2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0108] (S)-2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0109] (S)-2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0110] (S)-2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0111] (S)-2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0112] (S)-2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0113] (S)-2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0114] (S)-2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0115] (S)-2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0116] (S)-2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0117] (S)-2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0118] 2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl)propanoic acid;
- [0119] 2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0120] 2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0121] 2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0122] 2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0123] 2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0124] 2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0125] 2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl)propanoic acid;
- [0126] 2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0127] 2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0128] 2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0129] 2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl)propanoic acid;
- [0130] 2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0131] 2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0132] 2-amino-3-(7-bromo-7-nitro-1H-indol-3-yl)propanoic acid;
- [0133] 2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl)propanoic acid;
- [0134] 2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0135] 2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0136] 2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0137] 2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0138] 2-amino-3-(5-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0139] 2-amino-3-(6-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0140] 2-amino-3-(7-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0141] 2-amino-3-(4-amino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0142] 2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0143] 2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0144] 2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0145] 2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0146] 2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0147] 2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0148] 2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;

- [0149] 2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0150] 2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0151] 2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0152] 2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0153] 2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0154] 2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0155] 2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0156] 2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0157] 2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0158] 2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0159] 2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0160] 2-amino-3-(7-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0161] 2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0162] 2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0163] 2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0164] 2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0165] 2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0166] 2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0167] 2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0168] 2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0169] 2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0170] 2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0171] 2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0172] 2-amino-3-(7-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0173] 2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0174] 2-amino-3-(1,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0175] 2-amino-3-(1,6-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0176] 2-amino-3-(1,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0177] 2-amino-3-(1,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0178] 2-amino-3-(6-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0179] 2-amino-3-(7-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0180] 2-amino-3-(4-fluoro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0181] 2-amino-3-(5-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0182] 2-amino-3-(6-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0183] 2-amino-3-(7-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0184] 2-amino-3-(4-chloro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0185] 2-amino-3-(5-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0186] 2-amino-3-(6-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0187] 2-amino-3-(7-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0188] 2-amino-3-(4-bromo-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0189] 2-amino-3-(5-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0190] 2-amino-3-(6-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0191] 2-amino-3-(7-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0192] 2-amino-3-(4-methoxy-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0193] 2-amino-3-(5-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0194] 2-amino-3-(6-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0195] 2-amino-3-(7-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0196] 2-amino-3-(4-amino-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0197] 2-amino-3-(5-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0198] 2-amino-3-(6-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0199] 2-amino-3-(7-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0200] 2-amino-3-(4-hydroxy-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0201] 2-amino-3-(1-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0202] 2-amino-3-(1-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0203] 2-amino-3-(1-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0204] 2-amino-3-(1-methyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0205] 2-amino-3-(5-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0206] 2-amino-3-(6-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0207] 2-amino-3-(7-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0208] 2-amino-3-(4-cyclopropyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0209] 2-amino-3-(1-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0210] 2-amino-3-(1-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0211] 2-amino-3-(1-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0212] 2-amino-3-(1-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;

- [0213] 2-amino-3-(5-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0214] 2-amino-3-(6-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0215] 2-amino-3-(7-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0216] 2-amino-3-(4-ethynyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0217] 2-amino-3-(1-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0218] 2-amino-3-(1-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0219] 2-amino-3-(1-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0220] 2-amino-3-(1-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
[0221] 2-amino-3-(1-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0222] 2-amino-3-(1-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0223] 2-amino-3-(1-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0224] 2-amino-3-(1-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
[0225] 2-amino-3-(1-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0226] 2-amino-3-(1-methyl-4-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0227] 2-amino-3-(1-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0228] 2-amino-3-(1-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0229] 2-amino-3-(2,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0230] 2-amino-3-(2,6-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0231] 2-amino-3-(2,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0232] 2-amino-3-(2,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0233] 2-amino-3-(6-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0234] 2-amino-3-(7-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0235] 2-amino-3-(4-fluoro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0236] 2-amino-3-(5-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0237] 2-amino-3-(6-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0238] 2-amino-3-(7-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0239] 2-amino-3-(4-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0240] 2-amino-3-(5-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0241] 2-amino-3-(6-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0242] 2-amino-3-(7-bromo-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0243] 2-amino-3-(4-bromo-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0244] 2-amino-3-(5-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0245] 2-amino-3-(6-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0246] 2-amino-3-(7-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0247] 2-amino-3-(4-methoxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0248] 2-amino-3-(5-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0249] 2-amino-3-(6-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0250] 2-amino-3-(7-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0251] 2-amino-3-(4-amino-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0252] 2-amino-3-(5-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0253] 2-amino-3-(6-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0254] 2-amino-3-(7-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0255] 2-amino-3-(4-hydroxy-2-ethyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0256] 2-amino-3-(2-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
[0257] 2-amino-3-(2-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
[0258] 2-amino-3-(2-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
[0259] 2-amino-3-(2-methyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
[0260] 2-amino-3-(5-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0261] 2-amino-3-(6-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0262] 2-amino-3-(7-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0263] 2-amino-3-(4-cyclopropyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0264] 2-amino-3-(2-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
[0265] 2-amino-3-(2-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
[0266] 2-amino-3-(2-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
[0267] 2-amino-3-(2-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
[0268] 2-amino-3-(6-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0269] 2-amino-3-(6-ethyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0270] 2-amino-3-(7-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0271] 2-amino-3-(4-ethynyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0272] 2-amino-3-(2-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0273] 2-amino-3-(2-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0274] 2-amino-3-(2-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0275] 2-amino-3-(2-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
[0276] 2-amino-3-(2-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;

- [0277] 2-amino-3-(2-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0278] 2-amino-3-(2-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0279] 2-amino-3-(2-methyl-4-methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0280] 2-amino-3-(2-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0281] 2-amino-3-(2-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0282] 2-amino-3-(2-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0283] 2-amino-3-(2-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0284] 2-amino-3-(1,2,5-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0285] 2-amino-3-(1,2,6-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0286] 2-amino-3-(1,2,7-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0287] 2-amino-3-(1,2,4-trimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0288] 2-amino-3-(6-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0289] 2-amino-3-(7-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0290] 2-amino-3-(4-fluoro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0291] 2-amino-3-(5-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0292] 2-amino-3-(6-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0293] 2-amino-3-(7-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0294] 2-amino-3-(4-chloro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0295] 2-amino-3-(5-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0296] 2-amino-3-(6-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0297] 2-amino-3-(7-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0298] 2-amino-3-(4-bromo-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0299] 2-amino-3-(5-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0300] 2-amino-3-(6-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0301] 2-amino-3-(7-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0302] 2-amino-3-(4-methoxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0303] 2-amino-3-(5-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0304] 2-amino-3-(6-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0305] 2-amino-3-(7-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0306] 2-amino-3-(4-amino-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0307] 2-amino-3-(5-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0308] 2-amino-3-(6-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0309] 2-amino-3-(7-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0310] 2-amino-3-(4-hydroxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0311] 2-amino-3-(1,2-dimethyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0312] 2-amino-3-(1,2-dimethyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0313] 2-amino-3-(1,2-dimethyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0314] 2-amino-3-(1,2-dimethyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0315] 2-amino-3-(5-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0316] 2-amino-3-(6-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0317] 2-amino-3-(7-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0318] 2-amino-3-(4-cyclopropyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0319] 2-amino-3-(1,2-dimethyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0320] 2-amino-3-(1,2-dimethyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0321] 2-amino-3-(1,2-dimethyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0322] 2-amino-3-(1,2-dimethyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0323] 2-amino-3-(5-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0324] 2-amino-3-(6-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0325] 2-amino-3-(7-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0326] 2-amino-3-(4-ethynyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0327] 2-amino-3-(1,2-dimethyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0328] 2-amino-3-(1,2-dimethyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0329] 2-amino-3-(1,2-dimethyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0330] 2-amino-3-(1,2-dimethyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0331] 2-amino-3-(1,2-dimethyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0332] 2-amino-3-(1,2-dimethyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0333] 2-amino-3-(1,2-dimethyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0334] 2-amino-3-(1,2-dimethyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0335] 2-amino-3-(1,2-dimethyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0336] 2-amino-3-(1,2-dimethyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0337] 2-amino-3-(1,2-dimethyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid; or
- [0338] 2-amino-3-(1,2-dimethyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0339] and a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof.
- [0340] In some embodiments, a composition has a temperature below 37° C. (e.g., the temperature of the bacterial

culture media of a composition is below 37° C.). In some embodiments, a composition has a temperature between 10 to 30° C. (e.g., the temperature of the bacterial culture media of a composition is between 10 to 30° C.). In some embodiments, a composition at a temperature of 28° C. (e.g., the temperature of the bacterial culture media of a composition is 28° C.).

[0341] In some embodiments, the disclosure relates to methods of producing a recombinant bacterial cell as described by the disclosure, the comprising the steps of: transforming a bacterial cell with an isolated nucleic acid engineered to express a fusion protein comprising a TxtE enzyme linked to a catalytic domain of a CYPI2A1 (P450BM3) reductase enzyme via an amino acid linker sequence that can be varied in terms of identities and length, e.g., that is between 14 and 27 amino acids in length; and an isolated nucleic acid engineered to express a nitric oxide synthase (NOS) enzyme; and culturing (e.g., growing) the bacterial cell.

[0342] In some embodiments of methods described by the disclosure a bacterial cell is transformed with an isolated nucleic acid engineered to express a glucose-1 dehydrogenase (GHD) enzyme.

[0343] In some embodiments of methods described by the disclosure, a bacterial cell is transformed with one or more an isolated nucleic acids comprising the sequence set forth in any one of SEQ ID NOS: 8-13.

[0344] In some aspects, the disclosure relates to methods for producing a composition as described by the disclosure, comprising the step of inoculating a bacterial culture medium with a recombinant bacterial cell as described by the disclosure.

[0345] In some aspects, the disclosure relates to methods for producing a nitrated L-tryptophan or nitrated L-tryptophan analogue, comprising the steps of: introducing into a bacterial cell culture comprising a one or more of a recombinant bacterial cell as described by the disclosure one or more L-Trp molecules and/or one or more L-Trp analogue molecules; and growing the bacterial cell culture under conditions under which a fusion protein expressed by the recombinant bacterial cell catalyzes a nitration reaction which produces one or more nitrated L-Trp molecules and/or one or more nitrated L-Trp analog molecules. In some embodiments, methods further comprise the step of isolating nitrated L-Trp molecules and/or nitrated L-Trp analog molecules from the bacterial cell culture. In some embodiments, the nitrated tryptophan or nitrated tryptophane analogue is a compound of Formulae I-VI. In some embodiments, the nitrated tryptophan or nitrated tryptophane analogue is:

[0346] (S)-2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl) propanoic acid;

[0347] (S)-2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl) propanoic acid;

[0348] (S)-2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl) propanoic acid;

[0349] (S)-2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl) propanoic acid;

[0350] (S)-2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl) propanoic acid;

[0351] (S)-2-amino-3-(5-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;

[0352] (S)-2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;

- [0353] (S)-2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0354] (S)-2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl) propanoic acid;
- [0355] (S)-2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0356] (S)-2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0357] (S)-2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0358] (S)-2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl) propanoic acid;
- [0359] (S)-2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0360] (S)-2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0361] (S)-2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0362] (S)-2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl) propanoic acid;
- [0363] (S)-2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0364] (S)-2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0365] (S)-2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0366] (S)-2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0367] (S)-2-amino-3-(5-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0368] (S)-2-amino-3-(6-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0369] (S)-2-amino-3-(7-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0370] (S)-2-amino-3-(4-amino-7-nitro-1H-indol-3-yl) propanoic acid;
- [0371] (S)-2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0372] (S)-2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0373] (S)-2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0374] (S)-2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0375] (S)-2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl) propanoic acid;
- [0376] (S)-2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl) propanoic acid;
- [0377] (S)-2-amino-3-(7-nitro-7-phenyl-1H-indol-3-yl) propanoic acid;
- [0378] (S)-2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl) propanoic acid;
- [0379] (S)-2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0380] (S)-2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0381] (S)-2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0382] (S)-2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl) propanoic acid;
- [0383] (S)-2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl) propanoic acid;
- [0384] (S)-2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl) propanoic acid;

- [0385] (S)-2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0386] (S)-2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0387] (S)-2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0388] (S)-2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0389] (S)-2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0390] (S)-2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0391] (S)-2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0392] (S)-2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0393] (S)-2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0394] (S)-2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0395] (S)-2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0396] (S)-2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0397] (S)-2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0398] (S)-2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0399] (S)-2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0400] (S)-2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0401] (S)-2-amino-3-(7-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0402] (S)-2-amino-3-(7-nitro-4-pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0403] 2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl)propanoic acid;
- [0404] 2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0405] 2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0406] 2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0407] 2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0408] 2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0409] 2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0410] 2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl)propanoic acid;
- [0411] 2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0412] 2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0413] 2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0414] 2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl)propanoic acid;
- [0415] 2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0416] 2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0417] 2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0418] 2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl)propanoic acid;
- [0419] 2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0420] 2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0421] 2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0422] 2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0423] 2-amino-3-(5-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0424] 2-amino-3-(6-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0425] 2-amino-3-(7-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0426] 2-amino-3-(4-amino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0427] 2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0428] 2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0429] 2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0430] 2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0431] 2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0432] 2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0433] 2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0434] 2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0435] 2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0436] 2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0437] 2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0438] 2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0439] 2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0440] 2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0441] 2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0442] 2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0443] 2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0444] 2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0445] 2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0446] 2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0447] 2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0448] 2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;

- [0449] 2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0450] 2-amino-3-(5-morpholino-7-nitro-1H-indol-3-yl) propanoic acid;
[0451] 2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0452] 2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0453] 2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0454] 2-amino-3-(4-(methylthio)-nitro-1H-indol-3-yl) propanoic acid;
[0455] 2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0456] 2-amino-3-(4-nitro-6-pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0457] 2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0458] 2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0459] 2-amino-3-(1,5-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0460] 2-amino-3-(1,6-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0461] 2-amino-3-(1,7-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0462] 2-amino-3-(6,4-dimethyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0463] 2-amino-3-(6-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0464] 2-amino-3-(7-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0465] 2-amino-3-(4-fluoro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0466] 2-amino-3-(5-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0467] 2-amino-3-(6-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0468] 2-amino-3-(7-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0469] 2-amino-3-(4-chloro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0470] 2-amino-3-(5-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0471] 2-amino-3-(6-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0472] 2-amino-3-(7-bromo-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0473] 2-amino-3-(4-bromo-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0474] 2-amino-3-(5-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0475] 2-amino-3-(6-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0476] 2-amino-3-(7-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0477] 2-amino-3-(4-methoxy-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0478] 2-amino-3-(5-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0479] 2-amino-3-(6-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0480] 2-amino-3-(7-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0481] 2-amino-3-(4-amino-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0482] 2-amino-3-(5-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0483] 2-amino-3-(6-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0484] 2-amino-3-(7-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0485] 2-amino-3-(4-hydroxy-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0486] 2-amino-3-(1-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
[0487] 2-amino-3-(1-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
[0488] 2-amino-3-(1-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
[0489] 2-amino-3-(5-methyl-7-nitro-phenyl-1H-indol-3-yl)propanoic acid;
[0490] 2-amino-3-(5-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0491] 2-amino-3-(6-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0492] 2-amino-3-(7-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0493] 2-amino-3-(4-cyclopropyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0494] 2-amino-3-(1-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
[0495] 2-amino-3-(1-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
[0496] 2-amino-3-(1-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
[0497] 2-amino-3-(1-methyl-7-nitro-4-viny-1H-indol-3-yl)propanoic acid;
[0498] 2-amino-3-(5-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0499] 2-amino-3-(6-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0500] 2-amino-3-(7-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
[0501] 2-amino-3-(4-ethynyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
[0502] 2-amino-3-(1-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0503] 2-amino-3-(1-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0504] 2-amino-3-(1-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
[0505] 2-amino-3-(1-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
[0506] 2-amino-3-(1-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0507] 2-amino-3-(1-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0508] 2-amino-3-(1-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
[0509] 2-amino-3-(1-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
[0510] 2-amino-3-(1-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0511] 2-amino-3-(1-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
[0512] 2-amino-3-(1-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;

- [0513] 2-amino-3-(1-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0514] 2-amino-3-(2,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0515] 2-amino-3-(2,6-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0516] 2-amino-3-(2,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0517] 2-amino-3-(2,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0518] 2-amino-3-(6-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0519] 2-amino-3-(7-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0520] 2-amino-3-(4-fluoro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0521] 2-amino-3-(5-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0522] 2-amino-3-(6-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0523] 2-amino-3-(7-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0524] 2-amino-3-(4-chloro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0525] 2-amino-3-(5-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0526] 2-amino-3-(6-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0527] 2-amino-3-(7-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0528] 2-amino-3-(4-bromo-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0529] 2-amino-3-(5-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0530] 2-amino-3-(6-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0531] 2-amino-3-(7-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0532] 2-amino-3-(4-methoxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0533] 2-amino-3-(5-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0534] 2-amino-3-(6-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0535] 2-amino-3-(7-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0536] 2-amino-3-(4-amino-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0537] 2-amino-3-(5-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0538] 2-amino-3-(6-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0539] 2-amino-3-(7-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0540] 2-amino-3-(4-hydroxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0541] 2-amino-3-(2-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0542] 2-amino-3-(2-methyl-4-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0543] 2-amino-3-(2-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0544] 2-amino-3-(2-methyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0545] 2-amino-3-(5-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0546] 2-amino-3-(6-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0547] 2-amino-3-(7-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0548] 2-amino-3-(4-cyclopropyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0549] 2-amino-3-(2-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0550] 2-amino-3-(2-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0551] 2-amino-3-(2-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0552] 2-amino-3-(2-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0553] 2-amino-3-(5-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0554] 2-amino-3-(6-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0555] 2-amino-3-(7-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0556] 2-amino-3-(4-ethynyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0557] 2-amino-3-(2-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0558] 2-amino-3-(2-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0559] 2-amino-3-(2-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0560] 2-amino-3-(2-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0561] 2-amino-3-(2-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0562] 2-amino-3-(2-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0563] 2-amino-3-(2-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0564] 2-amino-3-(2-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0565] 2-amino-3-(2-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0566] 2-amino-3-(2-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0567] 2-amino-3-(2-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0568] 2-amino-3-(2-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0569] 2-amino-3-(1,2,5-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0570] 2-amino-3-(1,2,6-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0571] 2-amino-3-(1,2,7-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0572] 2-amino-3-(1,2,4-trimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0573] 2-amino-3-(6-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0574] 2-amino-3-(7-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0575] 2-amino-3-(4-fluoro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0576] 2-amino-3-(5-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;

- [0577] 2-amino-3-(6-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0578] 2-amino-3-(7-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0579] 2-amino-3-(4-chloro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0580] 2-amino-3-(5-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0581] 2-amino-3-(6-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0582] 2-amino-3-(7-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0583] 2-amino-3-(4-bromo-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0584] 2-amino-3-(5-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0585] 2-amino-3-(6-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0586] 2-amino-3-(7-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0587] 2-amino-3-(4-methoxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0588] 2-amino-3-(5-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0589] 2-amino-3-(6-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0590] 2-amino-3-(7-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0591] 2-amino-3-(4-amino-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0592] 2-amino-3-(5-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0593] 2-amino-3-(6-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0594] 2-amino-3-(7-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0595] 2-amino-3-(4-hydroxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0596] 2-amino-3-(1,2-dimethyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0597] 2-amino-3-(1,2-dimethyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0598] 2-amino-3-(1,2-dimethyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0599] 2-amino-3-(1,2-dimethyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0600] 2-amino-3-(5-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0601] 2-amino-3-(6-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0602] 2-amino-3-(7-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0603] 2-amino-3-(4-cyclopropyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0604] 2-amino-3-(1,2-dimethyl-4-nitro-5-vinyl-4H-indol-3-yl)propanoic acid;
- [0605] 2-amino-3-(1,2-dimethyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0606] 2-amino-3-(1,2-dimethyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0607] 2-amino-3-(1,2-dimethyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0608] 2-amino-3-(5-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0609] 2-amino-3-(6-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0610] 2-amino-3-(7-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0611] 2-amino-3-(4-ethynyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0612] 2-amino-3-(1,2-dimethyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0613] 2-amino-3-(1,2-dimethyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0614] 2-amino-3-(1,2-dimethyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0615] 2-amino-3-(1,2-dimethyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0616] 2-amino-3-(1,2-dimethyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0617] 2-amino-3-(1,2-dimethyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0618] 2-amino-3-(1,2-dimethyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0619] 2-amino-3-(1,2-dimethyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0620] 2-amino-3-(1,2-dimethyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0621] 2-amino-3-(1,2-dimethyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0622] 2-amino-3-(1,2-dimethyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid; or
- [0623] 2-amino-3-(1,2-dimethyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0624] and a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof.
- [0625] In some embodiments of methods described by the disclosure, one or more compounds of Formula Ia or IVa. In some embodiments of methods described by the disclosure, one or more L-Trp analogue molecules are selected from the group consisting of α -Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-Trp, 6-F-Trp, and 7-Me-Trp.
- [0626] In some embodiments of methods described by the disclosure, the step of growing the bacterial cell culture comprises introducing one or more antibiotic and/or one or more inducer into the bacterial cell culture. In some embodiments, one or more antibiotic is selected from ampicillin and kanamycin. In some embodiments, one or more of the inducers is Isopropyl β -D-1-thiogalactopyranoside (IPTG).
- [0627] In some embodiments of methods described by the disclosure, the step of growing a bacterial cell culture is performed at a temperature below 37° C. In some embodiments, the step of growing the bacterial cell culture is performed at a temperature between 10 to 30° C. optionally at a temperature of 28° C.
- [0628] In some embodiments, a bacterial cell culture is grown for up to 25 hours (e.g., up to 25 hours post-transformation with one or more isolated nucleic acids).
- [0629] In some embodiments, isolating nitrated L-Trp molecules and/or nitrated L-Trp analog molecules comprises lysing one or more recombinant bacterial cells. In some embodiments, isolating L-Trp molecules and/or nitrated L-Trp analog molecules further comprises performing high-pressure liquid chromatography (HPLC) on a bacterial cell lysate, or purifying a bacterial lysate by performing a liquid/solid (e.g., carbon-based, such as C18) purification technique.

BRIEF DESCRIPTION OF DRAWINGS

[0630] FIG. 1 is schematic overview of bacterial cell factories for the production of nitro-chemicals.

[0631] FIGS. 2A-2B show representative data for activity testing of a whole cell nitration system. FIG. 2A shows SDS-PAGE analysis of a whole cell nitration system. M, marker; 1, pETDUET-TB14-BsNOS+pET28b-GDH; 2, pETDUET-GDH-BsNOS+pET28b-TB14; 3, pACYCDUET-TB14-BsNOS+pET28b-GDH; 4, pACYCDUET-GDH-BsNOS+pET28b-TB14. Three soluble recombinant proteins (TB14, BsNOS, and GDH) are identified with arrows. FIG. 2B shows LCMS analysis of products in the whole cell nitration.

[0632] FIGS. 3A-3B show analysis of different embodiments of a whole cell nitration system. FIG. 3A is a schematic representation of plasmids combination used in different embodiments of a whole cell nitration system. FIG. 3B shows nitrated tryptophan concentration produced by different embodiments of a whole cell nitration system. Bacterial growth was supported by M9 medium.

[0633] FIG. 4 shows nitrated tryptophan concentration produced by one embodiment of a whole cell nitration system supported by different types of growth medium (e.g., M9, LB, SOC, TB, each with or without supplemented L-Arg or L-Trp).

[0634] FIG. 5 shows nitrated tryptophan concentration produced by one embodiment of a whole cell nitration system fermented at different temperatures.

[0635] FIG. 6 shows production of nitrated tryptophan analogues by one embodiment of a whole cell nitration system.

[0636] FIG. 7 shows L-Trp, 4-N-L-Trp, and indole concentration as a function of incubation time during a whole cell transformation process.

[0637] FIG. 8 is a schematic showing biosynthesis pathways of aromatic amino acids and targeted genes (e.g., TyrA, PheA, TrpR, TnaA) in a host engineering study.

[0638] FIG. 9 shows a schematic depicting one embodiment of a Nitrotrp biosynthetic pathway that is integrated with select major metabolic pathways in *E. coli*. TB14, BsNOS, and GDH genes are shadowed. Cellular Nitrotrp and nitric oxide (NO) are also shown. Inhibition of the shikimate pathway and L-Trp biosynthesis by TrpR is shown in dashed lines. The X symbol indicates gene inactivation. Inactivation of trpR, pheA and tyrA increases synthesis of L-Trp shown as wider arrows, GLC glucose, G6P glucose-6-phosphate, F6P fructose-6-phosphate, G3P glyceraldehyde-3-phosphate, PEP phosphoenolpyruvate, PYR pyruvate, GLN glucono-1,5-lactone, 6PG 6-phosphogluconolactone, RSP ribose-5-phosphate, E4P erythrose-4-phosphate, DAHP 3-deoxy-D-arabino-heptulosonate, CHA chorismate, PPA prephenate, ANT anthranilate, IND indole, TCA tricarboxylic acid cycle, AKG α -ketoglutarate, Ctl L-citrulline, trpE component I of anthranilate synthase, trpR trp operon repressor, tnaA tryptophanase, pheA chorismate mutase/prephenate dehydratase and tyrA chorismate mutase/prephenate dehydrogenase.

[0639] FIGS. 10A-10C show one embodiments of an *E. coli*-based system to produce Nitrotrp. FIG. 10A shows design of four Nitrotrp biosynthetic pathways comprising TB14, BsNOS, and GDH. These genes were cloned in pETDuet-1 and pET28b or pACYCDuet-1 and pET28b. FIG. 10B shows SDS-PAGE analysis of soluble protein fractions of *E. coli* cells transformed with the pathway I-IV.

Protein expression in *E. coli*-I to -IV was induced by 0.5 mM IPTG in TB at 18° C., 250 rpm for 20 h. An equal volume of soluble protein fractions prepared from the same concentrations of cell resuspension solutions was used for SDS-PAGE analysis. Bands of three soluble recombinant proteins were indicated with arrows. FIG. 10C shows production of Nitrotrp by *E. coli*-I to -IV in the M9 medium at 20° C., 250 rpm. Aliquots (0.1 mL) of the fermentation culture were taken at days 1 to 4 and the concentration of Nitrotrp in the samples was measured in HPLC analysis. The data represent means \pm s. d. of at least two independent experiments.

[0640] FIG. 11 shows SDS-PAGE analysis of purified recombinant TB14, BsNOS, and GDH. All three proteins showed expected molecular weights, the same as those in *E. coli* soluble lysates.

[0641] FIGS. 12A-12B show *E. coli* cells carrying the pathway I produced Nitrotrp. FIG. 12A shows HPLC analysis of authentic Nitrotrp (I) and clear fermentation medium (II) demonstrated the production of Nitrotrp. FIG. 12B shows ESI-MS spectrum of Nitrotrp produced by *E. coli*. The calculated m/z of [M+H]⁺ is 250.1, identical to determined value.

[0642] FIG. 13 shows HPLC analysis of authentic 4-nitroindole (I) and clear fermentation medium prepared at day 4 (II) demonstrated no production of 4-nitroindole. The calculated m/z of [M+H]⁺ is 250.1, identical to determined value.

[0643] FIGS. 14A-14B show TnaA does not convert Nitrotrp into 4-nitroindole. FIG. 14A shows SDS-PAGE analysis of purified recombinant TnaA (around 56 kD). FIG. 14B shows HPLC analysis of TnaA reactions with L-Trp (I) and Nitrotrp (II) as substrates. The reactions contained 0.1 μ M purified TnaA and 0.5 mM substrate and incubated at 37° C. for 10 min. No 4-nitro indole was produced in the enzyme reaction.

[0644] FIG. 15 shows *E. coli* BL21-GOLD (DE3) transformed with the pathway I-IV showed similar growth rates in TB medium. Cultures were grown at 37° C., 250 rpm for 4 hours and protein expression was induced with 0.5 mM IPTG at 18° C., 250 rpm for 12 hours. OD600 were measured at serial time points. The data represent means \pm s. d. of at least two independent experiments.

[0645] FIGS. 16A-16B show improvement of Nitrotrp production by varying fermentation media and temperature. FIG. 16A shows the titers of Nitrotrp were varied when *E. coli*-II was fermented in M9, LB and TB media in the presence or absence of 5 mM L-Trp or L-Arg at 20° C., 250 rpm. FIG. 16B shows the titers of Nitrotrp were influenced by fermentation temperature. The fermentation was performed in TB medium at 15° C., 20° C., 28° C. or 37° C. and 250 rpm. Aliquots (0.1 mL) of the fermentation culture were taken at various time points and the concentration of Nitrotrp in the samples was measured in HPLC analysis. The data represent means \pm s. d. of at least two independent experiments.

[0646] FIG. 17 shows relative titers of Nitrotrp by five *E. coli* strains. All strains were cultured in TB at 28° C., 250 rpm. Aliquots (0.1 mL) of the fermentation culture were taken after 24 h and the concentration of Nitrotrp in the samples was measured in HPLC analysis. The amount of Nitrotrp by *E. coli*-II was set as 100% for normalizing the relative titer of other strains. The data represent means \pm s. d. of at least two independent experiments.

DETAILED DESCRIPTION

[0647] The disclosure relates, in some aspects, to compositions and methods useful for production of nitrated aromatic molecules. The disclosure is based, in part, on whole cell systems expressing artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. A significant advantage of whole cell nitration systems described by the disclosure compared to in vitro nitration reactions is the in situ production of NO from L-Arg, which enables recombinant bacterial cells to produce NO from L-Arg, which is synthesized by the bacterial cells from cheap carbon and nitrogen sources. Thus, it is believed that whole cell nitration systems described by the disclosure greatly lower the cost of biocatalytic nitration processes relative to currently utilized methods.

Recombinant Bacterial Cells

[0648] in some aspects, the disclosure relates to a recombinant bacterial cell comprising one or more isolated nucleic acids engineered to express: a fusion protein comprising a TxtE enzyme linked to a catalytic domain of a CYP102A1 (P450BM3) reductase enzyme via an amino acid linker sequence that is between 14 and 27 amino acids in length; and a nitric oxide synthase (NOS) enzyme.

[0649] As used herein “nucleic acid” refers to a DNA or RNA molecule. An “isolated nucleic acid” refers to a nucleic acid (e.g., DNA or RNA) that has been prepared in vitro, for example by recombinant technology. Nucleic acids are polymeric macromolecules comprising a plurality of nucleotides. In some embodiments, the nucleotides are deoxyribonucleotides or ribonucleotides. In some embodiments, the nucleotides comprising the nucleic acid are selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and inosine. In some embodiments, the nucleotides comprising the nucleic acid are modified nucleotides. Non-limiting examples of natural nucleic acids include genomic DNA and plasmid DNA. In some embodiments, the nucleic acids of the instant disclosure are synthetic. As used herein, the term “synthetic nucleic acid” refers to a nucleic acid molecule that is constructed via joining nucleotides by a synthetic or non-natural method. One non-limiting example of a synthetic method is solid-phase oligonucleotide synthesis. In some embodiments, the nucleic acids of the instant disclosure are isolated.

[0650] In some aspects, the disclosure relates to bacterial cells (e.g., populations of bacterial cells) that have been genetically engineered to express biocatalysts useful for aromatic nitration in situ (e.g., aromatic nitration inside the bacterial cell(s)). Generally, a bacterial cell of the disclosure may be any Gram-negative bacterial cell, including but not limited to bacteria of the genus *Escherichia* sp. (e.g., *E. coli*), *Pseudomonas* sp., *Xanthomonas* sp., *Rhizobium* sp., *Azotobacter* sp., *Acetobacter* sp., *Gluconobacter* sp., *Methylococcus* sp., *Klebsiella* sp., *Bacteroides* sp., *Yersinia* sp., *Vibrio* sp., *Bacillus* sp., *Clostridium* sp., *Lactococcus* sp., *Lactobacillus* sp., *Staphylococcus* sp., and *Streptococcus* sp. In some embodiments, a bacterial cell is an *E. coli* cell. Examples of *E. coli* bacterial strains include *E. coli* Dh5 α , *E. coli* BL21, *E. coli* DE3, *E. coli* Lemo21, *E. coli* NiCo21, *E. coli* Rosetta, etc. In some embodiments, a bacterial cell is an *E. coli* BL21-Gold cell.

[0651] In some embodiments, bacterial cells are genetically engineered to express certain biocatalysts (e.g., pro-

teins, such as enzymes) capable of aromatic nitration. Typically, the biocatalyst comprises a self-sufficient cytochrome P450 enzyme, or a portion thereof. Previously described self-sufficient cytochrome P450 enzymes typically comprise (i) a cytochrome P450 enzyme which catalyzes transfer of a nitro functional group to aromatic moieties (e.g., indole); (ii) an amino acid linker; and, (iii) a catalytic domain of a reductase enzyme. For example, TxtE-P450BM3 (also referred to as TB13-Q) is described in PCT Publication WO 2016/134145, the entire contents of which are incorporated by reference herein. In another example a TxtE-450BM3 variant having a 14-amino acid linker (also referred to herein as TB14) is described in PCT International Application Number PCT/US2017/058579, the entire contents of which are incorporated herein by reference. In some embodiments, a fusion protein expressed by a recombinant bacterial cell described by the disclosure is a TB14 fusion protein having the sequence set forth in SEQ ID NO: 1.

[0652] As used herein, the term “TxtE enzyme” refers to a (i) polypeptide comprising the entire amino acid sequence of TxtE, (ii) a portion of TxtE which maintains the function of catalyzing transfer of a nitro functional group to aromatic moieties (e.g., indole), or (iii) an enzyme which catalyzes transfer of a nitro functional group to aromatic moieties (e.g., indole) and is at least 95% homologous to the amino acid sequence of TxtE. For example, in some embodiments, a TxtE enzyme comprises or consists of a sequence set forth in Genbank Accession No. CBG70284.1 or a portion thereof (e.g., SEQ ID NO: 14).

[0653] The skilled artisan recognizes that for a portion of TxtE to maintain the nitration function, the portion must include active site residues of TxtE, for example Arg59, Asn293, Thr296 and Glu394. However, genetic modification of residues at a location of the TxtE polypeptide remote from the active site may maintain the activity of the enzyme. As used herein, the term “genetic modification” refers to amino acid substitution (conservative, missense and/or non-sense), deletion and/or insertion. Thus in some embodiments, a portion of TxtE comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 75, or at least 100 genetic modifications relative to wild-type TxtE. In some embodiments a portion of TxtE is truncated relative to wild-type TxtE. Truncations may occur at the N-terminus or C-terminus of the portion of TxtE. For example, a portion of TxtE may be truncated by 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 75, 100 or 200 amino acids at its N-terminus or C-terminus relative to wild-type TxtE.

[0654] In some embodiments, the disclosure provides a TxtE enzyme in which the loop region corresponding to residues A274 to V279 of GenBank Accession No. CBG70284.1 are replaced by the heme domain (e.g. loops “j” and “k”) of CYP102A1 (e.g., P450BM3, PDB ID: 1BVY). In some embodiments, a TxtE enzyme (e.g., TxtE-P450BM3) comprises the sequence set forth in SEQ ID NO: 14 or 15.

[0655] Methods of genetically modifying TxtE or portions thereof and screening for retention of functional activity are known in the art and available to the skilled artisan. For example, TxtE may be modified by directed evolution or random mutagenesis and biochemically assayed for the capability to transfer a nitro group to aromatic moieties (e.g., indole). In some embodiments, a TxtE enzyme may be an enzyme which catalyzes transfer of a nitro functional group

to aromatic moieties (e.g., indole) and has less than 95% homologous to the amino acid sequence of TxtE. In some embodiments, the enzyme has about 90%, about 80%, about 70%, about 60% or about 50% homology to the amino acid sequence of TxtE.

[0656] In some aspects, the disclosure provides fusion proteins comprising a catalytic domain of a reductase enzyme. As used herein, the term “reductase enzyme” refers to an enzyme that catalyzes a reduction reaction. Non-limiting examples of reductase enzymes include thioredoxin reductase, cytochrome P450 reductase and flavin adenine dinucleotide (FAD) reductase. In some embodiments, the reductase enzyme is a prokaryotic reductase enzyme. In some embodiments, the reductase enzyme is a bacterial reductase enzyme. In some embodiments, the bacterial reductase enzyme naturally occurs in a self-sufficient cytochrome P450, for example CYP102A1 (P450BM3) reductase or a P450RhF reductase. In some embodiments, the catalytic domain of a reductase enzyme comprises or consists of the sequence set forth in SEQ ID NO: 15.

[0657] In some embodiments, the fusion protein comprises an amino acid linker. As used herein, the term “linker” refers to an amino acid sequence that joins two larger polypeptide domains to form a single fusion polypeptide. Amino acid linkers are well known to those skilled in the art and include flexible linkers (e.g. glycine rich linkers such as [GGGS]_n, where n>2), rigid linkers (e.g. poly-proline rich linkers) and cleavable linkers (e.g. photocleavable and enzyme-sensitive linkers). In some embodiments, an amino acid linker is derived from a TxtE enzyme or a reductase enzyme (e.g., CYP102A1). For example, in some embodiments, an amino acid linker may comprise between about 3 and about 27 continuous (e.g., covalently linked) amino acids of a reductase enzyme (e.g., between about 3 and about 27 contiguous amino acids the sequence set forth in UniProtKB/Swiss-Prot Accession No. P14779.2. In some embodiments, an amino acid linker comprises between about 3 and about 27 contiguous amino acids, for example between about 3 and about 25 contiguous amino acids of SEQ ID NO: 16.

[0658] In some embodiments, amino acid linker length affects the folding and orientation of fusion polypeptides. For example, a linker that is too long can prevent the interaction of a reductase domain with the cytochrome P450 enzyme to which it is linked. (It is also known that long linkers can fold and take on specific orientations that can be desirable.) Conversely, a linker that is too short can cause a reductase enzyme to sterically inhibit binding of substrate to the active site of the P450 enzyme to which it is linked. In some embodiments, TxtE-BM3 fusion proteins comprising linkers having a certain length (e.g., 11, 12, 14, 15, 16, 17, etc. amino acids in length) exhibit improved function (e.g., increased nitration activity, coupling efficiency, total turnover number (TTN), etc.) compared to previously described self-sufficient cytochrome p450 enzymes. Accordingly, in some embodiments, a fusion protein described by the disclosure comprises an amino acid linker between about 3 and about 27 amino acids in length. In some embodiments, an amino acid linker is between about 11 and about 17 amino acids in length. In some embodiments, an amino acid linker is between about 14 and 16 amino acids in length. In some embodiments, the length of the linker is 1, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 amino acids in length.

[0659] In some embodiments, the amino acid linker joins a catalytic domain of a reductase enzyme to a terminus of a cytochrome P450 enzyme. As used herein, the term “terminus” refers to the ends of a polypeptide sequence relative to the start codon of said polypeptide. For example, the N-terminus of a polypeptide is the end of the polypeptide containing the start codon (AUG) of the polypeptide, whereas the C-terminus of the polypeptide is the end of the polypeptide opposite of the start codon. In some embodiments, the amino acid linker joins the 11 catalytic domain of a reductase enzyme to the C-terminus of a cytochrome P450 enzyme. In some embodiments, the amino acid linker joins CYP102A1 (P450BM3) reductase or P450RhF reductase to the C-terminus of a TxtE enzyme.

[0660] Generally, fusion proteins described by the disclosure can be produced by any suitable means known in the art. For example, in some embodiments, a fusion protein is produced by an overlap PCR method. As used herein, “overlap PCR” refers to the splicing (e.g., joining together) of two or more oligonucleotides by polymerase chain reaction employing primers that share complementarity with the terminus of each of the oligonucleotides, for example as described by Higuchi et al. (1988) *Nucleic Acids Res.* 16 (15): 7351-67. In some embodiments, fusion proteins described by the disclosure are not produced by overlap PCR. In some embodiments, fusion proteins described by the disclosure are produced by a restriction digest-based method (e.g., traditional cloning), for example as described in Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., Second Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.

[0661] The disclosure relates, in some aspects, to recombinant bacterial cells comprising an isolated nucleic acid engineered to express a nitric oxide synthase (NOS) enzyme. Generally, nitric oxide synthase (NOS) is a protein that catalyzes production of nitric oxide (NO) from L-arginine. Without wishing to be bound by any particular theory, NO is an important co-substrate for TxtE-based nitration reactions, and thus in some embodiments it is desirable to increase NO production in recombinant bacterial cells for the purpose of increasing nitration reaction yields. Generally, a NOS enzyme can be a prokaryotic or eukaryotic NOS enzyme. In some embodiments, a NOS enzyme is a bacterial NOS enzyme. Bacterial NOS enzymes are described, for example in Crane et al. (2010) *Annu Rev Biochem.* 79:455-70. In some embodiments, a NOS enzyme is a *Bacillus subtilis* NOS enzyme. In some embodiments, a *Bacillus subtilis* NOS enzyme is encoded by the sequence set forth in SEQ ID NO: 3. In some embodiments, a *Bacillus subtilis* NOS enzyme comprises the amino acid sequence set forth in SEQ 1) NO: 5. BsNOS enzymes are described, for example by Commichau et al. (2008) *J Bacteriol* 190(10):3557-3564.

[0662] In some aspects, the disclosure relates to recombinant bacterial cells comprising an isolated nucleic acid engineered to express a glucose dehydrogenase (GHD) enzyme. Glucose dehydrogenase (GDH) is an enzyme that catalyzes the reversible conversion of D-glucose to D-glucono-1,5-lactone while reducing NAD(P)+ to NAD(P)H. Without wishing to be bound by any particular theory, overexpression of GDH in recombinant bacterial cells (e.g., as part of a whole cell nitration system) may, in some embodiments, increase yield of nitration reactions by providing a sufficient supply of NADPH to fuel NOS-mediated conversion of L-Arg to L-citrulline. In some embodiments,

a GDH enzyme is a bacterial GDH enzyme. In some embodiments, a bacterial GDH enzyme is a *Bacillus megaterium* GDH enzyme.

[0663] As used herein, the term “engineered to express” refers to an isolated nucleic acid that comprises a gene to be expressed (e.g., TB14, BsNOS, GDH, etc.) and, optionally, one or more expression control sequences. Examples of expression control sequences include but are not limited to promoter sequences, enhancer sequences, repressor sequences, poly A tail sequences, internal ribosomal entry sites, Kozak sequences, antibiotic resistance genes (e.g., ampR, kanR, a chloramphenicol resistance gene, a β -lactamase resistance gene, etc.), an origin of replication (ori), etc.

[0664] In some embodiments, one or more isolated nucleic acid is operably linked to a promoter sequence. A promoter can be a constitutive promoter or an inducible promoter. In some embodiments, a promoter is a constitutive promoter. Examples of constitutive promoters include but are not limited to constitutive *E. coli* π^{70} promoters, constitutive *E. coli* σ^S promoters, constitutive *E. coli* σ^{32} promoters, constitutive *E. coli* σ^B promoters, constitutive *B. subtilis* σ^A promoters, constitutive *B. subtilis* σ^B promoters, constitutive bacteriophage T7 promoters, constitutive bacteriophage SP6 promoters, constitutive yeast promoters, etc.

[0665] In some embodiments, a promoter is an inducible promoter (e.g., induced in the presence of a small molecule, such as IPTG or tetracycline). Examples of inducible promoters include but are not limited to a promoter comprising a tetracycline responsive element (TRE), a pLac promoter, a pBad promoter, alcohol-regulated promoters (e.g., AlcA promoter), steroid-regulated promoters (e.g., LexA promoter), temperature-inducible promoters (e.g., Hsp70- or Hsp90-derived promoters, light-inducible promoters (e.g., YFI), etc.

[0666] In some embodiments, an isolated nucleic acid engineered to express a fusion protein is operably linked to a first promoter, an isolated nucleic acid engineered to express a NOS enzyme is operably linked to a second promoter, and an isolated nucleic acid engineered to express a GDH enzyme is operably linked to a third promoter. In some embodiments, a first promoter, a second promoter, and/or a third promoter is a T7 promoter.

[0667] In some embodiments, an isolated nucleic acid engineered to express a protein is a component of a vector. Examples of vectors include plasmids, viral vectors, cosmids, and artificial chromosomes. In some aspects, one or more isolated nucleic acids engineered to express a protein (e.g., TB14, NOS, GDH, etc.) are located (e.g., situated) on a plasmid, for example a bacterial plasmid. In some embodiments, the vector is a high-copy plasmid. In some embodiments, the vector is a low-copy plasmid. In some embodiments, a bacterial cell comprises one or more plasmids comprising the one or more isolated nucleic acids. For example, a plasmid may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 isolated nucleic acids. In some embodiments, a plasmid comprises 1, 2, or 3 isolated nucleic acids. In some embodiments, an isolated nucleic acid engineered to express the NOS enzyme and an isolated nucleic acid engineered to express the GDH enzyme are located on the same plasmid. In some embodiments, an isolated nucleic acid engineered to express the fusion protein is located on a plasmid that does not contain an isolated nucleic acid engineered to express the NOS enzyme and/or an isolated nucleic acid engineered to express the GDH enzyme. In some embodiments, a

recombinant bacterial cell as described by the disclosure comprises a first plasmid comprising an isolated nucleic acid engineered to express a TxtE fusion protein (e.g. TB14), a second plasmid comprising an isolated nucleic acid engineered to express a NOS enzyme (e.g., BsNOS), and a third plasmid comprising an isolated nucleic acid engineered to express a GDH enzyme.

[0668] In some embodiments, one or more isolated nucleic acids (e.g., one or more isolated nucleic acids encoding a fusion protein, a NOS enzyme, and/or a GDH enzyme) are integrated into a chromosome of a bacterial cell. Methods of integrating exogenous (e.g., foreign) DNA into a bacterial chromosome are known in the art and are described, for example, by Gu et al. (2015) *Scientific Reports* 5; Article number 9684.

[0669] The disclosure is based, in part, on recombinant bacterial cells that are capable of producing nitrated aromatic compounds. In some embodiments, recombinant bacterial cells are produced from bacterial strains that have been metabolically modified. As used herein, “metabolically modified” refers to a bacterial cell (or strain) that has been manipulated using recombinant DNA technology or other genome engineering methodologies to lack one or more genes in a particular metabolic pathway. For example, in some embodiments, a recombinant bacterial cell may be produced using a bacterial strain that has been engineered to lack one or more genes relating to tryptophan metabolism, tryptophan biosynthesis, L-tyrosine biosynthesis, phenylalanine biosynthesis, or any combination of the foregoing. In some embodiments, a bacterial cell is genetically modified to lack expression of one or more of the following genes: traA (tryptophanase), trpR (tryptophan repressor), tyrA (T protein), and pheA (P protein). In some embodiments, a bacterial cell comprises the genotype Δ trpR Δ tyrA Δ pheA (e.g., is a triple deletion mutant for trpR, tyrA, and pheA). In some embodiments, a bacterial cell comprises a tnaA gene, or a gene product (e.g., protein, enzyme, etc.) expressed from a tnaA gene.

Compositions Comprising Recombinant Bacterial Cells

[0670] In some aspects, the disclosure relates to a composition comprising one or more of a recombinant bacterial cell as described by the disclosure, and a bacterial culture media.

[0671] As used herein, a “bacterial culture media” is a nutrient rich composition that supports growth and reproduction of bacterial cells. Generally, bacterial culture media can be liquid or solid (e.g., culture media mixed with agar to form a gel). In some embodiments, bacterial culture media is a liquid. Examples of bacterial culture media include but are not limited to M9, Lysogeny Broth (LB), SOC media, Terrific Broth (TB), etc.

[0672] The volume of bacterial culture media in a composition comprising a recombinant bacterial cell can vary depending upon several factors including but not limited to the desired amount of nitrated aromatic compounds to be produced, the concentration (density) of bacterial cells desired in the composition, the volume of the container housing the composition, etc. In some embodiments, a composition comprises between about 10 μ L and 1 L bacterial culture media. In some embodiments, a composition comprises between about 10 μ L and about 1 mL bacterial culture media, for example about 10 μ L, about 50 μ L, about 100 μ L, about 500 μ L, about 750 μ L, or about 1 mL (e.g., any

volume between 10 μl and 1 mL, inclusive). In some embodiments, a composition comprises between about 750 μl and 5 mL (e.g., any volume between 750 μl and 5 mL, inclusive). In some embodiments, a composition comprises between about 2 mL and about 20 mL bacterial culture media (e.g., any volume between 2 mL and 20 mL, inclusive). In some embodiments, a composition comprises between about 10 mL and about 20 mL bacterial culture media (e.g., any volume between 10 mL and 200 mL inclusive). In some embodiments, a composition comprises between about 100 mL and about 500 mL bacterial culture media (e.g., any volume between 100 mL and 500 mL, inclusive). In some embodiments, a composition comprises between about 250 mL and about 1 L bacterial culture media (e.g., any volume between 250 mL and 1 L, inclusive). In some embodiments, a composition comprises more than 1 L (e.g., 5 L, 10 L, 100 L, 200 L, 1000 L, 10,000 L, 50,000 L, etc.) bacterial culture media.

[0673] In some embodiments, a composition further comprises one or more antibiotic agents. In some embodiments, one or more antibiotic agent is ampicillin or kanamycin. A composition may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibiotic agents. The concentration of an antibiotic agent can vary. In some embodiments, the concentration of an antibiotic agent ranges from about 0 (e.g., lacking antibiotic) to about 125 $\mu\text{g}/\text{ml}$.

[0674] Aspects of the disclosure relate to uptake and subsequent nitration of L-tryptophan (and L-tryptophan analogues) by recombinant bacterial cells described herein. Without wishing to be bound by any particular theory, compositions comprising recombinant bacterial cells described herein and bacterial culture media may be "fed" with exogenous L-tryptophan or analogues thereof, which are internalized by the bacteria (e.g., via permease transport across the bacterial cell membrane) and subsequently nitrated by a fusion protein (e.g., a TxtE fusion protein, such as TB14). Thus, in some embodiments, a composition further comprises one or more of the following: L-tryptophan (L-Trp), L-arginine (L Arg), or an analogue of L-tryptophan. In some embodiments, a composition further comprises one or more compounds of Formula Ia or IVa. In some embodiments, an analogue of L-tryptophan is selected from the group consisting of α -Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-Trp, 6-F-Trp, and 7-Me-Trp.

[0675] In some embodiments, a composition further comprises one or more compounds of Formulae I-VI. In some embodiments, a composition further comprises one or more of the following: 4-NO₂-L-Trp, α -Me-4-NO₂Trp, 4-F-7-NO₂-Trp, 4-Me-7-NO-Trp, 5-MeO-4-NO₂-Trp, 5-Me-4-NO₂-Trp, 5-F-4-NO₂-Trp, 6-F-4-NO₂-Trp, or 7-Me-4-NO₂-Trp. In some embodiments, the compound of Formulae I-VI is selected from:

- [0676] (S)-2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl) propanoic acid;
- [0677] (S)-2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0678] (S)-2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0679] (S)-2-amino-3-(4-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0680] (S)-2-amino-3-(4-methyl-7-nitro-1H-4-indol-3-yl) propanoic acid;
- [0681] (S)-2-amino-3-(5-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;

- [0682] (S)-2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0683] (S)-2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0684] (S)-2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl) propanoic acid;
- [0685] (S)-2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0686] (S)-2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0687] (S)-2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl) propanoic acid;
- [0688] (S)-2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl) propanoic acid;
- [0689] (S)-2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0690] (S)-2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0691] (S)-2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl) propanoic acid;
- [0692] (S)-2-amino-3-(5-bromo-7-nitro-1H-indol-3-yl) propanoic acid;
- [0693] (S)-2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0694] (S)-2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0695] (S)-2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0696] (S)-2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0697] (S)-2-amino-3-(5-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0698] (S)-2-amino-3-(6-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0699] (S)-2-amino-3-(7-amino-4-nitro-1H-indol-3-yl) propanoic acid;
- [0700] (S)-2-amino-3-(4-amino-7-nitro-1H-indol-3-yl) propanoic acid;
- [0701] (S)-2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0702] (S)-2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0703] (S)-2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid;
- [0704] (S)-2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl) propanoic acid;
- [0705] (S)-2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl) propanoic acid;
- [0706] (S)-2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl) propanoic acid;
- [0707] (S)-2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl) propanoic acid;
- [0708] (S)-2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl) propanoic acid;
- [0709] (S)-2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0710] (S)-2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0711] (S)-2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0712] (S)-2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl) propanoic acid;
- [0713] (S)-2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl) propanoic acid;

- [0714] (S)-2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0715] (S)-2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0716] (S)-2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0717] (S)-2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0718] (S)-2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0719] (S)-2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0720] (S)-2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0721] (S)-2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0722] (S)-2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0723] (S)-2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0724] (S)-2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0725] (S)-2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0726] (S)-2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0727] (S)-2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0728] (S)-2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0729] (S)-2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0730] (S)-2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0731] (S)-2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0732] (S)-2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0733] 2-amino-3-(4-methyl-5-nitro-1H-indol-3-yl)propanoic acid;
- [0734] 2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0735] 2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0736] 2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0737] 2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0738] 2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0739] 2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0740] 2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl)propanoic acid;
- [0741] 2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0742] 2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0743] 2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl)propanoic acid;
- [0744] 2-amino-3-(4-choo-7-nitro-1H-indol-3-yl)propanoic acid;
- [0745] 2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0746] 2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0747] 2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl)propanoic acid;
- [0748] 2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl)propanoic acid;
- [0749] 2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0750] 2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0751] 2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0752] 2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0753] 2-amino-3-(5-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0754] 2-amino-3-(6-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0755] 2-amino-3-(7-amino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0756] 2-amino-3-(4-amino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0757] 2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0758] 2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0759] 2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid;
- [0760] 2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl)propanoic acid;
- [0761] 2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0762] 2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0763] 2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0764] 2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0765] 2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0766] 2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0767] 2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0768] 2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0769] 2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0770] 2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0771] 2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0772] 2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0773] 2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0774] 2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0775] 2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0776] 2-amino-3-(4-ethynyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0777] 2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;

- [0778] 2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0779] 2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0780] 2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl) propanoic acid;
[0781] 2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0782] 2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0783] 2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0784] 2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl) propanoic acid;
[0785] 2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0786] 2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0787] 2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0788] 2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0789] 2-amino-3-(1,5-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0790] 2-amino-3-(1,6-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0791] 2-amino-3-(1,7-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0792] 2-amino-3-(1,4-dimethyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0793] 2-amino-3-(6-fluoro-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0794] 2-amino-3-(7-fluoro-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0795] 2-amino-3-(4-fluoro-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0796] 2-amino-3-(5-chloro-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0797] 2-amino-3-(6-chloro-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0798] 2-amino-3-(7-chloro-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0799] 2-amino-3-(4-chloro-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0800] 2-amino-3-(5-bromo-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0801] 2-amino-3-(6-bromo-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0802] 2-amino-3-(7-bromo-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0803] 2-amino-3-(4-bromo-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0804] 2-amino-3-(5-methoxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0805] 2-amino-3-(6-methoxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0806] 2-amino-3-(7-methoxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0807] 2-amino-3-(4-methoxy-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0808] 2-amino-3-(5-amino-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0809] 2-amino-3-(6-amino-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
- [0810] 2-amino-3-(7-amino-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0811] 2-amino-3-(4-amino-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0812] 2-amino-3-(5-hydroxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0813] 2-amino-3-(6-hydroxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0814] 2-amino-3-(7-hydroxy-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0815] 2-amino-3-(4-hydroxy-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0816] 2-amino-3-(1-methyl-4-nitro-5-phenyl-1H-indol-3-yl) propanoic acid;
[0817] 2-amino-3-(1-methyl-4-nitro-6-phenyl-1H-indol-3-yl) propanoic acid;
[0818] 2-amino-3-(1-methyl-4-nitro-7-phenyl-1H-indol-3-yl) propanoic acid;
[0819] 2-amino-3-(1-methyl-7-nitro-4-phenyl-1H-indol-3-yl) propanoic acid;
[0820] 2-amino-3-(5-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0821] 2-amino-3-(6-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0822] 2-amino-3-(7-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0823] 2-amino-3-(4-cyclopropyl-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0824] 2-amino-3-(1-methyl-4-nitro-5-vinyl-1H-indol-3-yl) propanoic acid;
[0825] 2-amino-3-(1-methyl-4-nitro-6-vinyl-1H-indol-3-yl) propanoic acid;
[0826] 2-amino-3-(1-methyl-4-nitro-7-vinyl-1H-indol-3-yl) propanoic acid;
[0827] 2-amino-3-(1-methyl-7-nitro-4-vinyl-1H-indol-3-yl) propanoic acid;
[0828] 2-amino-3-(5-ethynyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0829] 2-amino-3-(6-ethynyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0830] 2-amino-3-(7-ethynyl-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
[0831] 2-amino-3-(4-ethynyl-1-methyl-7-nitro-1H-indol-3-yl) propanoic acid;
[0832] 2-amino-3-(1-methyl-5-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0833] 2-amino-3-(1-methyl-6-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0834] 2-amino-3-(1-methyl-7-morpholino-4-nitro-1H-indol-3-yl) propanoic acid;
[0835] 2-amino-3-(1-methyl-4-morpholino-7-nitro-1H-indol-3-yl) propanoic acid;
[0836] 2-amino-3-(1-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0837] 2-amino-3-(1-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0838] 2-amino-3-(1-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl) propanoic acid;
[0839] 2-amino-3-(1-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl) propanoic acid;
[0840] 2-amino-3-(1-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;
[0841] 2-amino-3-(1-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl) propanoic acid;

- [0842] 2-amino-3-(1-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0843] 2-amino-3-(1-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0844] 2-amino-3-(2,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0845] 2-amino-3-(2,6-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0846] 2-amino-3-(2,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0847] 2-amino-3-(2,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0848] 2-amino-3-(6-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0849] 2-amino-3-(7-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0850] 2-amino-3-(4-fluoro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0851] 2-amino-3-(5-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0852] 2-amino-3-(6-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0853] 2-amino-3-(7-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0854] 2-amino-3-(4-chloro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0855] 2-amino-3-(5-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0856] 2-amino-3-(6-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0857] 2-amino-3-(7-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0858] 2-amino-3-(4-bromo-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0859] 2-amino-3-(5-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0860] 2-amino-3-(6-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0861] 2-amino-3-(7-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0862] 2-amino-3-(4-methoxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0863] 2-amino-3-(5-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0864] 2-amino-3-(6-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0865] 2-amino-3-(7-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0866] 2-amino-3-(4-amino-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0867] 2-amino-3-(5-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0868] 2-amino-3-(6-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0869] 2-amino-3-(7-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0870] 2-amino-3-(4-hydroxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0871] 2-amino-3-(2-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0872] 2-amino-3-(2-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0873] 2-amino-3-(2-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0874] 2-amino-3-(2-methyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0875] 2-amino-3-(5-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0876] 2-amino-3-(6-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0877] 2-amino-3-(7-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0878] 2-amino-3-(4-cyclopropyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0879] 2-amino-3-(2-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0880] 2-amino-3-(2-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0881] 2-amino-3-(2-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0882] 2-amino-3-(2-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0883] 2-amino-3-(5-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0884] 2-amino-3-(6-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0885] 2-amino-3-(4-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0886] 2-amino-3-(4-ethynyl-5-methyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0887] 2-amino-3-(2-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0888] 2-amino-3-(2-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0889] 2-amino-3-(2-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0890] 2-amino-3-(2-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0891] 2-amino-3-(2-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0892] 2-amino-3-(2-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0893] 2-amino-3-(2-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0894] 2-amino-3-(2-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0895] 2-amino-3-(2-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0896] 2-amino-3-(2-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0897] 2-amino-3-(2-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0898] 2-amino-3-(2-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0899] 2-amino-3-(1,2,5-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0900] 2-amino-3-(1,2,6-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0901] 2-amino-3-(1,2,7-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0902] 2-amino-3-(1,2,4-trimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0903] 2-amino-3-(6-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0904] 2-amino-3-(7-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0905] 2-amino-3-(4-fluoro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;

- [0906] 2-amino-3-(5-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0907] 2-amino-3-(6-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0908] 2-amino-3-(7-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0909] 2-amino-3-(4-chloro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0910] 2-amino-3-(5-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0911] 2-amino-3-(6-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0912] 2-amino-3-(7-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0913] 2-amino-3-(4-bromo-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0914] 2-amino-3-(5-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0915] 2-amino-3-(6-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0916] 2-amino-3-(7-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0917] 2-amino-3-(4-methoxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0918] 2-amino-3-(5-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0919] 2-amino-3-(6-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0920] 2-amino-3-(7-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0921] 2-amino-3-(4-amino-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0922] 2-amino-3-(5-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0923] 2-amino-3-(6-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0924] 2-amino-3-(7-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0925] 2-amino-3-(4-hydroxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0926] 2-amino-3-(1,2-dimethyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid;
- [0927] 2-amino-3-(1,2-dimethyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid;
- [0928] 2-amino-3-(1,2-dimethyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid;
- [0929] 2-amino-3-(1,2-dimethyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid;
- [0930] 2-amino-3-(5-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0931] 2-amino-3-(6-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0932] 2-amino-3-(7-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0933] 2-amino-3-(4-cyclopropyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0934] 2-amino-3-(1,2-dimethyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid;
- [0935] 2-amino-3-(1,2-dimethyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid;
- [0936] 2-amino-3-(1,2-dimethyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid;
- [0937] 2-amino-3-(5,2-dimethyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid;
- [0938] 2-amino-3-(5-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0939] 2-amino-3-(6-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0940] 2-amino-3-(7-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
- [0941] 2-amino-3-(4-ethynyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid;
- [0942] 2-amino-3-(1,2-dimethyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0943] 2-amino-3-(1,2-dimethyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0944] 2-amino-3-(1,2-dimethyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid;
- [0945] 2-amino-3-(1,2-dimethyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid;
- [0946] 2-amino-3-(1,2-dimethyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0947] 2-amino-3-(1,2-dimethyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0948] 2-amino-3-(1,2-dimethyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid;
- [0949] 2-amino-3-(1,2-dimethyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid;
- [0950] 2-amino-3-(1,2-dimethyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0951] 2-amino-3-(1,2-dimethyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0952] 2-amino-3-(1,2-dimethyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid; or
- [0953] 2-amino-3-(1,2-dimethyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid;
- [0954] and a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof.
- [0955] The skilled artisan recognizes that the conditions under which a composition as described herein is maintained may affect the production and/or stability of nitrated aromatic compounds by the recombinant bacterial cell(s). The disclosure is based, in part, on the recognition that production of nitrated aromatic compounds is reduced or absent at temperatures at which bacterial cells are generally cultured (e.g., 37° C.). In some embodiments, a composition has a temperature below 37° C. (e.g., the temperature of the bacterial culture media of a composition is below 37° C.). The disclosure is based, in part, on the recognition that production of nitrated aromatic compounds is increased at temperatures between 10 to 30° C. (e.g., 10° C., 1° IC, 12° C., 13° C., 4° C., 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., or 30° C.). In some embodiments, a composition has a temperature of 28° C. (e.g., the temperature of the bacterial culture media of a composition is 28° C.).
- [0956] In some embodiments, a composition as described by the disclosure comprises additional components, for example one or more cryopreservatives (e.g., glycol, DMSO, PEG, glycerol, etc.), antifungals, etc.

Methods of Producing Recombinant Bacterial Cells

[0957] In some embodiments, the disclosure relates to methods of producing a recombinant bacterial cell as described by the disclosure. Typically, the methods comprise the steps of: transforming a bacterial cell with an isolated nucleic acid engineered to express a fusion protein comprising a TxtE enzyme linked to a catalytic domain of a

CYP102A1 (P450BM3) reductase enzyme via an amino acid linker sequence that is between 14 and 27 amino acids in length; and an isolated nucleic acid engineered to express a nitric oxide synthase (NOS) enzyme; and culturing (e.g., growing) the bacterial cell.

[0958] Methods of introducing vectors into bacteria are well known in the art and described, for example, in Current Protocols in Molecular Biology. Ausubel et al. (Eds), John Wiley and Sons, New York, 2007.

[0959] In some embodiments of methods described by the disclosure, a bacterial cell is transformed with one or more an isolated nucleic acids comprising the sequence set forth in any one of SEQ ID NOS: 8-13.

Whole Cell-Based Nitration of L-Tryptophan and L-Tryptophan Analogues

[0960] In some aspects, the disclosure relates to methods for producing a nitrated L-tryptophan or nitrated L-tryptophan analogue, comprising the steps of: introducing into a bacterial cell culture comprising a one or more of a recombinant bacterial cell as described by the disclosure one or more L-Trp molecules and/or one or more L-Trp analogue molecules; and growing the bacterial cell culture under conditions under which a fusion protein expressed by the recombinant bacterial cell catalyzes a nitration reaction which produces one or more nitrated L-Trp molecules and/or one or more nitrated L-Trp analog molecules. In some embodiments, methods further comprise the step of isolating nitrated L-Trp molecules and/or nitrated L-Trp analog molecules from the bacterial cell culture.

[0961] In some embodiments of methods described by the disclosure, one or more L-Trp analogue molecules are selected from the group consisting of α -Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-Trp, 6-F-Trp, and 7-Me-Trp. The concentration of L-Trp or L-Trp analog added (introduced into) to a bacterial cell culture can vary. In some embodiments, L-Trp or an L-Trp analogue is added to a bacterial cell culture in an amount such that the final concentration of L-Trp or L-Trp analogue in the bacterial cell culture ranges from about 1 μ M to a saturation concentration or above (e.g., 1 μ M, 10 μ M, 50 μ M, 100 μ M, 500 μ M, 750 μ M, 1 mM, 10 mM, 100 mM, etc.).

[0962] In some embodiments, the order in which the proteins encoded by the isolated nucleic acids of the recombinant bacterial cell are expressed affects the production of nitrated aromatic compounds. In some embodiments, a TxtE fusion protein, NOS enzyme, and optionally GDH, are simultaneously expressed in a recombinant bacterial cell. In some embodiments, a TxtE fusion protein, NOS enzyme, and optionally GDH, are expressed sequentially in a recombinant bacterial cell. The order of sequential expression of the proteins can vary. For example a TxtE fusion protein may be expressed first prior to NOS and/or GDH. In some embodiments, a NOS enzyme is expressed prior to expression of a TxtE fusion protein. In some embodiments, a TxtE fusion protein, NOS enzyme, and optionally GDH, are expressed in a recombinant bacterial cell prior to addition of L-Trp or L-Trp analogue. In some embodiments, a TxtE fusion protein, NOS enzyme, and optionally GDH, are expressed in a recombinant bacterial cell after addition of L-Trp or L-Trp analogue.

[0963] In some embodiments of methods described by the disclosure, the step of growing the bacterial cell culture comprises introducing one or more antibiotic and/or one or

more inducer into the bacterial cell culture. In some embodiments, one or more antibiotic is selected from ampicillin and kanamycin. In some embodiments, one or more of the inducers is Isopropyl β -D-1-thiogalactopyranoside (IPTG). [0964] The skilled artisan recognizes that the conditions under which a composition as described herein is maintained may affect the production and/or stability of nitrated aromatic compounds by the recombinant bacterial cell(s). The disclosure is based, in part, on the recognition that production of nitrated aromatic compounds is reduced or absent at temperatures at which bacterial cells are generally cultured (e.g., 37° C.). In some embodiments, a composition has a temperature below 37° C. (e.g., the temperature of the bacterial culture media of a composition is below 37° C.). The disclosure is based, in part, on the recognition that production of nitrated aromatic compounds is increased at temperatures between 10 to 30° C. (e.g., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C., 29° C., or 30° C.). In some embodiments, a composition has a temperature of 28° C. (e.g., the temperature of the bacterial culture media of a composition is 28° C.).

[0965] The length of time a bacterial cell culture is grown after addition of L-Trp or a L-Trp analogue can vary. In some embodiments, a bacterial cell culture is grown for about 1 hour to about 30 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 hours) after the addition of L-Trp or L-Trp analogue. In some embodiments, a bacterial cell culture is grown for about 1 hour to about 30 hours (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 hours) post-transformation with one or more isolated nucleic acids. In some embodiments, a bacterial cell culture is grown for up to 25 hours (e.g., up to 25 hours post-transformation with one or more isolated nucleic acids).

[0966] In some embodiments, isolating nitrated L-Trp molecules and/or nitrated L-Trp analog molecules comprises lysing one or more recombinant bacterial cells. Lysis of bacterial cells is generally known in the art and may be achieved, for example, by incubating bacterial cells in a lysis buffer (e.g., a hypertonic solution, a solution containing lysozyme, a solution containing detergent, etc.) or by centrifugation.

[0967] In some embodiments, nitrated 1-Trp molecules and/or nitrated L-Trp analog molecules are isolated from a bacterial cell lysate by performing high-pressure liquid chromatography (HPLC) or other liquid extraction methods known in the art. Additional methods for purification and/or analysis of nitrated aromatic compounds (e.g., 4-NO₂-L-Trp, etc.) include mass spectroscopy and nuclear magnetic resonance (NMR) analysis.

[0968] The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

EXAMPLES

Example 1: Materials and Methods

General Chemicals, DNA sub-cloning, and Bacterial Strains [0969] Molecular biology reagents and enzymes were purchased from Fisher Scientific. Primers (Table 1) were ordered from Sigma-Aldrich, 4-Me-DLTrp was from MP Biomedical (Santa Ana, CA), while NOC-5 (3-(Aminopro-

pyl)-1-hydroxy-3-isopropyl-2-oxo-1-triazene) was purchased from EMD Millipore. Other chemicals and solvents were purchased from Sigma-Aldrich and Fisher Scientific. *Escherichia coli* DH5a (Life Technologies) was used for cloning and plasmid harvesting. *E. coli* BL21-GOLD (DE3) (Agilent) was used for protein overexpression. *E. coli* strains were grown in Luria-Bertani broth or Terrific broth. DNA sequencing was performed at Eurofins. A Shimadzu Prominence UHPLC system (Kyoto, Japan) fitted with an Agilent Poroshell 120 EC-C18 column (2.7 μ m, 3.0 \times 50 mm), coupled with a PDA detector was used for HPLC analysis.

Construction of Plasmids for Whole Cell Transformation

[0970] TB14 gene was amplified from TB14/pET28b using a pair of TB14FN and TB14RH primers in PCR reactions (Table 1). The PCR product was analyzed by agarose gel and extracted with a GeneJET Gel Extraction Kit (Thermo). Purified PCR products, pACYCDuet and pET-Duet were digested with the restriction enzymes NcoI and HindIII, and corresponding linear DNAs were ligated to generate expression constructs. GDH gene was amplified from GDH/pET21b using a pair of GDHFB and GDHRH primers in PCR reactions (Table 1). The PCR product was analyzed by agarose gel and extracted with a GeneJET Gel Extraction Kit (Thermo). Purified PCR products, pET28b, pACYCDuet and pETDuet were digested with the restriction enzymes BamHI and HindIII, and corresponding linear DNAs were ligated to generate expression constructs. BsNOS gene was amplified from BsNOS/pET15b using a pair of BsNOSFN and BsNOSRH primers in PCR reactions (Table 1). The PCR product was analyzed by agarose gel and extracted with a GeneJET Gel Extraction Kit (Thermo). Purified PCR products, pET28b, pACYCDuet and pETDuet were digested with the restriction enzymes NdeI and HindIII, and corresponding linear DNAs were ligated to generate expression constructs. SsTxtD and StTxtD were amplified from genomic DNA of *S. scabies* 87.22 (NRRL B-24449) and *S. turgidiscabies* Car8 using a pair of SsTxtDFN/SsTxtDRH and StTxtDFN/StTxtDRH primers in PCR reactions (Table 1). The PCR product was analyzed by agarose gel and extracted with a GeneJET Gel Extraction Kit (Thermo). Purified PCR products and pET28b were digested with the restriction enzymes NdeI and HindIII, and corresponding linear DNAs were ligated to generate expression constructs. All inserts in the constructs were sequenced to exclude mutations introduced during PCR amplification and gene manipulation,

Heterologous Expression and Purification of Recombinant Proteins

[0971] Protein expression and purification followed established protocols. The purified proteins were exchanged into storage buffer (25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 3 mM β ME, and 10% glycerol) by PD-10 column, aliquoted and stored at -80° C. until needed. CO difference spectroscopy was used to measure the concentrations of functional P450s.

Analytical HPLC Analysis

[0972] For analytical analysis, an HPLC column was kept at 40° C., water with 0.1% formic acid was used as solvent A and acetonitrile with 0.1% formic acid was used as solvent B. The column was eluted first with 1% solvent B for 1 min and then with a linear gradient of 1-20% solvent B in 8 min, followed by another linear gradient of 20-99% solvent B in 2 min. The column was further cleaned with 99% solvent B for 2 min and then re-equilibrated with 1% solvent B for 2 min. The flow rate was set as 1 mL/min, and the products were detected at 211 nm with a PDA detector.

Whole-Cell Biotransformation

[0973] *E. coli* BL21 Gold cells containing pETDuet and pET28b derived plasmids were grown from glycerol stock overnight in 5 mL Luria broth with 0.1 mg/mL ampicillin and 0.05 mg/mL kanamycin (37° C., 250 rpm). The pre-culture was used to inoculate 100 mL of Terrific broth medium (0.1 mg/mL ampicillin and 0.05 mg/mL kanamycin) in a 500 mL flask; this culture was incubated at 37° C., 250 rpm to OD₆₀₀=0.6-0.8. The cultures were cooled on water-ice mixture and induced with 0.5 mM IPTG. Expression was conducted at 18° C., 250 rpm, for 20 h. For the culture of *E. coli* BL21 Gold cells containing pACYCDuet and pET28b derived plasmids, 0.05 mg/mL chloramphenicol was used instead of 0.05 mg/mL kanamycin. The cultures were then harvested and resuspended to OD₆₀₀=30 in test medium. Aliquots of the cell suspension were used in the whole cell transformation. To a test tube was added 5 mL cell suspension, 25 μ L 100 mM L-Trp or L-Trp analogues, and 25 μ L 100 mM L-Arg when necessary. The mixture was then incubated at different conditions. The reactions were quenched by adding equal volume of methanol and the resulting mixture was aliquoted and transferred to a micro-centrifuge tube and centrifuged at 14,000 rpm for 10 minutes. The supernatant was transferred to an HPLC vial and analyzed by LC-MS.

TABLE 1

Primers for construction of whole cell transformation plasmids.		
Name	Sequence (5'→3')	Function
TB14FN	ATACCATGGTACCGTCCCCCTCGCCG (SEQ ID NO: 17)	TB14 cloning
TB14RH	ATCAAGCTTCCCAGCCCACACGTCTTTGC (SEQ ID NO: 18)	TB14 cloning
GDHFB	CAGGATCCGATGTATAAAGATCTGGAAGGTAAAGTGGTG (SEQ ID NO: 19)	GDH cloning
GDHRH	CAAAAGCTTTAGCCACGACCTGCCTGAAAG (SEQ ID NO: 20)	GDH cloning
BsNOSFN	ACTCATATGATGGAAGAAAAAGAAATC (SEQ ID NO: 21)	BsNOS cloning

TABLE 1-continued

Primers for construction of whole cell transformation plasmids.		
Name	Sequence (5'→3')	Function
BsNOSRH	ACTAAGCTTCTATTACATACGGTTGTC (SEQ ID NO: 22)	BsNOS cloning
SsTxtDFN	CTACATATGGTGACTIONTCGAAGTCGC (SEQ ID NO: 23)	SsTxtD cloning
SsTxtDRH	CTCAAGCTTCTGATGAGGGTAAAAGTTG (SEQ ID NO: 24)	SsTxtD cloning
StTxtDFN	ACTCATATGGTGACTIONCGCCCTG (SEQ ID NO: 25)	StTxtD cloning
StTxtDRH	ACTAAGCTTCTGATGAGGGTAAAAGTTGGGG (SEQ ID NO: 26)	StTxtD cloning

Example 2: Whole Cell Nitration System

[0974] This example describes an *E. coli*-based biotransformation system for the production of nitrated L-Trp was developed (FIG. 1). The engineered *E. coli* strain contained three functional genes, TB14 (TB14), nitro oxide synthase (NOS), and Glucose Dehydrogenase 1 (GDH). TB14 is a self-sufficient nitration biocatalyst that is a fusion protein comprising a cytochrome P450 (e.g., a *Streptomyces* TxtE enzyme) and a catalytic domain of a reductase enzyme (e.g., a prokaryotic reductase enzyme, such as a CYP102A1 (P450BM3) reductase). TB14 is soluble in *E. coli*. In some embodiments, TB14 is represented by SEQ ID NO: 1.

[0975] The co-substrate NO is indispensable for a TxtE nitration reaction. In the in vitro assays, NO was derived from the NO precursor NOC-5 that is expensive, has a short-life, and is often incompatible with bacterial cells (e.g., NO at high concentration is toxic to bacterial cells). The thaxtomin biosynthetic gene cluster in *Streptomyces scabies* contains a TxtD gene encoding a nitric oxide synthase that converts L-Arg into L-citrulline and NO along with the consumption of NADPH. The expression of the NOS gene in *E. coli* can, in some embodiments, provide a sustainable and environment-friendly approach to eliminate the dependence of the high-cost and unstable NO precursors in whole cell nitration biotransformation.

[0976] It was observed that expression of the TxtD gene from two thaxtomin-producing *Streptomyces* strains (*Streptomyces scabies* and *Streptomyces turgidiscabies*) and yielded only insoluble proteins after optimizing expression conditions. However, expression of a codon-optimized NOS gene from *Bacillus subtilis* resulted in production of soluble NOS protein in *E. coli* and was used in the subsequent experiments.

[0977] The reaction of NOS requires redox partners for transferring electrons from NADPH. It was observed that non-specific redox partners of *E. coli* effectively support the BsNOS reaction, making BsNOS containing *E. coli* strain a viable biosystem to supply NO for the nitration reaction. In some embodiments, insufficient supply of NADPH limits the productivity of biotransformation. Thus, in some embodiments of whole cell nitration systems described in this example, the GDH gene from *Bacillus megaterium* was also engineered into *E. coli* to regenerate NADPH that is consumed in both TB14 and BsNOS reactions. GDH catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP⁺ to NADPH, and may be applied in biocatalysis procedures to regenerate NADPH.

[0978] In some experiments, TB14 and BsNOS genes were co-expressed using vector pETDuet, while the GDH gene was separately expressed in the vector pET28b. Both vectors have the same, medium copy numbers (15 to 60) in the host and drive the expression of each gene with a strong inducible promoter T7. In addition, the different antibiotic resistant markers (ampicillin R and kanamycin R) in these two vectors make them suitable for simultaneous expression of three genes in the same host. The two constructs described above were transformed into *E. coli* BL21-GOLD strain. The overexpression of the three enzymes was induced by IPTG. SDS-PAGE analysis of the soluble crude extract (FIG. 2A, lane 1) indicated successful overexpression of BsNOS (42 kD) and GDH (28 kD). Soluble TB14 (110 kD) expression was also observed. In some embodiments, co-expression of BsNOS and/or GDH negatively influences the expression of TB14. Nevertheless, this engineered *E. coli* strain was used in whole-cell biotransformation to produce 4-NO₂-L-Trp from fed L-Trp. After 20-h incubation, the successful production of 4-NO₂-L-Trp was confirmed by LC-MS (FIG. 2B).

Optimization of Heterologous Enzyme Expression

[0979] Next, the copy numbers of the three genes (e.g., TB14, BsNOS, GDH) were varied in order to improve TB14 expression and to improve plasmid stability. Plasmid pACYCDuet was used for the co-expression of two target genes. The pACYCDuet plasmid includes two T7 promoters to drive the proteins expression carries the P15A replicon instead of pBR322-derived ColE1 replicon as in pETDuet and pET28b, which can provide higher plasmid stability when two plasmids are used. Three new pairs of expression constructs were created, pETDuet-GDH-BsNOS+pET28b-TB14, pACYCDuet-TB14-BsNOS+pET28b-GDH, and pACYCDuet-GDH-BsNOS+pET28b-TB14, and the corresponding engineered *E. coli* strains (FIG. 3A). Protein expression levels in these strains was then examined by SDS-PAGE (FIG. 2A). The bacterial strain transformed with the pair of pETDuet-GDH-BsNOS and pET28b-TB14 plasmids showed significantly increased TB14 expression level, and it also demonstrated the high nitration activity (FIG. 3B). This strain was used in the following experiments.

Optimization of Fermentation Conditions

[0980] Fermentation conditions, including medium, temperature, substrate supplement, and harvesting time were then investigated. Minimal medium M9 was used in previously described experiments. As M9 medium is nutritiously

poor, it was investigated whether nutrition availability could influence the whole cell nitration efficiency. Three nutrition rich media, including LB medium, SOC medium and TB medium, were tested along with the M9 medium in a whole cell nitration system. As shown in (FIG. 4), transformations supported by nutrition richer media generally had higher efficiency than those supported by the M9. Notably, TB medium supported transformation yielded as high as 600 μM of nitrated tryptophan (149 mg/L) after 20-hour fermentation.

[0981] The time profile of the product formation (FIG. 4) was then tested. In all the nutrition rich media, the highest productivity was observed at approximately 20 hours. By contrast, it required 3 days in the M9 medium. Notably, the concentration of nitrated tryptophan in the rich media started to decrease after 30-hour fermentation. In some embodiments, *E. coli* endogenous tryptophanase (EC 4.1.99.1), which converts tryptophan to indole, pyruvate and NH_3 , mediates production decomposition. *E. coli* tryptophanase (tnaA) was cloned and recombinant enzyme was prepared. In vitro biochemical assay data indicated that TnaA was not able to decompose $4\text{-NO}_2\text{-Trp}$.

[0982] In TB14 reactions, the co-substrate NO is generated from L-arginine by BsNOS. The effect of increasing the concentration of L-Arg was then tested (FIG. 4). No significant change in nitro-tryptophan production was observed when 5 mM of L-Arg was added to each of the transformation systems tested. This result indicates that L-Arg or NO is not the limiting factor in the whole cell transformation. The effect of increased concentration of the substrate L-Trp was also tested (FIG. 4). No significant change of the production was observed when 5 mM of L-Trp was added to the transformation system.


[0983] The temperature effects on the whole cell nitration were also investigated. In vitro studies indicated TB14 was active at temperatures between 10 to 30° C. All previous experiments were performed at 20° C., Productivity of the whole cell system at four different fermentation temperatures (15° C., 20° C., 28° C. and 37° C.) at different time points was investigated (FIG. 5). The transformations at 15° C., 20° C. and 28° C. each resulted in product yield. At 28° C., product concentration was observed to be 700 μM after 24-hour fermentation. Interestingly, the optimal growth temperature of *E. coli*, 37° C., almost completely abolished the nitration transformation.

Production of Nitrated Tryptophan Analogues by Whole Cell Nitration System

[0984] A series of tryptophan analogues that can be nitrated by TxtE and its variants in vitro have been identified. In this example, the substrate scope of whole cell systems was investigated using these tryptophan analogues. These unnatural analogues generally compete with the native substrate L-Trp abundant in the TB medium in the whole cell transformation. However, data indicate that α -Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-Trp, 6-F-Trp, and 7-Me-Trp all were successfully nitrated using the whole cell nitration system. Similar to observations in the in vitro enzymatic reactions, whole cell-based nitration demonstrated the highest conversion rates with 4-Me-Trp, 5-Me-Trp and 5-F-Trp (FIG. 6). The substrate 5-Me-Trp product concentration reached approximately 250 μM after 24-hour fermentation, along with approximately 320 μM of nitrated tryptophan (FIG. 6). The following


nitro-tryptophan and nitro-tryptophan analogs can be synthesized using any of the methods delineated herein:

Example 3: Preparation of (S)-2-amino-3-(5-methyl-4-nitro-1H-iodol-3-yl)propanoic acid (3)




[0985] Example 3 can be prepared from 5-methylindole as shown above.

Example 4: Preparation of (S)-2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl)propanoic acid (4)




[0986] Example 4 can be prepared from 6-methylindole as shown above.

Example 5: Preparation of (S)-2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl)propanoic acid (5)




[0987] Example 5 can be prepared from 7-methylindole as shown above.

Example 6: Preparation of (S)-2-amino-3-(5-fluoro-4-nitro-1H-indol-3-yl)propanoic acid (6)




[0988] Example 6 can be prepared from 5-fluoroindole as shown above.

Example 7: Preparation of (S)-2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl)propanoic acid (7)




[0989] Example 7 can be prepared from 6-fluoroindole.

Example 8: Preparation of (S)-2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl)propanoic acid (8)




[0990] Example 8 can be prepared from 7-fluoroindole as shown above.

Example 9: Preparation of (S)-2-amino-3-(4-fluoro-7-nitro-1H-indol-3-yl)propanoic acid (9)




[0991] Example 9 can be prepared from 4-fluoroindole as shown above.

Example 10: Preparation of (S)-2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl)propanoic acid




[0992] Example 10 can be prepared from 5-chloroindole as shown above.

Example 11: Preparation of (S)-2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl)propanoic acid (11)




[0993] Example 11 can be prepared from 6-chloroindole as shown above.

Example 12: Preparation of (S)-2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl)propanoic acid (12)




[0994] Example 12 can be prepared from 7-chloroindole as shown above.

Example 13: Preparation of (S)-2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl)propanoic acid (13)




[0995] Example 13 can be prepared from 4-chloroindole as shown above.

Example 14: Preparation of (S)-2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl)propanoic acid (14)




[0996] Example 14 can be prepared from 5-bromoindole as shown above.

Example 15: Preparation of (S)-2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl)propanoic acid (15)




[0997] Example 15 can be prepared from 6-bromoindole as shown.

Example 16: Preparation of (S)-2-amino-3-(7-bromo-4-nitro-1H-indol-3-yl)propanoic acid (16)




[0998] Example 16 can be prepared from 7-bromoindole as shown above.

Example 17: Preparation of (S)-2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl)propanoic acid (17)




[0999] Example 17 can be prepared from 4-bromoindole as shown above.

Example 18: Preparation of (S)-2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (18)




[1000] Example 18 can be prepared from 5-methoxyindole as shown above.

Example 19: Preparation of (S)-2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (19)




[0999] Example 19 can be prepared from 6-methoxyindole as shown above.

Example 20: Preparation of (S)-2-amino-3-(7-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (20)




[1001] Example 20 can be prepared from 7-methoxyindole as shown above.

Example 21: Preparation of (S)-2-amino-3-(4-methoxy-7-nitro-1H-indol-3-yl)propanoic acid (21)




[1002] Example 21 can be prepared from 4-methoxyindole as shown above.

Example 22: Preparation of (S)-2-amino-3-(5-amino-4-nitro-1H-indol-3-yl)propanoic acid (22)




[1003] Example 22 can be prepared from 5-aminoindole as shown above.

Example 23: Preparation of (S)-2-amino-3-(6-amino-4-nitro-1H-indol-3-yl)propanoic acid (23)




[1004] Example 23 can be prepared from 6-aminoindole as shown above.

Example 24: Preparation of (S)-2-amino-3-(7-amino-4-nitro-1H-indol-3-yl)propanoic acid (24)




[1005] Example 24 can be prepared from 7-aminoindole as shown above.

Example 25: Preparation of (S)-2-amino-3-(4-amino-7-nitro-1H-indol-3-yl)propanoic acid (25)





[1006] Example 25 can be prepared from 4-aminoindole as shown above.

Example 26: Preparation of (S)-2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid (26)




[1007] Example 26 can be prepared from (S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid as shown above.

Example 27: Preparation of (S)-2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid (27)




[1008] Example 27 can be prepared from 6-hydroxyindole as shown above.

Example 28: Preparation of (S)-2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid (25)




[1009] Example 28 can be prepared from 7-hydroxyindole as shown above.

Example 29: Preparation of (S)-2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl)propanoic acid (29)




[1010] Example 29 can be prepared from 4-hydroxyindole as shown above.

Example 30: Preparation of (S)-2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid (30)




[1011] Example 30 can be prepared from 5-phenylindole as shown above.

Example 31: Preparation of (S)-2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid (31)




[1012] Example 31 can be prepared from 6-phenylindole as shown above.


Example 32: Preparation of (S)-2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (32)



-continued




-continued






[1013] Example 32 can be prepared from 7-phenylindole as shown above.

Example 33: Preparation of (S)-2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid (33)





[1015] Example 34 can be prepared from 5-cyclopropylindole as shown above.

Example 35: Preparation of (S)-2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (35)




[1014] Example 33 can be prepared from 4-phenylindole as shown above.

Example 34: Preparation of (S)-2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (34)




[1016] Example 35 can be prepared from 6-cyclopropylindole as shown above.

Example 36: Preparation of (S)-2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (36)




[1017] Example 36 can be prepared from 7-cyclopropylindole as shown above.

Example 37: Preparation of (S)-2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid (37)




[1018] Example 37 can be prepared from 4-cyclopropylindole as shown above.

Example 38: Preparation of (S)-2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid (38)




[1019] Example 38 can be prepared from 5-vinylindole as shown above.

Example 39: Preparation of (S)-2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid (39)




[1020] Example 39 can be prepared from 6-vinylindole as shown above.

Example 40: Preparation of (S)-2-amino-3-(4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid (40)




Example 42: Preparation of (S)-2-amino-3-(5-ethyl-4-nitro-1H-indol-3-yl)propanoic acid (42)



[1021] Example 40 can be prepared from 7-vinylindole as shown above.


Example 41: Preparation of (S)-2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid (41)



[1022] Example 41 can be prepared from 4-vinylindole as shown above.


[1023] Example 42 can be prepared from 5-ethylindole as shown above.

Example 43: Preparation of (S)-2-amino-3-(6-ethyl-4-nitro-1H-indol-3-yl)propanoic acid (43)




[1024] Example 43 can be prepared from 6-ethylindole as shown above.

Example 44: Preparation of (S)-2-amino-3-(7-ethyl-4-nitro-1H-indol-3-yl)propanoic acid (44)




[1025] Example 44 can be prepared from 7-ethylindole as shown above.

Example 45: Preparation of (S)-2-amino-3-(4-ethyl-7-nitro-1H-indol-3-yl)propanoic acid (45)




[1026] Example 45 can be prepared from 4-ethylindole as shown above.

Example 46: Preparation of (S)-2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (46)




[1027] Example 46 can be prepared from 5-morpholinooindole as shown above.


Example 47: Preparation of (S)-2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (47)



-continued




Example 49: Preparation of (S)-2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid (49)




[1028] Example 47 can be prepared from 6-morpholinoindole as shown above.

Example 48: Preparation of (S)-2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (48)



[1030] Example 49 can be prepared from 4-morpholinoindole as shown above.


Example 50: Preparation of (S)-2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (50)



[1029] Example 48 can be prepared from 7-morpholinoindole as shown above.


[1031] Example 50 can be prepared from 5-(methylthio)indole as shown above.

Example 51: Preparation of (S)-2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (51)




[1032] Example 51 can be prepared from 6-(methylthio)indole as shown above.

Example 52: Preparation of (S)-2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (52)




[1033] Example 52 can be prepared from 7-(methylthio)indole as shown above.

Example 53: Preparation of (S)-2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid (53)




[1034] Example 53 can be prepared from 4-(methylthio)indole as shown above.

Example 54: Preparation of (S)-2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (54)




[1035] Example 54 can be prepared from 5-(pyridin-4-yl)indole as shown above.

Example 55: Preparation of (S)-2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (55)




[1036] Example 55 can be prepared from 6-(pyridin-4-yl)indole as shown above.

Example 56: Preparation of (S)-2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (56)




-continued




Example 56 can be prepared from 7-(pyridin-4-yl)indole as shown above.

Example 57: Preparation of (S)-2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (57)




[1037] Example 57 can be prepared from 4-(pyridin-4-yl)indole as shown above.


Example 58: Preparation of 2-amino-3-(5-methyl-4-nitro-1H-indol-3-yl)propanoic acid (58)



-continued




-continued




[1038] Example 58 can be prepared from 2-amino-3-(5-methyl-1H-indol-3-yl)propanoic acid as shown above.

Example 59: Preparation of 2-amino-3-(6-methyl-4-nitro-1H-indol-3-yl)propanoic acid (59)




[1039] Example 59 can be prepared from 6-methylindole as shown above.

Example 60: Preparation of 2-amino-3-(7-methyl-4-nitro-1H-indol-3-yl)propanoic acid (60)




[1040] Example 60 can be prepared from 2-amino-3-(7-methyl-1H-indol-3-yl)propanoic acid as shown above.

Example 61: Preparation of 2-amino-3-(4-methyl-7-nitro-1H-indol-3-yl)propanoic acid (61)




[1041] Example 61 was prepared from 2-amino-3-(4-methyl-1H-indol-3-yl)propanoic acid as shown above.


Example 62: Preparation of 2-amino-3-(6-fluoro-4-nitro-1H-indol-3-yl)propanoic acid (62)



-continued




-continued




[1042] Example 62 can be prepared from 2-amino-3-(6-fluoro-1H-indol-3-yl)propanoic acid as shown above.

Example 63: Preparation of 2-amino-3-(7-fluoro-4-nitro-1H-indol-3-yl)propanoic acid (63)




[1043] Example 63 can be prepared from 7-fluoroindole as shown above.

Example 64: Preparation of 2-amino-3-(4-fluor-7-nitro-1H-indol-3-yl)propanoic acid (64)




[1044] Example 64 can be prepared from 2-amino-3-(4-fluoro-1H-indol-3-yl)propanoic acid as shown above.

Example 65: Preparation of 2-amino-3-(5-chloro-4-nitro-1H-indol-3-yl)propanoic acid (65)




[1045] Example 65 can be prepared from 5-chromandiol as shown above.

Example 66: Preparation of 2-amino-3-(6-chloro-4-nitro-1H-indol-3-yl)propanoic acid (66)




-continued




[1046] Example 66 can be prepared from 6-chloroindole as shown above.

Example 67: Preparation of 2-amino-3-(7-chloro-4-nitro-1H-indol-3-yl)propanoic acid (67)




[1047] Example 67 can be prepared from 7-chloroindole as shown above.

Example 68: Preparation of 2-amino-3-(4-chloro-7-nitro-1H-indol-3-yl)propanoic acid (68)




-continued




[1048] Example 68 can be prepared from 4-chloroindol as shown above.

Example 69: Preparation of 2-amino-3-(5-bromo-4-nitro-1H-indol-3-yl)propanoic acid (69)




[1049] Example 69 can be prepared from 5-bromoindole as shown above.

Example 70: Preparation of 2-amino-3-(6-bromo-4-nitro-1H-indol-3-yl)propanoic acid (70)







-continued



[1050] Example 70 can be prepared from 6-bromoindole as shown above.

Example 71: Preparation of 2-nitro-3-(7-bromo-4-nitro-1H-indol-3-yl)propanoic acid (71)


-continued



71




[1051] Example 71 can be prepared from 7-bromoindole as shown above.

Example 72: Preparation of 2-amino-3-(4-bromo-7-nitro-1H-indol-3-yl)propanoic acid (72)



[1052] Example 72 can be prepared from 4-bromoindole as shown above.


Example 73: Preparation of 2-amino-3-(5-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (73)




73

Example 73 can be prepared from 5-methoxyindole as shown above.

Example 74: Preparation of 2-amino-3-(6-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (74)




-continued




[1053] Example 74 can be prepared from 6-methoxyindole as shown above.

Example 76: Preparation of 2-amino-3-(4-methoxy-7-nitro-1H-Indol-3-yl)propanoic acid (76)




Example 75: Preparation of 2-nitro-3-(7-methoxy-4-nitro-1H-indol-3-yl)propanoic acid (75)



[1054] Example 75 can be prepared from 7-methoxyindole as shown above.


[1055] Example 76 can be prepared from 4-methoxyindole as shown above.

Example 77: Preparation of 2-amino-3-(5-amino-4-nitro-1H-indol-3-yl)propanoic acid (77)




[1056] Example 77 can be prepared from 5-aminoindole as shown above.

Example 78: Preparation of 2-amino-3-(6-amino-4-nitro-1H-indol-3-yl)propanoic acid (78)




[1057] Example 78 can be prepared from 6-aminoindole as shown above.

Example 79: Preparation of 2-amino-3-(7-amino-4-nitro-1H-indol-3-yl)propanoic acid (79)




[1058] Example 79 can be prepared from 7-aminoindole as shown above.

Example 80: Preparation of 2-amino-3-(4-amino-7-nitro-1H-indol-3-yl)propanoic acid (80)




[1059] Example 80 can be prepared from 4-aminoindole as shown above.

Example 81: Preparation of 2-amino-3-(5-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid (81)




[1060] Example 81 can be prepared from 5-hydroxyindole as shown above.

Example 82: Preparation of 2-amino-3-(6-hydroxy-4-nitro-1H-indol-3-yl) propanoic acid (82)




[1061] Example 82 can be prepared from 6-hydroxyindole as shown above.

Example 83: Preparation of 2-amino-3-(7-hydroxy-4-nitro-1H-indol-3-yl)propanoic acid (83)




[1062] Example 83 can be prepared from 7-hydroxyindole as shown above.

Example 84: Preparation of 2-amino-3-(4-hydroxy-7-nitro-1H-indol-3-yl)propanoic acid (84)




[1063] Example 84 can be prepared from 4-hydroxyindole as shown above.

[1064] Example 85: Preparation of 2-amino-3-(4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid (85)




[1065] Example 85 can be prepared from 5-phenylindole as shown above.


Example 86: Preparation of 2-amino-3-(4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid (86)



-continued





87



[1067] Example 87 can be prepared from 7-phenylindole as shown above.


Example 88: Preparation of 2-amino-3-(7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid (88)



86


[1066] Example 86 can be prepared from 6-phenylindole as shown above.

Example 87: Preparation of 2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (87)




[1068] Example 88 can be prepared from 4-phenylindole as shown above.

Example 89: Preparation of 2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (89)




-continued




[1069] Example 89 can be prepared from 5-cyclopropylindole as shown above.

Example 90: Preparation of 2-amino-3-(6-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (90)




[1070] Example 90 can be prepared from 6-cyclopropylindole as shown above.

Example 91: Preparation of 2-amino-3-(7-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (91)




[1071] Example 91 can be prepared from 7-cyclopropylindole as shown above.

Example 92: Preparation of 2-amino-3-(4-cyclopropyl-7-nitro-1H-indol-3-yl)propanoic acid (92)




[1072] Example 92 can be prepared from 4-cyclopropylindole as shown above.

Example 93: Preparation of 2-amino-3-(4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid (93)




[1073] Example 93 can be prepared from 5-vinylindole as shown above.

Example 94: Preparation of 2-amino-3-(4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid (94)




[1074] Example 94 can be prepared from 6-vinylindole as shown above.

Example 95: Preparation of 2-amino-3-(4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (95)




[1075] Example 95 can be prepared from 7-vinylindole as shown above.

Example 96: Preparation of 2-amino-3-(7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid (96)




[1076] Example % can be prepared from 4-vinylindole as shown above.

Example 97: Preparation of 2-amino-3-(5-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid (97)




[1077] Example 97 can be prepared from 5-ethylindole as shown above.

Example 97: Preparation of 2-amino-3-(6-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid (98)




[1078] Example 98 can be prepared from 6-ethylindole as shown above.

Example 99: Preparation of 2-amino-3-(7-ethynyl-4-nitro-1H-indol-3-yl)propanoic acid (99)




[1079] Example 99 can be prepared from 7-ethylindole as shown above.

Example 100: Preparation of 2-amino-3-(4-phenyl-7-nitro-1H-indol-3-yl)propanoic acid (100)




[1080] Example 100 can be prepared from 4-ethylindole as shown above.


Example 101: Preparation of 2-amino-3-(5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (101)



-continued





102





[1082] Example 102 can be prepared from 6-morpholinoindole as shown above.

Example 103: Preparation of 2-amino-3-(7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (103)



[1081] Example 101 can be prepared from 5-morpholinoindole as shown above,


Example 102: Preparation of 2-amino-3-(6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (102)



103


[1083] Example 103 can be prepared from 7-morpholinoindole as shown above.

Example 104: Preparation of 2-amino-3-(4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid (104)




[1084] Example 104 can be prepared from 4-morpholinoindole as shown above.

Example 105: Preparation of 2-amino-3-(5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (105)




[1085] Example 105 can be prepared from 5-(methylthio)indole as shown above.

Example 106: Preparation of 2-amino-3-(6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (106)




[1086] Example 106 can be prepared from 6-(methylthio)indole as shown above.

Example 107: Preparation of 2-amino-3-(7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (107)




[1087] Example 107 can be prepared from 7-(methylthio)indole as shown above.

Example 108: Preparation of 2-amino-3-(4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid (108)




[1088] Example 108 can be prepared from 4-(methylthio)indole as shown above.

Example 109: Preparation of 2-amino-3-(4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (109)




Example 110: Preparation of 2-amino-3-(4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (110)



[1089] Example 109 can be prepared from 5-(pyridin-4-yl)indole as shown above.


[1090] Example 110 can be prepared from 6-(pyridin-4-yl)indole as shown above.

Example 111: Preparation of 2-amino-3-(4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (111)




[1089] Example 109 can be prepared from 5-(pyridin-4-yl)indole as shown above.

-continued



111


-continued



113

[1091] Example 111 can be prepared from 7-(pyridin-4-yl)indole as shown above.



Example 112: Preparation of 2-amino-3-(7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (112)



112

[1092] Example 112 can be prepared from 4-(pyridin-4-yl)indol as shown above.


Example 113: Preparation of 2-amino-3-(1,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (113)



114


[1094] Example 114 can be prepared from 1,6-dimethyl-1H-indole as shown above.

Example 115: Preparation of 2-amino-3-(1,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (115)




[1095] Example 115 can be prepared from 1,7-dimethyl-1H-indole as shown above.

Example 116: Preparation of 2-amino-3-(1,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (116)




[1096] Example 116 can be prepared from 1,4-dimethyl-1H-indole as shown above.

Example 117: Preparation of 2-amino-3-(6-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (117)




[1097] Example 117 can be prepared from 6-fluoro-1-methyl-1H-indole as shown above.

Example 118: Preparation of 2-amino-3-(7-fluoro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (118)




[1098] Example 118 can be prepared from 7-fluoro-1-methyl-indole as shown above.

Example 119: Preparation of 2-amino-3-(4-fluoro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (119)




[1099] Example 119 can be prepared from 4-fluoro-1-methyl-indole as shown above.

Example 120: Preparation of 2-amino-3-(5-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (120)




-continued




[1100] Example 120 can be prepared from 5-chloro-1-methyl-indole as shown above.

Example 121: Preparation of 2-amino-3-(6-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (121)




[1101] Example 121 can be prepared from 6-chloro-1-methyl-indole as shown above.

Example 122: Preparation of 2-amino-3-(7-chloro-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (122)




-continued




[1102] Example 122 can be prepared from 7-chloro-1-methyl-indole as shown above.

Example 123: Preparation of 2-amino-3-(4-chloro-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (123)




[1103] Example 123 can be prepared from 4-chloro-1-methyl-indole as shown above.

Example 124: Preparation of 2-amino-3-(5-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (124)




-continued




[1104] Example 124 can be prepared from 5-bromo-1-methyl-indole as shown above.

Example 125: Preparation of 2-amino-3-(6-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (125)




[1105] Example 125 can be prepared from 6-bromo-1-methyl-indole as shown above.

Example 126: Preparation of 2-amino-3-(7-bromo-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (126)





-continued



[1106] Example 126 can be prepared from 7-bromo-1-methyl-indole as shown above.

Example 127: Preparation of 2-amino-3-(4-bromo-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid
(127)

-continued




[1107] Example 127 can be prepared from 4-bromo-1-methyl-indole as shown above.

Example 128: Preparation of 2-amino-3-(5-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (128)


[1108] Example 128 can be prepared from 5-methoxy-1-methyl-indole as shown above.

Example 129: Preparation of 2-amino-3-(6-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (129)




[1109] Example 129 can be prepared from 6-methoxy-1-methyl-indole as shown above.

Example 130: Preparation of 2-amino-3-(7-methoxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (130)





Example 132: Preparation of 2-amino-3-(5-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (132)





[1110] Example 130 can be prepared from 7-methoxy-1-methyl-indole as shown above.

Example 131: Preparation of 2-amino-3-(4-methoxy-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (131)




[1112] Example 132 can be prepared from 5-amino-1-methyl-indole as shown above.

Example 133: Preparation of 2-amino-3-(6-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (133)




[1111] Example 131 can be prepared from 4-methoxy-1-methyl-indole as shown above.

-continued




-continued




[1113] Example 133 can be prepared from 6-amino-1-methyl-indole as shown above.

Example 134: Preparation of 2-amino-3-(7-amino-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (134)




[1114] Example 134 can be prepared from 7-amino-1-methyl-indole as shown above.

Example 135: Preparation of 2-amino-3-(4-amino-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (135)




[1115] Example 135 can be prepared from 4-amino-1-methyl-indole as shown above.


Example 136: Preparation of 2-amino-3-(5-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (136)



[1116] Example 136 can be prepared from 5-hydroxy-1-methyl-indole as shown above.


Example 137: Preparation of 2-amino-3-(6-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (137)





[1117] Example 137 can be prepared from 6-hydroxy-1-methyl-indole as shown above.


Example 138: Preparation of 2-amino-3-(7-hydroxy-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (138)




[1118] Example 138 can be prepared from 7-hydroxy-1-methyl-indole as shown above.

[1120] Example 140 can be prepared from 5-phenyl-1-methyl-indole as shown above.

Example 141: Preparation of 2-amino-3-(1-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid (141)




-continued



142


[1122] Example 142 can be prepared from 7-phenyl-1-methyl-indole as shown above.



143


[1121] Example 141 can be prepared from 6-phenyl-1-methyl-indole as shown above.

Example 142: Preparation of 2-amino-3-(1-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (142)




[1123] Example 143 can be prepared from 4-phenyl-1-methyl-indole as shown above.

Example 144: Preparation of 2-amino-3-(5-cyclopropyl-4-nitro-1H-indol-3-yl)propanoic acid (144)




[1124] Example 144 can be prepared from 5-cyclopropyl-1-methyl-indole as shown above.

Example 145: Preparation of 2-amino-3-(6-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (145)




[1125] Example 145 can be prepared from 6-cyclopropyl-1-methyl-indole as shown above.

Example 146: Preparation of 2-amino-3-(7-cyclopropyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (146)




[1126] Example 146 can be prepared from 7-cyclopropyl-1-methyl-indole as shown above.

Example 147: Preparation of 2-amino-3-(4-cyclopropyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (147)




[1127] Example 147 can be prepared from 4-cyclopropyl-1-methyl-indole as shown above.

Example 148: Preparation of 2-amino-3-(1-methyl-4-nitro-5-viny-1H-indol-3-yl)propanoic acid (148)




[1128] Example 148 can be prepared from 5-vinyl-1-methyl-indole as shown above.

Example 149: Preparation of 2-amino-3-(1-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid (149)




[1129] Example 149 can be prepared from 6-vinyl-1-methyl-indole as shown above.

Example 150: Preparation of 2-amino-3-(1-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid (150)




[1130] Example 150 can be prepared from 7-vinyl-1-methyl-indole as shown above.

Example 151: Preparation of 2-amino-3-(1-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid (151)





[1131] Example 151 can be prepared from 4-vinyl-1-methyl-indole as shown above.

Example 152: Preparation of 2-amino-3-(5-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (152)




-continued




[1133] Example 153 can be prepared from 6-ethynyl-1-methyl-indole as shown above.

Example 154: Preparation of 2-amino-3-(7-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (154)




[1132] Example 152 can be prepared from 5-ethynyl-1-methyl-indole as shown above.

Example 153: Preparation of 2-amino-3-(6-ethynyl-1-methyl-4-nitro-1H-indol-3-yl)propanoic acid (153)




[1134] Example 154 can be prepared from 7-ethynyl-1-methyl-indole as shown above.


Example 155: Preparation of 2-amino-3-(4-ethynyl-1-methyl-7-nitro-1H-indol-3-yl)propanoic acid (155)



-continued






-continued




[1135] Example 155 can be prepared from 4-ethynyl-1-methyl-indole as shown above.

Example 156: Preparation of 2-amino-3-(1-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(156)




[1136] Example 156 can be prepared from 5-morpholino-1-methyl-indole as shown above.

Example 157: Preparation of 2-amino-3-(1-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(157)




[1137] Example 157 can be prepared from 6-morpholino-1-methyl-indole as shown above.

Example 158: Preparation of 2-amino-3-(1-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(158)




[1138] Example 158 can be prepared from 7-morpholino-1-methyl-indole as shown above.

Example 159: Preparation of 2-amino-3-(1-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid (159)




[1139] Example 159 can be prepared from 4-morpholino-1-methyl-indole as shown above.

Example 160: Preparation of 2-amino-3-(1-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (160)




[1140] Example 160 can be prepared from 5-(methylthio)-1-methyl-indole as shown above.

Example 161: Preparation of 2-amino-3-(1-methyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (161)




[1141] Example 161 can be prepared from 6-(methylthio)-1-methyl-indole as shown above.

Example 162: Preparation of 2-amino-3-(1-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (162)




[1142] Example 162 can be prepared from 7-(methylthio)-1-methyl-indole as shown above.

Example 163: Preparation of 2-amino-3-(1-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid (163)




[1144] Example 164 can be prepared from 5-(pyridin-4-yl)-1-methyl-indole as shown above.

Example 165: Preparation of 2-amino-3-(1-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (165)




[1143] Example 163 can be prepared from 4-(methylthio)-1-methyl-indole as shown above.

Example 164: Preparation of 2-amino-3-(1-methyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (164)




[1145] Example 165 can be prepared from 6-(pyridin-4-yl)-1-methyl-indole as shown above.

Example 166: Preparation of 2-amino-3-(1-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (166)




-continued




[1146] Example 166 can be prepared from 7-(pyridin-4-yl)-1-methyl-indole as shown above.

Example 167: Preparation of 2-amino-3-(1-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propionic acid (167)




[1147] Example 167 can be prepared from 4-(pyridin-4-yl)-1-methyl-indole as shown above.

Example 168: Preparation of 2-amino-3-(2,5-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (168)




-continued




[1148] Example 168 can be prepared from 2,5-dimethyl-1H-indole as shown above.


Example 169: Preparation of 2-amino-3-(2,6-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (169)



[1149] Example 169 can be prepared from 2,6-dimethyl-1H-indole as shown above.


Example 170: Preparation of 2-wino-3-(2,7-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (170)





[1150] Example 170 can be prepared from 2,7-dimethyl-1H-indole as shown above.


Example 171: Preparation of 2-amino-3-(2,4-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (171)



[1151] Example 171 can be prepared from 2,4-dimethyl-1H-indole as shown above.


[1153] Example 173 can be prepared from 7-fluoro-2-methyl-indole as shown above.

Example 174: Preparation of 2-amino-3-(4-fluoro-2-methyl-7-nitro-1H-indole-3-yl)propanoic acid
(174)




[1154] Example 174 can be prepared from 4-fluoro-2-methyl-indole as shown above.

Example 175: Preparation of 2-amino-3-(5-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(175)




-continued




[1155] Example 175 can be prepared from 5-chloro-2-methyl-indole as shown above.

Example 176: Preparation of 2-amino-3-(6-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(176)




[1156] Example 176 can be prepared from 6-chloro-2-methyl-indole as shown above.

Example 177: Preparation of 2-amino-3-(7-chloro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(177)




-continued




[1157] Example 177 can be prepared from 7-chloro-2-methyl-indole as shown above.

Example 178: Preparation of 2-amino-3-(4-chloro-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid
(178)




[1158] Example 178 can be prepared from 4-chloro-2-methyl-indole as shown above.

Example 179: Preparation of 2-amino-3-(5-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(179)




[1159] Example 179 can be prepared from 5-bromo-2-methyl-indole as shown above.

Example 180: Preparation of 2-amino-3-(6-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(180)





[1160] Example 180 can be prepared from 6-bromo-2-methyl-indole as shown above.

Example 181: Preparation of 2-amino-3-(7-bromo-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (191)



-continued






[1161] Example 181 can be prepared from 7-bromo-2-methyl-indole as shown above.

Example 182: Preparation of 2-amino-3-(4-bromo-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid (182)


[1162] Example 182 can be prepared from 4-bromo-2-methyl-indole as shown above.


Example 183: Preparation of 2-amino-3-(5-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (183)



[1163] Example 183 can be prepared from 5-methoxy-2-methyl-indole as shown above.


Example 184: Preparation of 2-amino-3-(6-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (184)






[1164] Example 184 can be prepared from 6-methoxy-2-methyl-indole as shown above.

Example 185: Preparation of 2-amino-3-(7-methoxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (185)




[1165] Example 185 can be prepared from 7-methoxy-2-methyl-indole as shown above.

Example 186: Preparation of 2-amino-3-(4-methoxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid (186)




[1166] Example 186 can be prepared from 4-methoxy-2-methyl-indole as shown above.

Example 187: Preparation of 2-amino-3-(5-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (187)




[1167] Example 187 can be prepared from 5-amino-2-methyl-indole as shown above.

Example 188: Preparation of 2-amino-3-(6-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (188)




-continued




[1169] Example 189 can be prepared from 7-amino-2-methyl-indole as shown above.

Example 190: Preparation of 2-amino-3-(4-amino-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid (190)




[1168] Example 188 can be prepared from 6-amino-2-methyl-indole as shown above.


Example 189: Preparation of 2-amino-3-(7-amino-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (189)




[1170] Example 190 can be prepared from 4-amino-2-methyl-indole as shown above.

Example 191: Preparation of 2-amino-3-(5-hydroxy-2-methyl-4-nitro-1H-Indol-3-yl)propanoic acid (191)






Example 193: Preparation of 2-amino-3-(7-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (193)



[1171] Example 191 can be prepared from 5-hydroxy-2-methyl-indole as shown above.


Example 192: Preparation of 2-amino-3-(6-hydroxy-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (192)




[1172] Example 192 can be prepared from 6-hydroxy-2-methyl-indole as shown above.

[1173] Example 193 can be prepared from 7-hydroxy-2-methyl-indole as shown above.


Example 194: Preparation of 2-amino-3-(4-hydroxy-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid (194)



-continued





-continued




[1174] Example 194 can be prepared from 4-hydroxy-2-methyl-indole as shown above.

Example 195: Preparation of 2-amino-3-(2-methyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid (195)





[1176] Example 196 can be prepared from 6-phenyl-2-methyl-indole as shown above.

Example 197: Preparation of 2-amino-3-(2-methyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (197)




[1175] Example 195 can be prepared from 5-phenyl-2-methyl-indole as shown above.

Example 196: Preparation of 2-amino-3-(2-methyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid (196)




-continued





[1177] Example 197 can be prepared from 7-phenyl-2-methyl-indole as shown above.

Example 198: Preparation of 2-amino-3-(2-methyl-7-nitro-4-phenyl-1H-indol-3-yl)propanoic acid (19)





[1178] Example 198 can be prepared from 4-phenyl-2-methyl-indole as shown above.

Example 199: Preparation of 2-amino-3-(5-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (199)




[1179] Example 199 can be prepared from 5-cyclopropyl-2-methyl-indole as shown above.


Example 200: Preparation of 2-amino-3-(6-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (200)



-continued




Example 202: Preparation of 2-amino-3-(4-cyclopropyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid (202)



[1180] Example 200 can be prepared from 6-cyclopropyl-2-methyl-indole as shown above.


Example 201: Preparation of 2-amino-3-(7-cyclopropyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (201)



[1181] Example 201 can be prepared from 7-cyclopropyl-2-methyl-indole as shown above.


[1182] Example 202 can be prepared from 4-cyclopropyl-2-methyl-indole as shown above.

Example 203: Preparation of 2-amino-3-(2-methyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid (203)





[1183] Example 203 can be prepared from 5-vinyl-2-methyl-indole as shown above.

Example 204: Preparation of 2-amino-3-(2-methyl-4-nitro-6-vinyl-1H-indol-3-yl)propanoic acid (204)




-continued





[1184] Example 204 can be prepared from 6-vinyl-2-methyl-indole as shown above.

Example 205: Preparation of 2-amino-3-(2-methyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid (205)




[1185] Example 205 can be prepared from 7-vinyl-2-methyl-indole as shown above.


Example 206: Preparation of 2-amino-3-(2-methyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid (206)




[1186] Example 206 can be prepared from 4-vinyl-2-methyl-indole as shown above.

Example 207: Preparation of 2-amino-3-(5-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid (207)






Example 209: Preparation of 2-amino-3-(7-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(209)



[1187] Example 207 can be prepared from 5-ethynyl-2-methyl-indole as shown above.


Example 208: Preparation of 2-amino-3-(6-ethynyl-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid
(208)




[1188] Example 208 can be prepared from 6-ethynyl-2-methyl-indole as shown above.

[1189] Example 209 can be prepared from 7-ethynyl-2-methyl-indole as shown above.


Example 210: Preparation of 2-amino-3-(4-ethynyl-2-methyl-7-nitro-1H-indol-3-yl)propanoic acid
(210)



-continued




-continued




[1190] Example 210 can be prepared from 4-ethynyl-2-methyl-indole as shown above.

Example 211: Preparation of 2-amino-3-(2-methyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(211)





[1191] Example 211 can be prepared from 5-morpholino-2-methyl-indole as shown above.

Example 212: Preparation of 2-amino-3-(2-methyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(212)




[1192] Example 212 can be prepared from 6-morpholino-2-methyl-indole as shown above.


Example 213: Preparation of 2-amino-3-(2-methyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid
(213)



-continued




Example 215: Preparation of 2-amino-3-(2-methyl-5-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (215)




[1193] Example 213 can be prepared from 7-morpholino-2-methyl-indole as shown above.

Example 214: Preparation of 2-amino-3-(2-methyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid (214)




[1195] Example 215 can be prepared from 5-(methylthio)-2-methyl-indole as shown above.

Example 216: Preparation of 2-amino-3-(2-methyl-6-(methylthio)-4-nitro-1H-4-indol-3-yl)propanoic acid (216)




[1194] Example 214 can be prepared from 4-morpholino-2-methyl-indole as shown above.

[1196] Example 216 can be prepared from 6-(methylthio)-2-methyl-indole as shown above.




Example 217: Preparation of 2-amino-3-(2-methyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (217)




[1198] Example 218 can be prepared from 4-(methylthio)-2-methyl-indole as shown above.

Example 219: Preparation of 2-amino-3-(2-ethyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (219)




[1197] Example 217 can be prepared from 7-(methylthio)-2-methyl-indole as shown above.

Example 218: Preparation of 2-amino-3-(2-methyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid (218)




[1199] Example 219 can be prepared from 5-(pyridin-4-yl)-2-methyl-indole as shown above.


Example 220: Preparation of 2-amino-3-(2-methyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (220)



-continued





Example 222: Preparation of 2-amino-3-(2-methyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (222)



[1200] Example 220 can be prepared from 6-(pyridin-4-yl)-2-methyl-indole as shown above.


Example 221: Preparation of 2-amino-3-(2-methyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (221)



[1201] Example 221 can be prepared from 7-(pyridin-4-yl)-2-methyl-indole as shown above.


[1202] Example 222 can be prepared from 4-(pyridin-4-yl)-2-methyl-indole as shown above.

Example 223: Preparation of 2-amino-3-(1,2,5-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid (223)




[1203] Example 223 can be prepared from 1,2,5-trimethyl-1H-indole as shown above.

Example 224: Preparation of 2-amino-3-(1,2,6-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid (224)




[1204] Example 224 can be prepared from 1,2,6-trimethyl-1H-indole as shown above.

Example 225: Preparation of 2-amino-3-(1,2,7-trimethyl-4-nitro-1H-indol-3-yl)propanoic acid (225)




[1205] Example 225 can be prepared from 1,2,7-trimethyl-1H-indole as shown above.

Example 226: Preparation of 2-amino-3-(1,2,4-trimethyl-7-nitro-1H-indol-3-yl)propanoic acid (226)




[1206] Example 226 can be prepared from 1,2,4-trimethyl-1H-indole as shown above.

Example 227: Preparation of 2-amino-3-(6-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (227)




[1207] Example 227 can be prepared from 6-fluoro-1,2-dimethyl-1H-indole as shown above.

Example 228: Preparation of 2-amino-3-(7-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (228)





-continued





[1209] Example 229 can be prepared from 4-fluoro-1,2-dimethyl-indole as shown above.

Example 230: Preparation of 2-amino-3-(5-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (230)




[1208] Example 228 can be prepared from 7-fluoro-1,2-dimethyl-indole as shown above.


Example 229: Preparation of 2-amino-3-(4-fluoro-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (229)



[1210] Example 230 can be prepared from 5-chloro-1,2-dimethyl-indole as shown above.


Example 231: Preparation of 2-amino-3-(6-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (231)





[1211] Example 231 can be prepared from 6-chloro-1,2-dimethyl-indole as shown above.


Example 232: Preparation of 2-amino-3-(7-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (232)




[1212] Example 232 can be prepared from 7-chloro-1,2-dimethyl-indole as shown above.

[1213] Example 233 can be prepared from 4-chloro-1,2-dimethyl-indole as shown above.


Example 234: Preparation of 2-amino-3-(5-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (234)



-continued




-continued




[1214] Example 234 can be prepared from 5-bromo-1,2-dimethyl-indole as shown above.

Example 235: Preparation of 2-amino-3-(6-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid
(235)




[1215] Example 235 can be prepared from 6-bromo-1,2-dimethyl-indole as shown above.

Example 236: Preparation of 2-amino-(7-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid
(236)




[1216] Example 236 can be prepared from 7-bromo-1,2-dimethyl-indole as shown above.

Example 237: Preparation of 2-amino-3-(4-bromo-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid
(237)




[1217] Example 237 can be prepared from 4-bromo-1,2-dimethyl-indole as shown above.


Example 238: Preparation of 2-amino-3-(5-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (238)



-continued




239




[1218] Example 238 can be prepared from 5-methoxy-1,2-dimethyl-indole as shown above.

Example 239: Preparation of 2-amino-3-(6-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (239)




[1219] Example 239 can be prepared from 6-methoxy-1,2-dimethyl-indole as shown above.


Example 240: Preparation of 2-amino-3-(7-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (240)




[1220] Example 240 can be prepared from 7-methoxy-1,2-dimethyl-indole as shown above.

Example 241: Preparation of 2-amino-3-(4-methoxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (241)






Example 243: Preparation of 2-amino-3-(6-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (243)




[1221] Example 241 can be prepared from 4-methoxy-1,2-dimethyl-indole as shown above.

Example 242: Preparation of 2-amino-3-(5-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (242)




[1223] Example 243 can be prepared from 6-amino-1,2-dimethyl-indole as shown above.

Example 244: Preparation of 2-amino-3-(7-amino-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (244)




[1222] Example 242 can be prepared from 5-amino-1,2-dimethyl-indole as shown above.

-continued




-continued




[1224] Example 244 can be prepared from 7-amino-1,2-dimethyl-indole as shown above.

Example 245: Preparation of 2-amino-3-(4-amino-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (245)




[1225] Example 245 can be prepared from 4-amino-1,2-dimethyl-indole as shown above.

Example 246: Preparation of 2-amino-3-(5-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (246)




[1226] Example 246 can be prepared from 5-hydroxy-1,2-dimethyl-indole as shown above.

Example 247: Preparation of 2-amino-3-(6-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (247)




[1227] Example 247 can be prepared from 6-hydroxy-1,2-dimethyl-indole as shown above.


Example 248: Preparation of 2-amino-3-(7-hydroxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (248)



-continued




249





[1228] Example 248 can be prepared from 7-hydroxy-1,2-dimethyl-indole as shown above.

Example 249: Preparation of 2-amino-3-(4-hydroxy-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (249)



[1229] Example 249 can be prepared from 4-hydroxy-1,2-dimethyl-indole as shown above.


Example 250: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-5-phenyl-1H-indol-3-yl)propanoic acid (250)






250

[1230] Example 250 can be prepared from 5-phenyl-1,2-dimethyl-indole as shown above.


Example 251: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-6-phenyl-1H-indol-3-yl)propanoic acid (251)







[1231] Example 251 can be prepared from 6-phenyl-1,2-dimethyl-indole as shown above.

Example 252: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (253)




[1232] Example 252 can be prepared from 7-phenyl-1,2-dimethyl-indole as shown above.

Example 253: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-7-phenyl-1H-indol-3-yl)propanoic acid (250)




[1233] Example 253 can be prepared from 4-phenyl-1,2-dimethyl-indole as shown above.


Example 254: Preparation of 2-amino-3-(5-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (254)



-continued




[1235] Example 255 can be prepared from 6-cyclopropyl-1,2-dimethyl-indole as shown above.




[1234] Example 254 can be prepared from 5-cyclopropyl-1,2-dimethyl-indole as shown above.


Example 255: Preparation of 2-amino-3-(6-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (255)




Example 256: Preparation of 2-amino-3-(7-cyclopropyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (256)




[1236] Example 256 can be prepared from 7-cyclopropyl-1,2-dimethyl-indole as shown above.




Example 257: Preparation of 2-amino-3-(4-cyclopropyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (257)



-continued




[1238] Example 258 can be prepared from 5-vinyl-1,2-dimethyl-indole as shown above.




[1237] Example 257 can be prepared from 4-cyclopropyl-1,2-dimethyl-indole as shown above.


Example 258: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-5-vinyl-1H-indol-3-yl)propanoic acid (258)




[1239] Example 259 can be prepared from 6-vinyl-1,2-dimethyl-indole as shown above.

Example 260: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-7-vinyl-1H-indol-3-yl)propanoic acid (260)






Example 262: Preparation of 2-amino-3-(5-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (262)



[1240] Example 260 can be prepared from 7-vinyl-1,2-dimethyl-indole as shown above.


Example 261: Preparation of 2-amino-3-(1,2-dimethyl-7-nitro-4-vinyl-1H-indol-3-yl)propanoic acid (261)




[1241] Example 261 can be prepared from 4-vinyl-1,2-dimethyl-indole as shown above.

[1242] Example 262 can be prepared from 5-ethynyl-1,2-dimethyl-indole as shown above.


Example 263: Preparation of 2-amino-3-(6-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (263)



-continued






Example 265: Preparation of 2-amino-3-(4-ethynyl-1,2-dimethyl-7-nitro-1H-indol-3-yl)propanoic acid (265)





[1243] Example 263 can be prepared from 6-ethynyl-1,2-dimethyl-indole as shown above.

Example 264: Preparation of 2-amino-3-(7-ethynyl-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid (264)




[1245] Example 265 can be prepared from 4-ethynyl-1,2-dimethyl-indole as shown above.

Example 266: Preparation of 2-amino-3-(1,2-dimethyl-5-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (266)




[1244] Example 264 can be prepared from 7-ethynyl-1,2-dimethyl-indole as shown above.

-continued







Example 268: Preparation of 2-amino-3-(1,2-dimethyl-7-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (268)



[1246] Example 266 can be prepared from 5-morpholino-1,2-dimethyl-indole as shown above.



Example 267: Preparation of 2-amin-3-(1,2-dimethyl-6-morpholino-4-nitro-1H-indol-3-yl)propanoic acid (267)




268

[1248] Example 268 can be prepared from 7-morpholino-1,2-dimethyl-indole as shown above.

Example 269: Preparation of 2-amino-3-(1,2-dimethyl-4-morpholino-7-nitro-1H-indol-3-yl)propanoic acid (269)






[1247] Example 267 can be prepared from 6-morpholino-1,2-dimethyl-indole as shown above.



[1249] Example 269 can be prepared from 4-morpholino-1,2-dimethyl-indole as shown above.

Example 270: Preparation of 2-amino-3-(1,2-dimethyl-4-methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (270)


Example 271: Preparation of 2-amino-3-(1,2-dimethyl-6-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (271)




[1250] Example 270 can be prepared from 5-(methylthio)-1,2-dimethyl-indole as shown above.

[1251] Example 271 can be prepared from 6-(methylthio)-1,2-dimethyl-indole as shown above.


Example 272: Preparation of 2-amino-3-(1,2-dimethyl-7-(methylthio)-4-nitro-1H-indol-3-yl)propanoic acid (272)



-continued





Example 274: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-5-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (274)




[1252] Example 272 can be prepared from 7-(methylthio)-1,2-dimethyl-indole as shown above.

Example 273: Preparation of 2-amino-3-(1,2-dimethyl-4-(methylthio)-7-nitro-1H-indol-3-yl)propanoic acid (273)




[1254] Example 274 can be prepared from 5-(pyridin-4-yl)-1,2-dimethyl-indole as shown above.


Example 275: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-6-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (275)



[1253] Example 273 can be prepared from 4-(methylthio)-1,2-dimethyl-indole as shown above.




-continued




[1255] Example 275 can be prepared from 6-(pyridin-4-yl)-1,2-dimethyl-indole as shown above.

Example 276: Preparation of 2-amino-3-(1,2-dimethyl-4-nitro-7-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (276)



[1256] Example 276 can be prepared from 7-(pyridin-4-yl)-1,2-dimethyl-indole as shown above.

Example 277: Preparation of 2-amino-3-(1,2-dimethyl-7-nitro-4-(pyridin-4-yl)-1H-indol-3-yl)propanoic acid (277)



[1257] Example 277 can be prepared from 4-(pyridin-4-yl)-1,2-dimethyl-indole as shown above.

Example 278: Genetic Engineering of *E. coli* for Further Improving the Productivity

[1258] In *E. coli*, L-Trp has been observed to be converted into indole, pyruvate and NH₃ by tryptophanase TnaA. L-Trp consumption and the formation of 4-NO₂-L-Trp and indole was monitored during the whole cell transformation process (FIG. 7). The concentration of L-Trp in the medium was constantly decreased. Concomitantly, the concentration of indole reached as high as 1100 μM after 36 h, while the concentration of 4-NO₂-L-Trp was topped at 600 μM at 25 h and then decreased. This result indicated that L-Trp degradation is a strong competitive pathway of 4-NO₂-L-Trp synthesis. Therefore, inhibiting the L-Trp degradation pathway, in some embodiments, improves the productivity of 4-NO₂-L-Trp in whole cell systems. Accordingly, the tryptophanase encoding gene tnaA was knocked down in the engineered *E. coli* strain by the markerless Red recombination method,

[1259] During the biological synthesis of 1-Trp in *E. coli*, TrpR has been observed to repress the transcription of genes involved in L-Trp synthesis and transport when high concentration of L-Trp are present. In addition, in the biosynthesis pathways of aromatic amino acids, carbon flux from

chorismite has been observed to flow to the synthesis of L-Phe, L-Tyr and L-Trp (FIG. 8). In some embodiments, to improve the cellular availability of L-Trp, the negative regulator trpR of L-Trp biosynthesis and tyrA and pheA which catalyze the first two steps of the L-Tyr and L-Phe branch pathways, respectively, are knocked out. A triple knockout *E. coli* strain (Δ trpR Δ tyrA Δ pheA) was produced, and L-Trp concentration in serial fermentation cultures of the mutant is evaluated. The mutant is also transformed with a plasmid combination of pETDUET-GDH-BsNOS and pET28b-TB14 to evaluate the productivity of 4-NO₂-L-Trp. Examples of primers used to generate gene knockout of target metabolic genes are shown in Table 2.

TABLE 2

Primers used for the gene knockout.	
tnaA_fw	ACATCCTTATAGCCACTCTGTAGTATTAAACTCTTTAAGTT TTGCATTGGGGATCCGTCGACC (SEQ ID NO: 27)
tnaA_rev	AATATTACAGGGATCACTGTAATTAAAATAATGAAGGATTAT GTAATGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 28)
trpR-FRT_fw	TACAACCGGGGGAGGCATTTGCTTCCCCGCTAACATGGCGA CATATTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 29)
trpR-FRT_rev	ATTCGGTGCACGATGCCGTGATGCCAACGTCTTATCAGGCCTACA AAACATATGAATATCCTCCTTA (SEQ ID NO: 30)
pheA-FRT_fw	GGCCTCCAAATCGGGGGCCTTTTATTGATAAACAAAAAGGC AACACTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 31)
pheA-FRT_rev	GCCAGTAATAATCCAGTGCCGGATGATTCACATCATCCGGCACCT TTTCACATATGAATATCCTCCTTA (SEQ ID NO: 32)
tyrA-FRT_fw	TCAGGATCTGAACGGGAGCTGACGGCTCGCGTGGCTTAAGAGG TTTATTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 33)
tyrA-FRT_rev	CAACCTGATGAAAAGGTGCCGGATGATGTGAATCATCCGGCACT GGATTACATATGAATATCCTCCTTA (SEQ ID NO: 34)

Example 279: Direct Aromatic Nitration System for Synthesis of Nitrotryptophans in *Escherichia coli*

[1260] This example describes design of a biosynthetic pathway for nitrotrp production in *E. coli*. The production of Nitrotrp and its derivatives primarily uses complicated, heavily polluting synthetic methods, while biocatalytic nitration processes typically require the use of costly, unstable nitric oxide donors. Native thaxtomin-producing plant pathogenic *Streptomyces* species produce trace amounts of Nitrotrp along with N—CH₃-Nitrotrp and the txtB-inactivated mutant accumulates only up to 6 mg/L of Nitrotrp after 5-day fermentation. TxtB is a nonribosomal peptide synthase that utilizes Nitrotrp as substrate to synthesize thaxtomin D. Production of up to 0.22 g/L of thaxtomins within 6 days by heterologously expressing the thaxtomin gene cluster from *S. scabiei* 87.22 in *S. albus* 11074 (*S. albus*-thx2) has been observed. The *S. albus*-thx2 and its mutant carrying only the txtE and txtD genes have been observed to produce up to 80 mg/L of Nitrotrp derivatives, mainly N-acetyl-Nitrotrp, but not Nitrotrp.

[1261] A biosynthetic route to Nitrotrp, in some embodiments, comprises TxtE for 1-Trp nitration and one bacterial NOS for the generation of NO from 1-Arg (FIG. 9). Both TxtE and NOS require reducing agent NADPH for their reactions. In *E. coli*, NADPH is primarily produced in the pentose phosphate pathway (FIG. 9), but the predominant

reducing equivalent is NADH, which potentially limits the production of Nitrotrp. Instead, a glucose dehydrogenase (GDH), specifically *Bacillus subtilis* GDH, was included in an engineered biosynthetic route to regenerate NADPH from NADP⁺ via converting glucose into glucono-1,5-lactone (FIG. 9), which is then entered the pentose phosphate pathway. A self-sufficient TxtE variant, TB14, was used to construct this pathway. For the bacterial NOS, TxtD, which is naturally coexpressed with TxtE to produce Nitrotrp, was initially selected for use in several *Streptomyces* strains. However, both wild type and codon-optimized txtD genes from multiple thaxtomin-producing *Streptomyces* strains were either not expressed or formed inclusion body in *E.*

coli. Codon-optimized NOS from *Bacillus subtilis* (BsNOS) in *E. coli* was included in the engineered pathway (FIG. 9). Of note, although *E. coli* encodes no NOS, its unspecific redox partners support the reaction of BsNOS.

[1262] TB14 and BsNOS were cloned into the first and second multiple cloning sites (MCS) of pETDuet-1, respectively (FIG. 10A). Each gene is preceded by a T7 promoter/lac operator. The pETDuet-1 vector contains an ampicillin resistant marker (Ap). The GDH gene was expressed under the control of the T7 promoter in pET28b carrying a kanamycin resistant marker (Kan) (FIG. 10A). Both pET vectors have a medium copy number (15 to 60) in *E. coli* BL21 strain. The above two constructs were co-transformed into *E. coli* BL21-GOLD (DE3) (Table 3).

TABLE 3

Bacterial strains	
Name	Function
<i>E. coli</i> DH5α	Routine molecular biology studies
<i>E. coli</i> BL21-GOLD (DE3)	Protein expression and production host
<i>E. coli</i> AttnA	<i>E. coli</i> BL21-GOLD (DE3) carrying inactivated tnaA
<i>E. coli</i> ΔtrpRtyrApheA	<i>E. coli</i> BL21-GOLD (DE3) carrying inactivated trpR, tyrA, and pheA

TABLE 3-continued

Bacterial strains	
Name	Function
<i>E. coli</i> -I	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway I
<i>E. coli</i> -II	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway II
<i>E. coli</i> -III	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway III
<i>E. coli</i> -IV	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway IV
<i>E. coli</i> -II-TB14	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway II without TB14
<i>E. coli</i> -II-BsNOS	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway II without BsNOS
<i>E. coli</i> -II-GDH	<i>E. coli</i> BL21-GOLD (DE3) carrying the pathway II without GDH
<i>E. coli</i> ΔtrpRtyrApheA-II	<i>E. coli</i> ΔtrpRtyrApheA carrying the pathway II
<i>E. coli</i> -TB14	<i>E. coli</i> BL21-GOLD (DE3) carrying only TB14

[1263] After the selection with both ampicillin and kanamycin, one positive colony (*E. coli*-I) was picked up to express proteins in TB medium induced with 0.5 mM IPTG for 20 h. The SDS-PAGE analysis of the soluble crude extract revealed the successful overexpression of BsNOS (42 kD) and GDH (28 kD) (Lane I, FIG. 10B and FIG. 11). By contrast, TB14 (110 kD) was expressed to a low level, different from the high solubility of TB14 when expressed alone in the same host. This result indicated that the co-expression with BsNOS and/or GDH negatively influenced the expression level of TB14 in *E. coli*. Nevertheless, *E. coli*-I was used for the synthesis of Nitrotrp from cellular 1-Trp and 1-Arg in the M9 minimal medium that has been most widely used for the whole cell transformations. After 24 h, HPLC analysis revealed 7.8 ± 0.7 mg/L of Nitrotrp in the fermentation medium (FIG. 10C, FIG. 12A), which was further confirmed in LC-MS analysis (FIG. 12B). The titer of Nitrotrp increased until day 3, reaching 16.2 ± 2.3 mg/L and then quickly dropped to 5.5 ± 1.5 mg/L on day 4 (FIG. 10C). TnaA is one tryptophanase in *E. coli* that is known to catalyze the β-elimination of 1-Trp to produce indole (FIG. 9). HPLC analysis of the fermentation medium failed to identify 4-nitro-indole, the potential product of Nitrotrp degradation by TnaA (FIG. 13). The tnaA gene from *E. coli* was cloned and recombinant enzyme was prepared (FIG. 14A). Recombinant TnaA produced indole from 1-Trp: degraded Nitrotrp was not observed in an in vitro assay (FIG. 14B). On the other hand, *E. coli* encodes two oxygen-insensitive nitroreductases NsfA and NsfB that are known to reduce nitroaromatics: one or both of these enzymes are involved in the rapid degradation of Nitrotrp in *E. coli*-I (FIG. 10C). Data described herein indicate a novel cell-based biocatalytic route to Nitrotrp.

[1264] Despite the successful production of Nitrotrp by *E. coli*-I (I, FIG. 10A), low expression level of TB14 may constrain the nitration process. To address this potential issue, three additional pathways were constructed by varying copy numbers and replicons of plasmid backbones and coexpression of these genes (FIG. 10A). As high expression level is obtained when TB14 is expressed alone, the second design shuffled the TB14 and GDH genes between pET-Duet-1 and pET28b (II, FIG. 10A). Furthermore, coexpression of the two genes was investigated in the pACYCDuet-1

backbone that has a low copy number (~10), contains two T7 promoters in two MCSs, carries the P15A replicon, and includes a chloramphenicol resistant marker (CmR) (III-IV, FIG. 10A). These features allowed the assessment of the effects of improved plasmid stability with two different replicons and varied gene dosages on the production of Nitrotrp. The three new Nitrotrp pathways were transformed into *E. coli* BL21-GOLD (DE3) to generate *E. coli*-II, -II and -IV as described above (Table 3). All four strains showed similar growth rates when cultured in TB medium and induced with 0.5 mM IPTG (FIG. 15). SDS-PAGE analysis revealed increased levels of TB14 but the decreased levels of GDH in *E. coli*-II and -IV in comparison to *E. coli*-I and -III (FIG. 10B). Another finding of the SDS-PAGE analysis was that the co-expression of TB14 and BsNOS on the plasmids of both low and medium copy numbers yielded the same low levels of both enzymes. The three *E. coli* strains were further fermented along with *E. coli*-I in the M9 medium for 4 days. HPLC analysis revealed that *E. coli*-III and -IV, which both carried the separately expressed TB14, produced more Nitrotrp than *E. coli*-I and -III (FIG. 10C). This data indicates that the low level of GDH in *E. coli*-II and -IV is sufficient to support the reactions of TB14 and BsNOS (FIG. 10B). The titer of Nitrotrp by all four strains increased until day 3 and then dropped at day 4. The highest titer of Nitrotrp was observed at 36.5 ± 4.0 mg/L with *E. coli*-II on day 3, the 2.3-fold improvement compared with *E. coli*-I at day 3 (FIG. 10C). *E. coli*-II was therefore selected for subsequent studies.

[1265] The fermentation processes in two commonly used, nutritionally rich media, LB and TB were investigated. As cellular 1-Trp and 1-Arg are consumed to produce Nitrotrp (FIG. 9), the effects of supplemented amino acids (5 mM) in M9, LB and TB media on the production of Nitrotrp by *E. coli*-II at 20° C. were also examined. HPLC analysis measured the concentration of Nitrotrp in the cell-free media at 5 h, 10 h, 15 h, 20 h, and 30 h (FIG. 16A). *E. coli*-II reached the highest titer of Nitrotrp in the M9 medium at day 3 (FIG. 10C), but the highest amount appeared after 20 h in both LB and TB, which was then decreased at 30 h. The titer of Nitrotrp was increased from 18.0 ± 2.0 mg/L in M9 to 39.0 ± 3.3 mg/L in LB and 152.8 ± 10.5 mg/L in TB after 20 h, indicating the faster and increased production of Nitrotrp in nutritionally rich media (FIG. 16A). Supplementation of 1-Trp or 1-Arg in all three media resulted in no increase in the production of Nitrotrp.

[1266] Temperature effects on the whole-cell nitration process were also examined. Fermentation experiments were performed at 20° C., 15° C., 28° C., and 37° C. Crude extracts of fermentation media of *E. coli*-II cultured at the four temperatures were prepared at 0 h, 8 h, 16 h, 20 h, 24 h, 28 h, and 40 h. HPLC analysis indicated a similar level of Nitrotrp at 8 h and 16 h when *E. coli*-II was fermented at 15° C., 20° C., and 28° C. (FIG. 16B). At 15° C., the titer of Nitrotrp remained largely unchanged (about 110 mg/L) from 16 h to 24 h and then decreased to about 63 mg/L at 40 h. By contrast, *E. coli*-II produced the highest amount of Nitrotrp after 24 h at 20° C. and 28° C., and fermentation at 28° C. resulted in production of 175.5 ± 5.3 mg/L Nitrotrp, *E. coli*-II produced less than 14 mg/L of Nitrotrp at any time point when fermented at 37° C. Data indicate increased production of Nitrotrp in *E. coli* from 36.5 mg/L for 3 days to 175.5 mg/L for 1 day based upon changes to fermentation media and temperature conditions.

[1267] Nitrotrp pathway II comprises TB14, BsNOS, and GDH (FIG. 10A) that together lead to the production of 175 mg/L of Nitrotrp by *E. coli*-II (FIG. 16B). Removal of each enzyme was investigated. TB14, BsNOS, and GDH genes were removed individually from the pathway II and the three resultants were transformed into *E. coli* BL21-GOLD (DE3) to generate *E. coli*-II-TB14, -BsNOS, and -GDH. As the control, pBT28b-TB14 was used to create *E. coli*-TB14 following the same procedure (Table 3). These four new strains along with *E. coli*-II were cultured in TB at 28°C for 24 h. HPLC analysis then quantitated the titers of Nitrotrp by all five strains (FIG. 17). *E. coli*-II-TB14 completely lost the ability to produce Nitrotrp. *E. coli*-II-BsNOS retained 17.2±1.5% of the titer of *E. coli*-II, indicating the presence of additional sources of NO for the TB14 reaction (FIG. 17). For example in some embodiments, an indoor atmosphere can supply more than 2 μM of NO for the biotransformation. Similarly, *E. coli*-TB14 also produced a relatively low level of Nitrotrp (12.5±1.2% of the titer of *E. coli*-II). Among the three enzymes in the pathway II, GDH was observed to provide a supporting role to the reactions of TB14 and BsNOS as *E. coli*-II-GDH showed 66.8±6.4% of the titer of *E. coli*-II (FIGS. 9 and 17).

[1268] The production of Nitrotrp consumes cellular 1-Trp and 1-Arg of *E. coli* (FIG. 9). The concentrations of 1-Trp in TB were measured at varying time points when fermenting *E. coli*-II; a quick decrease from 260.8±12.0 mg/L at 0 h to 25.3±9.8 mg/L after 24 h was observed (FIG. 18). However, 1-Trp supplementation to TB was not observed to have an effect on improving the production of Nitrotrp (FIG. 16A), indicating the increased cellular availability of 1-Trp may be more important to increase Nitrotrp production. Tuning of 1-Trp metabolic pathways in *E. coli* (FIG. 9) was investigated. Of note, 1-Arg biosynthesis was not selected as the primary engineering target as the increased 1-Arg may lead, in some embodiments, to the higher production of NO that can be detrimental to *E. coli*. The tnaA gene in *E. coli* BL21-GOLD(DE3) was knocked out by the λ red recombination approach. to prevent the conversion of cellular 1-Trp into indole (FIGS. 9 and 19). Pathway II was then transferred into the *E. coli* ΔtnaA mutant for the production of Nitrotrp (Table 3). Neither recombinant TB14 and BsNOS nor GDH was detectable from soluble protein fraction of *E. coli* AttnaA-II by SDS-PAGE analysis (FIG. 20), leading to no observed production of Nitrotrp.

[1269] Increasing the metabolic flux to 1-Trp biosynthesis was investigated (FIG. 9). The biosynthetic pathways of 1-Trp, 1-Phe, and 1-Tyr require the same cellular metabolite chorismate that is produced from the shikimate biosynthetic pathway. TyrA and PheA convert chorismate into prephenate for the production of 1-Tyr and 1-Phe, while TrpE produces anthranilate from chorismate to synthesize 1-Trp. The inactivation of both tyrA and pheA genes in *E. coli* BL21-GOLD (DE3), in some embodiments, eliminates the competitive consumption of chorismate for the increased production of 1-Trp in the fermentation stage. TrpR has also been observed to provide a negative feedback regulation on the 1-Trp biosynthesis by acting on 1-Trp biosynthetic gene and the shikimate biosynthetic gene (FIG. 9). and the inactivation of the trpR gene has been observed to overproduce 1-Trp in *E. coli*. These three genes were inactivated in *E. coli* BL21-GOLD (DE3) to create *E. coli* ΔtrpRtyrApheA using the λ red recombination approach (Table 3. FIG. 19). Both wild type *E. coli* and the ΔtrpRtyrApheA mutant were fermented

in TB medium under the same conditions for 20 h. HPLC analysis revealed 273±33 mg/L of free 1-Trp in the fermentation medium of the mutant and 142±25 mg/L for the wild type, indicating an increased intracellular supply of 1-Trp in the mutant. *E. coli* ΔtrpRtyrApheA-II was then generated by transforming the designed Nitrotrp pathway II into the mutant. HPLC analysis revealed the concentration of 1-Trp in the culture of *E. coli* ΔtrpRtyrApheA-I was decreasing in the fermentation process but remained higher than *E. coli*-I at the majority of time points (FIG. 18), indicating that the mutant production strain may have a slower rate to consume medium 1-Trp than *E. coli*-II as it synthesizes more cellular 1-Trp. *E. coli* ΔtrpRtyrApheA-III produced a higher level of Nitrotrp than *E. coli*-II at 10 h and 20 h (FIG. 18), and reached the highest titer, 191.8±10.3 mg/L, at 20 h, which was about 10% increased compared with *E. coli*-II at 24 h (FIG. 16B).

[1270] Production of Nitrotrp analogs was examined by feeding eight unnatural racemic 1-Trp analogs (except for 5-F-1-Trp) (5 mM) to the fermentation medium of *E. coli*-II (FIGS. 21 and 22A). HPLC analysis revealed that α-Me-Trp, 4-F-Trp, 4-Me-Trp, 5-MeO-Trp, 5-Me-Trp, 5-F-1-Trp, 6-F-Trp and 7-Me-Trp all were nitrated along with 1-Trp to varying extents by *E. coli*-II (FIG. 22B). The 1-amino acid substrate was observed to be nitrated by TB14 in in vitro studies. The strain demonstrated the highest nitration activity toward 5-Me-Trp, followed by 5-F-Trp and 4-Me-Trp, while only about 2.5 mg/L of the nitro product was produced from fed 4-F-Trp (FIG. 21). This data agreed with the observed in vitro catalytic performance of TB14 toward these substrates. The titer of nitro-5-Me-Trp reached 61.5 ± 5.5 mg/L, along with 80.3±10.4 mg/L of Nitrotrp after culturing *E. coli*-IH for 24 h (FIG. 21).

Materials and Methods

General Chemicals, DNA Sub-Cloning, and Bacterial Strains

[1271] Molecular biology reagents and enzymes were purchased from Fisher Scientific. Primers were ordered from Sigma-Aldrich, Racemic 4-Me-Trp was from MP Biomedical (Santa Ana, CA). Other chemicals and solvents were purchased from Sigma-Aldrich or Fisher Scientific. *Escherichia coli* DH5α (Life Technologies) was used for molecular biology work, while *E. coli* BL21-GOLD (DE3) (Agilent) was used for protein overexpression and the development of the whole cell nitration systems (Table 3). *E. coli* strains were grown in M9, LB or TB. DNA sequencing was performed at Eurofins. A Shimadzu Prominence UHPLC system (Kyoto, Japan) fitted with an Agilent Poroshell 120 EC-C18 column (2.7 μm, 3.0×50 mm), coupled with a PDA detector was used for HPLC analysis.

Creation of Nitrotrp Biosynthetic Pathways

[1272] BsNOS, TB14 and GDH genes were amplified from pET15b-BsNOS, pET28b-TB14, and pET21b-GDH, respectively using primers listed in Table 4. PCR amplicons were analyzed by agarose gel and extracted with GeneJET Gel Extraction Kit (Thermo). Purified PCR products, pACYCDuet-1, pETDuet-1, and pET28b were digested with corresponding restriction enzymes, purified and then ligated to create expression constructs. All inserts in the constructs

were sequenced to exclude potential errors introduced during PCR amplification and gene manipulation.

Whole-cell Biotransformation

[1273] *E. coli* BL21-GOLD (DE3) competent cells were transformed with the designed pathway I-IV individually (Table 3). Positive colonies of *E. coli*-I, to -IV were selected on LB agar supplemented with 0.1 mg/mL ampicillin and 0.05 mg/mL kanamycin or 0.05 mg/mL chloramphenicol and 0.05 mg/mL kanamycin. One colony of each strain was then grown in LB with proper antibiotics at 37° C., 250 rpm overnight. The seed cultures were used to inoculate 100 mL of TB with proper antibiotics and 1× trace metal solution (1000× stock solution: 50 mM FeCl₃, 20 mM CaCl₂, 10 mM MnSO₄, 10 mM ZnSO₄, 2 mM CoSO₄, 2 mM CuCl₂, 2 mM NiCl₂, 2 mM Na₂MoO₄, and 2 mM H₃BO₃) for culturing at 37° C., 250 rpm until OD₆₀₀ reached 0.6-0.8. We then induced protein expression by 0.5 mM IPTG at 18° C., 250 rpm for 20 h. For the evaluation of protein expression, cell pellets were then collected after centrifugation (5,000 g, 10 min, and 4° C.), and resuspended in the suitable volume of lysis buffer (cell biomass:volume=1:4) [25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 20 mM imidazole, 3 mM 0-mercaptoethanol (BME) and 10% glycerol]. Soluble proteins were released by sonication and collected after centrifugation at 35,000×g at 4° C. for 30 min. Clear supernatants (20 μL) was mixed with dye and subject to SDS-PAGE analysis. For the whole cell biotransformation, bacterial cells in TB were harvested after centrifugation (2,000 g at 4° C. for 10 min) and resuspended to OD₆₀₀=30 in fresh test media (M9, LB, or TB with or without 5 mM 1-Trp or 1-Arg). The fermentation was then performed at different temperatures, 250 rpm and aliquots (0.1 mL) of the fermentation culture were taken at various time points. The whole-cell biotransformation in aliquots was quenched by mixing with 0.2 mL of methanol. After centrifugation at 14,000 rpm for 30 minutes, the supernatant was subject to HPLC analysis. All experiments were independently repeated at least twice.

Inactivation of Genes in *E. coli*

[1274] Inactivation of tnaA, trpR, tyrA, and pheA in *E. coli* BL21-GOLD (DE3) was performed following the λ red recombination protocol (FIG. 19). Specific primers used were included in Table 4.

TnaA Assay

[1275] The tnaA gene was amplified from *E. coli* genomic DNA using primers listed in Table 4. PCR amplicons were analyzed by agarose gel and extracted with GeneJET Gel Extraction Kit (Thermo). Purified PCR products and pET28b were digested with corresponding restriction enzymes, purified and then ligated to create expression constructs. Insert in the construct was sequenced to exclude potential errors introduced during PCR amplification and gene manipulation. Recombinant TnaA was prepared in *E. coli* BL21-GOLD (DE3). The enzyme assay (0.1 mL) contained 100 mM potassium phosphate buffer (pH 8.3), 0.2 mM pyridoxal 5-phosphate and 0.1 μM purified tnaA. The reaction mixtures were pre-warmed at 37° C. for 5 minutes, and initiated by adding 0.5 mM 1-Trp or Nitrotrp as substrate. After 10 minutes, the reactions were quenched by mixing well with 0.2 mL of methanol. After centrifugation at 14,000 rpm for 30 minutes, the supernatant was subject to HPLC analysis. All experiments were independently repeated at least twice.

HPLC and LC-MS Methods

[1276] For HPLC analysis, the C18 column was kept at 30° C. and ran first with 5% solvent B (acetonitrile, 0.1% formic acid) for 2 min and then a linear gradient of 5-15% solvent B in 5 min, followed by another linear gradient of 15-95% solvent B in 10 min. The column was further cleaned with 95% solvent B for 3 min and then re-equilibrated with 5% solvent B for 2 min. Solvent A was water with 0.1% formic acid. The flow rate was set as 0.5 mL/min, and the products were detected at 211 nm with a PDA detector. The concentrations of Nitrotrp and/or 1-Trp in the samples were determined on the basis of standard curves of two authentic compounds after HPLC analysis (FIGS. 22A-22B). LC-MS analysis was performed by established protocols.

TABLE 4

Name	Sequence (5' → 3')	Function
TB14FN	ATACCATGGTGACCGTCCCCTCGCCG (SEQ ID NO: 35)	TB14 cloning
TB14RH	ATCAAGCTTCCCAGCCCACACGTCTTTGC (SEQ ID NO: 36)	TB14 cloning
GDHFB	CAGGATCCGATGTATAAGATCTGGAAGGTAAAGTGGTG (SEQ ID NO: 37)	GDH cloning
GDHRH	CAAAGCTTTAGCCACGACCTGCCTGAAAG (SEQ ID NO: 38)	GDH cloning
BsNOSFN	ACTCATATGATGGAAGAAAAGAAATC (SEQ ID NO: 39)	BsNOS cloning
BsNOSRH	ACTAAGCTTCTATTACATACGGTTGTC (SEQ ID NO: 40)	BsNOS cloning
tnaAFB	ACTGGATCCGATGGAAAACCTTAAACATCTCC (SEQ ID NO: 41)	tnaA cloning
tnaARE	ACTGAATTGAAACTCTTTAAGTTTGCCTG (SEQ ID NO: 42)	tnaA cloning
trpR-F	TACAACCGGGGGAGGCATTTGCTCCCCCGTAACAATGGCAGC ATATTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 43)	trpR knock out
trpR-R	ATTGGTGCACGATGCCGTGATGCCACGTCTATCAGGCTACA AACACATATGAATATCCTCCTTA (SEQ ID NO: 44)	trpR knock out

TABLE 4-continued

Name	Sequence (5'→3')	Function
pheA-F	GGCCTCCCAAATCGGGGGGCCTTTTATTGATAACAAAAAGCA ACACTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 45)	pheA knock out
pheA-R	GCCAGTAATAATCCAGTGCCGATGATTCACATCATCCGGCACCTT TTCACATATGAATATCCTCCTTA (SEQ ID NO: 46)	pheA knock out
tyrA-F	TCAGGATCTGAACGGGCAGCTGACGGCTCGCGTGGCTTAAGAGG TTTATTGTGTAGGCTGGAGCTGCTTC (SEQ ID NO: 47)	tyrA knock out
tyrA-R	CAACCTGATGAAAAGGTGCCGGATGATGTGAATCATCCGGCACTG GATTACATATGAATATCCTCCTTA (SEQ ID NO: 48)	tyrA knock out
tnaA-F	GGATCACTGTAATTAAAATAATGAAGGATTATGTAATGGTAGGC TGGAGCTGCTTC (SEQ ID NO: 49)	tnaA knock out
tnaA-R	GTGGCTAACATCCTTATAGCCACTCTGTAGTATTAATTACATATGAAT ATCCTCCTTA (SEQ ID NO: 50)	tnaA knock out

EQUIVALENTS

[1277] While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.

[1278] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.

[1279] All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

[1280] The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."

[1281] The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean

"either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[1282] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[1283] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at

least one of A or B." or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

[1284] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

[1285] In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including,"

"carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. It should be appreciated that embodiments described in this document using an open-ended transitional phrase (e.g., "comprising") are also contemplated, in alternative embodiments, as "consisting of" and "consisting essentially of" the feature described by the open-ended transitional phrase. For example, if the disclosure describes "a composition comprising A and B", the disclosure also contemplates the alternative embodiments "a composition consisting of A and B" and "a composition consisting essentially of A and B".

SEQUENCE LISTING

```

Sequence total quantity: 50
SEQ ID NO: 1      moltype = AA length = 992
FEATURE          Location/Qualifiers
REGION           1..992
source            note = Synthetic Polypeptide
                  1..992
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 1
MTVPSPALADP SIVPDPPVY ADLAQRRPVH WVERLNAAW LTYADCAAGL KDPRLTADRG 60
TEVLAAKFPQ QPLPPDNIH RWTKNVVMYT DPPLHDALRR SVRAGFTRAA HQHYDQVLQK 120
VAHDLVASIP AGATEIDAVP ALAAELPVRS AVHAFCVPEE DLGFLIPRVN TIMTYHSGPK 180
DQPVTQEIII EKLTLHLHTYA SELLQQMRGK VLPDTVIARL AAAQDGLTET TPEQTVHQLA 240
LVFVIALFAPT TPGSLSSGTL AFAPRNPRQVE RFLADQACVD NTANEVLRYN ASNQFTWRVA 300
AKDVEMGGVIR IEAGQTLALF LGSANRDAVN FERPNPDFDLD RPNSARHLSF GQGVHACLAA 360
QLISLQLKWF YVALLNRFFP IRTAGEPIWN ENLEFRSRLS LPLSLRELQS AKKVRKKAEN 420
AHNTPLLVLY GSNNMCTAEGT ARDLADIAMS KGFAPQVATL DSHAGNLPRE GAVLIVTASY 480
NGHPPDNAKQ FVDWLQDQASA FGDVKVRYSV FGCGDKNWAT TYQKVPAFID ETLAAKGAEN 540
IADRGEADAS DDFECTYEWEW REHMWSDVAAY FNLDIENSE DNKSTLSSLQF VDSAADMPLA 600
KMHGAFSTNV VASKELQQPG SARSTRHLEI ELPKEASYQE GDHLLGVIPRN YEGIVNRVTA 660
RFGLDASQQI RLEAEEEKL A HLPLAKTVSV EELLQYVELQ DPVTRTQLRA MAAKTVCPHH 720
KVELEALLEK QAYKEQVQLA RLTMLLELK YPACEMKFSE FIAILPSIRP RYYSISSSPR 780
VDEKQASITV SVVSGEAWSG YGEYKGILASN YLAELQEGDT ITCFISTPQS EFTLPKDPET 840
PLIMVGPGTG VAPFRGFVQA RKQLKEEQGS LGEAHLYFGC RSPHEDYLYQ EELENAQSEG 900
IITLHTAFSR MPNQPKTYVQ HVMEQDGKKL IELLDQGAHF YICGDGSQMA PAVEATLMKS 960
YADVHQVSEA DARLWLQQLE EKGRYAKDVW AG
992

SEQ ID NO: 2      moltype = DNA length = 2985
FEATURE          Location/Qualifiers
misc_feature     1..2985
source            note = Synthetic Polynucleotide
                  1..2985
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 2
atgggcattgttccgcgag cccgcgtggct gatcccgacca tcgtgcgcaga tccgtaccgg 60
gtttacgcgg atctggcgca acgtcgcccg gtgcactggg ttgagcgctct gaacgcctgg 120
gcagtgcgtt cctatgcaga ttgcgcggcg ggtctgaaagg acccgcgtt gacccggat 180
agaggatccg aggtgcgttgc acggaaaggtt ccgggtcagc cactgcgcgc ggataacatc 240
tttcaccgtt ggaccaaaa ttgtgttatg tacaccgttgc cgcgcgttgc tgatgttttgc 300
cgtcgcggcg tgcgtgcagg tttcacccgc gggctcacc aacattatga tcaggctcg 360
caaaaatgtt cccacgtat ggttgcagaatcccgccgg gtgcacccga gattgtatgt 420
gttcccgatc tgccggcgga gctgcggcg gctagegcggc tgcatgcatt cggtgttccg 480
gaggaaaggat tgggttttgc gatcccgctgtt gttggacacacca ttatgtactt ccactctgtt 540
ccgaaggatc agccgggttac ccaagagatc attctggaga aactgaccga tctgcacacg 600
tatgcgtcg agctgttgc gggatgttgc ggttaaggccc tgccggatata cgtaatttgc 660
agacttgcgtt cggcgcaaga tggctgttgc accaaacccccc cggaaacagac ggttccaccaa 720
ctggcggttgc tggttatttgc tctgttttgc ccaaccaccc cggtagctt gaggacgggt 780
accctggcat ttgcacaaaa cccgcgttgc gttggagcggtt ttctggccga tcaagcgttc 840
gttgataaca cccgcgttgc agtgcgttgc tacaacgcgtt ctaatcgtt cacctggcg 900
gtcgccgcga aggatgttgc gatgggttgc gttcgattt aagctgttgc aaccctggcg 960
ctgttccgtt gtagcgttgc cccgcgttgc aatatgttgc aegcggccaa cgattttgtat 1020
ctggatgcgtt cccgcgttgc aagacacccgtt agtgcgttgc tgggttgc tccgtgttgc 1080

```

-continued

gctgcacagt	tgatcagcct	gcaactgaaa	tggttctatg	tggcgctgtt	gaaccgttt	1140
ccgggttattc	gcacccgggg	tgaatccgatt	tggaatgaga	acctggagg	tcgttagctg	1200
cgtagcctgc	cgctgagcct	cggtgagctc	cagtctgtca	aaaaagtacg	caaaaaggca	1260
gaaaacgcgc	ataatacgcc	gctgtttgt	ctatacggtt	caaatatggg	aacagctgaa	1320
ggaacggcgc	gtgatttagc	agatattgca	atgagcaaag	gatttgcacc	gcaggctcga	1380
acgcttgatt	cacacccggg	aaatcttcgg	cgccgaaggag	ctgtatataat	tgttaacggcg	1440
tcttataacg	gtcatccggc	tgataaacgca	aagcaatttt	tcgactgggt	agaccaacag	1500
tctgctgatg	aagtaaaaagg	cggtcgctac	tcggatattt	gatgcggcga	taaaaactgg	1560
gctactacgt	atcaaaaagt	gctgttttt	atcgatgaaa	cgcttgcgc	taaaggggca	1620
gaaaacatcg	ctgacccggg	tgaagcagat	gcaagcgcac	actttgaagg	cacatatgaa	1680
gaatggctgt	acacatatgt	gagtgacgta	gcagctact	ttAACCTCGA	cattgaaaaac	1740
agtgaagata	ataaatctac	tctttcactt	caatttgcg	acagcgcgc	ggatgtccg	1800
cttgcgaaaa	tgcacgggtc	gttttcaacg	aacgtcgtag	caagcaaaa	acttcaacag	1860
ccaggcagtg	cacgaacgc	gcccacatct	gaaattgaaac	ttccaaaaaa	agcttcttat	1920
caagaaggtag	atcattttag	tgtttatctt	cgcaactat	aaggaaatgt	aaaccgtgt	1980
acaccaaggt	tccgccttag	tgcatcacag	caaatccgc	tggacgcaga	agaqaaaaaa	2040
ttagctcatt	tgccactcgc	taaaaacagta	tccgttagaa	agcttctgca	atacgtggag	2100
cttcaagatc	ctgttacgc	caacgcacgtt	cgccgaatgg	ctgtcaaaaac	ggtctgc	2160
ccgcataaaag	tagagcttg	agccttgcgt	gaaaaggcaac	cctacaaaaga	acaagtgt	2220
gcaaaaacggt	taacaatgt	tgaactgtt	gaaaataacc	cgccgtgtg	aatgtaaattc	2280
agcgaattta	tcgccttct	gccaagcata	cgccccgcgt	attactcgat	ttcttcatca	2340
cctcgtgtcg	atgaaaaaaa	agcaagcata	acggtcacgc	ttgttctcagg	agaagcgtgg	2400
agggatatgc	gagaatataa	aggaatttgc	tcaactat	ttccggagct	gcaagaagga	2460
gatacgttata	cgtgtttat	ttccacacgg	caagtcgat	ttacgtgtc	aaaagaccc	2520
gaaacgcgc	ttatcatgg	cgggacgggg	acaggcgtcg	cgccgtttag	aggcttgc	2580
caggcgcgc	aacgcgtaaa	agaacaagg	cagtcaactt	gagaagcaca	tttatactt	2640
ggtgcgtt	cacctatcg	agactatgt	tatcaagaa	agcttgc	cgcccaaaac	2700
gaaggcatca	ttaacgttca	taccgc	tctcgatc	caatcagcc	gaaaacatac	2760
gttcagcact	taatggaa	agacggcaag	aaattgtatt	aacttcttga	tcaaggagcg	2820
cacttctata	tttgcggaga	cggagccaa	atggcacctt	ccgttgaagc	aacgctttag	2880
aaaagctatc	ctgacgttgc	ccaaatgt	gaagcagac	ctcgctttag	gctgcagcag	2940
ctagaagaaa	aaggccata	cgcaaaagac	gtgtgggt	ggtaa		2985

SEQ ID NO: 3	moltype = DNA	length = 1092				
FEATURE	Location/Qualifiers					
misc_feature	1..1092					
	note = Synthetic Polynucleotide					
source	1..1092					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 3						
ttgaaagaaa	aagaaatact	ctggaacgaa	gcfgaaagcgt	ttatttgcgc	atgctatcag	60
gaatttggaa	aggaggagg	agtggaaagac	cgcttcgcgg	acattaaaag	tgaaatttgc	120
ctgaccggaa	gtatgtaca	tacgaaaggaa	gagctggagc	acggagcggaa	aatggcttgc	180
agaaacacgca	accgcgtcat	cgccagattt	tctggaaat	cgctgaatgt	tatcgacaga	240
cgagacgtcc	ggacgaaggaa	ggaaggcgtgt	gatgccctct	ttcaccat	tgaaaccgc	300
accaataacg	ggaaaatctag	accgcattt	acgattttc	ctccggaa	gaagggtgaa	360
aacgaatgt	cgatcttgc	tatcgatgt	atccggat	tcggatata	gtcagacgg	420
aaaaaaatcg	cgacccggc	ttctcttcc	ctgacagtag	cttgcgaa	gctcgcttgc	480
cgccggagac	gaacggattt	tgacttgcgt	ccgctcattt	ttcgatgaa	agggggacag	540
cagcctgtct	gttatgtat	gcccgttca	cttgcgttgc	agggttccat	cacacatcc	600
gacatcgagg	cgttttctga	tttgcgttgc	aaatggatgc	aggtgttgc	tatttctgt	660
atgaagcttgc	aggtcgggg	catttattat	aatggccgc	catttaacgg	ctggatata	720
ggcacggaga	tcggagcgg	aaacctcgca	gatggaaa	ggtacgacaa	gctcaaaaa	780
gtacgcgtcg	tgatcgat	ccgcgttgc	tacaatacg	atttatggaa	ggatcaacg	840
ctatgttataat	tgaataaaac	tgtatgtc	tcgtatgt	aaagggtgt	cagcatcg	900
gaccatcatca	cagccggca	ccatgtttaaa	cggttgc	aaacaggagg	agaagcggc	960
agaaagctgt	cgggggactt	gacgtggctg	attccgc	tttcacccgc	tgccactat	1020
atttccacc	gtccctatga	taactcaatc	gtaaggcga	actattttta	tcaagataag	1080
ccttatgtat	aa					1092

SEQ ID NO: 4	moltype = DNA	length = 1092				
FEATURE	Location/Qualifiers					
misc_feature	1..1092					
	note = Synthetic Polynucleotide					
source	1..1092					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 4						
atgaaagaaa	aagaaatctt	gtgaaacgaa	gccaagcat	tatcgacgc	gtgttaccaa	60
gaacttggca	aaaagaaga	agtcaaaat	cgccgttgc	acattaaaag	tgaaatcgat	120
ctgaccgggtt	cctatgttca	tacgaaaggaa	gaaactggaa	acggcgc	aaaatggcttgc	180
cgtaacacgca	atcgctgt	tttgttgcgt	tttgcgttgc	actctgtat	gatcgatcg	240
cgccgacgttc	gcacgaaaga	agaatgttgc	gatgcgttgc	ttcatttgc	tgaaaccgc	300
acgaacaaatcg	tgtttatcc	tcgcattt	acgtatcc	ccggaa	aaaaggc	360
aaacaggttgc	aaatggaa	ccatcaact	caggctac	aagcgcac	ggc	420

-continued

gaacgtattg	gtgatccggc	tagctgtct	ctgaccgcgg	cctgtgaaga	actgggctgg	480
cgttgcggaa	gcacggattt	tgacgtgtcg	ccgctgattt	tccgcgttgc	agggtgtgaa	540
cagccgggtt	ggtatgaaact	gcccgttct	ctgggttgc	aagtccgtt	caccatccg	600
gacatcgaa	ccttttgta	tctggaaact	aaatggtacg	gctgtcccgat	tatctccgt	660
atgaaaactgg	aagtggcg	tattcaactat	aacgcagctc	cgttcaatgg	ctggtacatg	720
ggcacccaaa	tccggcgccg	caatctggc	gacgaaaaaa	tttacgttac	actgaaaaaa	780
gtcgcgtat	tgatgtgtat	cgccggcgat	tacaacacgg	acctgtggaa	agatcaggca	840
cttggtaaac	tgaataaaagc	tgtttgtcac	tcataaaaaa	aacaaggcg	ttcgatgtg	900
gatcatcaca	ccgcagctc	acagttaaa	cgtttcaatgg	aacaggaga	agaagcgggt	960
cgttaaactgg	ccggcgattt	gacgttgcgt	attccgcgcg	tctcgcggc	agcaaccat	1020
atcttccacc	gtctgtatga	caatagcatt	gtgaaaccga	attacttcta	ccaggacaaa	1080
ccgtataat	ag					1092

SEQ ID NO: 5	moltype = AA	length = 363
FEATURE	Location/Qualifiers	
REGION	1..363	
source	note = Synthetic Polypeptide	
	1..363	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 5		
MEKEEILWNE AKAFIAACYQ	ELGKEEEVKD RLADIKESEID	LTGSYVHTKE ELEHGAKM
RNSNRCIGRL FWNSLNVIDR	RDVRTKEEVRL DALFHHIET	TA TNNGKIRPTI TIFPPEEKGE
KQEVEIWNHQL IRYAGYESDG	ERIGDPASCS LTAACEELGW	RGERTDFDLL PLIFRMKGDE
QPWVYELPRS LVIEVPITHP	DIEAFSDLEL KWYGVPIISD	MKLEVGGIHY NAAPFNGWYM
GTEIGARNLA DEKRYDKLKK	VASVIGIAAD YNTDLWKDQA	LVELNKAVLH SYKKQGVSV
DHHTAASQFK RFEQQEEEAG	RKLTDWWTWL IPPISPAATH	I FHRSYDNSI VPKNYFYQDK
PYE		363

SEQ ID NO: 6	moltype = DNA	length = 786			
FEATURE	Location/Qualifiers				
misc_feature	1..786				
source	note = Synthetic Polynucleotide				
	1..786				
	mol_type = other DNA				
	organism = synthetic construct				
SEQUENCE: 6					
atgtataaag atctggagg	taaagtgggt	gtgattaccg	gcagcagcac	cggctctggc	60
aaagcattag cgattcggtt	tgccgaccgg	aaagcgaaa	ttgtgtttaa	ctatcgac	120
aaagaagaag aagcgaacag	cgttctggaa	gaaataaaaa	aagtgggtgg	cgaagcgatt	180
gcgcgttggaa	gtgtatgtac	cgtggaaagc	gtatgttata	acctgtgtca	240
aaagaatttg gcaacttgg	tgtgtatgtt	aacaatcgcc	gtatggaaa	tccggtgagc	300
agccatgaaa tgaggctgt	cgatggaa	aaagtgttgc	atccaaact	gaccgggtgc	360
tttctggca gccgttggaa	gattaaatac	tccgtggaaa	agatattaa	aggcacccgt	420
attaacatgc gcaatgtgt	tgaaaaattt	ccgtggccgc	tgtttgtca	ttatgcac	480
agcaaaaggcg gtatgttgc	gtatgttgc	gtatgttgc	accctggccc	tggaaatatgc	540
attctgtgt	acaacatgttgc	tccgggtgc	attaacatcc	cgatggatgc	600
gcccgttggaa aacagctgt	ggatgttgc	ggatgttgc	cgatggatgc	ggaaaaattt	660
cccgaaatggaa ttgcacgttgc	ggcgcgttgc	ctggcaacgc	cgcaaggcg	ctatgttgc	720
ggcattatccc tggatgttgc	tggatgttgc	accctgttgc	cgatggatgc	ggcagggtgt	780
ggctaa					786

SEQ ID NO: 7	moltype = AA	length = 261	
FEATURE	Location/Qualifiers		
REGION	1..261		
source	note = Synthetic Polypeptide		
	1..261		
	mol_type = protein		
	organism = synthetic construct		
SEQUENCE: 7			
MYKDLEGKVV VITGSSTGLG	KAMAIRFATE KAKVVVNYRS	KEEEANSVLE EIKKVGGEAI	60
AVKGDTVTES DVINLVQSSI	KEFGKLDVM	NNAGMENPV	120
FLGSREAIKY PVENDIKGT	INMSSVHEKI	PWPLFVHYAA	180
IRVNNIGPGA INTPINAEEKF	ADPEQRADVE	SMIPMGYIGE	240
GITLFADGGM TQYPSPFQAGR G		PEEIAAVAW LASSEASYVT	261

SEQ ID NO: 8	moltype = DNA	length = 8215			
FEATURE	Location/Qualifiers				
misc_feature	1..8215				
source	note = Synthetic Polynucleotide				
	1..8215				
	mol_type = other DNA				
	organism = synthetic construct				
SEQUENCE: 8					
atccggatat agttccctct	ttcagcaaaa	aaccctcaa	gaccgttta	gaggccccaa	60
gggggttatgc tagtattgc	tcagcggtgg	cagcagccaa	ctcagttcc	tttcgggctt	120

-continued

tgtagcagc	cggatctcg	tgggtgtgt	gggtgtctc	gagccagcc	cacacgttt	180
ttcgatcg	gccttttct	tctactgtc	gcagccataa	gcgagcgctc	gttcactca	240
cttggtaaac	gtcagcatag	ctttcataa	cggttgc	aacggcagg	gccatttggc	300
ttccgtctcc	gaaatata	aagtgcgtc	cttgatcaag	aagtcaatc	aatttcttc	360
cgtctgttc	cattacgtc	tgaacgtat	tttcggctg	atttggcatg	cgagaaaaag	420
cggtatgaa	cgtatgtat	ccttcgtt	gggcgtttt	aagcttctt	tgatcacat	480
agtcttcat	aggtaacgg	cagecga	ataaatgtc	ttctccaat	gactgtc	540
gttcttttag	ctgttgtgc	gcgtgcacaa	agectctaa	eggcgcgc	cctgtcccc	600
gtccgaccat	gataagcggc	gtttcagggt	ctttggca	cgtaaattt	gactgcgtg	660
tggaaataaa	gcacgtata	gtatcttcc	cttgcagctc	ggcaagatag	ttcgcacca	720
ttcccttata	ttctccat	ccgtccac	cttctctg	gacaacgtc	accgtgtatc	780
ttgcttgtt	ttcatcgaca	cgagggtat	aagaatcg	gtaatagc	gggcgtatgc	840
ttggcagaag	ggcgataaaat	tcgctgaaatt	tcatttcaca	cgccggat	tttcaagca	900
gttcaagcat	gtttaaacgt	tttgcacca	cttgcgtt	gtaggcttc	tttcaagca	960
aggcttcag	ctctacttta	tgccggggc	agaccgtt	agcagecatt	gcccgaagct	1020
gcgtgcgt	aacaggatc	tgaatc	cgtattc	aagcttctt	acggatact	1080
ttttagcgag	ttggcaatga	gctaatttt	cttcttgc	ttccagacgg	atttgcgtg	1140
atgcatctag	gcccgaacct	gtcttacac	ggtttactat	tcatttcata	ttgcgaggaa	1200
taaacacat	atgatcttc	tcttgcata	aagcttctt	tggaaatgc	atttcaagat	1260
gtcgcgtct	tcgtgcact	cctggctt	gaatctt	gttgc	acggtcgtt	1320
aaaacgcacc	gtgcatttc	gcaagcggc	tatccgcggc	gtgtc	gacaaatgt	1380
aaagagtaga	tttattatc	tcactgtt	caatgtc	gtttaaagt	gctgtacgt	1440
cactccat	atgttcacgc	catttcat	atgtgc	tttgcgtc	tttgcac	1500
cttcacccgc	gtcagcgat	ttttgc	ctttagcgc	aagcgttca	tcgataaaag	1560
caggactt	ttgatcgt	gtagccgt	tttategc	gcatccaa	acggatgac	1620
gaacgcctt	tacttcatc	gcagacgtt	ggtctaacc	gtcgacaa	atgtgcgt	1680
tatcaggogg	atgacgtt	taagacgc	ttacaattaa	taacgtc	tcgcgcgg	1740
gatttccggc	gtgtcata	acgtgtc	cctgcgtgc	aaatctt	ctcattgc	1800
tatctgtta	atcacccgc	gttcttgc	ctgttccat	atttgcac	tatagcacaa	1860
gcagcggcgt	attatgacg	ttttgc	ttttgc	tttttagc	gactggagct	1920
cacgcggcgt	cagcggcgg	ctaegcagg	taegc	caggatc	ttccaaatcg	1980
gttcacccgc	gtgtcgaata	ccccggaaa	ggtcaac	cgccacat	aaccattc	2040
gttgcaggct	gatcaactgt	gcagccagac	acccat	gcgc	aaatcggt	2100
gttgcgcgt	gttgcgcga	tccagat	aatcg	gcgtc	gatattgc	2160
cacgggtac	gttcccccgg	aaacgcgc	gggttgc	agcttca	cgacacccac	2220
ccatctccac	atccctcg	gcgcgc	gcgcgc	agggt	attagacgc	2280
gcacttcatt	cgccgtt	tcaacgc	cttgc	tcgc	cagaaaaacgc	2340
gccccgttct	tgcaatgc	agggtacc	tgctc	accgcgggt	tttgc	2400
acagacat	aaacacca	gcccgtt	ggaccgtt	ttccgggg	gttgcgtc	2460
gaccatcttgc	gttgcgttgc	actgttgc	ttacgc	cgccagg	ttaccacgc	2520
taccctgc	cagtc	gcatacgt	gagatc	cgttcc	agaatgtat	2580
tttgcgttac	gggtgtatc	ttcggacc	agtgtt	cataatc	ttcacacgc	2640
ggatcagaaa	acccaaatc	tcctccgg	caccgt	atgcacccgc	ctacgcac	2700
gcagctcgc	cgccgttgc	ggaacag	caatctc	tgacccgc	gggatgtt	2760
caaccagatc	gtgggtact	ttttgc	cctgtat	atgttgc	ggcgcgcgg	2820
tgaacatgc	acgcacgt	cgacgc	catcatc	cgccggatc	gtgtacataa	2880
ccacatcttgc	gttccaa	tgaaatgt	tatccgg	cagtgg	cccgaaact	2940
tcgtgcac	acccctgg	cctctatc	cggtcaac	cggttctt	agacccgc	3000
cgcacatcgc	ataggtc	actgccc	cggtc	ctcaaccc	tgacccggc	3060
gacgttgc	cgatcc	taaaccgg	acggat	cacgt	ggatc	3120
geggggctgg	cacgggtc	gcccgtt	atccctt	taaagt	aaaattt	3180
tctagagggg	aatttgc	cgctcaca	tccctata	tgagtc	ttatttgc	3240
ggatcagat	ctcgatc	tacgc	qcacgt	cgcc	ggcgcac	3300
gtgcgttgc	ttggcgtt	atcgc	tcacc	gttgc	ggcgcac	3360
tcgggctcat	gagcgtt	ttcggcgt	gtatgt	ggcc	gggggg	3420
tggttgtgc	catcttc	catgc	accat	tttgc	aaaggcc	3480
acctactat	gggtgttgc	ctatgc	agtc	gggc	atcc	3540
gacaccatcg	aatggc	aaccttgc	ggtat	ggcgc	ggaagagat	3600
caattcagg	ttgtaaat	gaaacagg	actgttac	atgtc	gatagc	3660
gtcttcttgc	agaccgtt	ccgcgttgc	aaaggc	gcacgtt	tggtaaaac	3720
cggggaaa	ttggacgc	gttgcgttgc	tttgc	tttgc	tttgc	3780
caactggcg	gaaacatgc	tttgcgtt	gggtgt	cccttgc	ggccctgc	3840
gcccgtcgc	aaatttgc	ggcgat	tcc	tttgc	tttgc	3900
gtgtgtc	ttgtaaat	gagcgcgt	tttgc	tttgc	tttgc	3960
ctcgcgca	cgctcgttgc	gtctt	aaat	tttgc	tttgc	4020
gtctgttgc	atgttgc	actgttgc	tttgc	tttgc	tttgc	4080
ccatcaaca	gttattat	cttccat	gacgttgc	gactgg	ggatc	4140
gtcgcatttgc	gtcacc	aatgcgt	ttagc	tttgc	tttgc	4200
cgtctgttgc	ttgttgcgt	gtcata	aaat	tttgc	tttgc	4260
gaacggaa	gcaactgg	ttccatgt	gggtt	aaat	tttgc	4320
gagggtatcg	ttccactgc	gttgcgtt	gttgc	gttgc	gttgc	4380
cgccat	ccgatcc	gctgcgtt	gggtgc	tttgc	tttgc	4440
gataccga	acagctat	ttatatcc	ccgtt	tttgc	tttgc	4500
ctgctggggc	aaaccagg	ggaccgttgc	tttgc	tttgc	tttgc	4560
ggcaatc	ttgttgcgt	ctcaact	ctcagg	tttgc	tttgc	4620
caaccgcct	ctcccg	gttgcgtat	ccat	tttgc	tttgc	4680

-continued

cgactggaaa	gcgggcagtg	agcgcacacgc	aattaatgtta	agtttagctca	ctcatttaggc	4740
accgggatct	cgaccgatcg	cctcaacccaa	gtcagcttc	tccgggtggc	4800	
gcggggcatg	actatcgctcg	ccgcacttat	gactgtcttc	tttcatatgc	4860	
acagggtcgc	gaagegctct	gggtcatttt	cggcgaggac	cgcttcgct	4920	
gatgatcgcc	ctgtcgcttg	cggttattcg	aatcttgcac	gccctcgctc	4980	
caactggccc	gocacccaaac	gtttccggca	gaagcaggcc	attatcgccg	5040	
ccccacgggtg	cgcatgtcg	tgcctctgtc	gttgaggac	cggttaggt	5100	
ccttactgtt	tagcagaatg	aatcacatg	acgcgcgacg	acgtgaacgc	5160	
caaaacgtct	gcgacctgag	caacaacatg	aatggtcttc	ggtttccgtg	5220	
tctggaaacg	cggaagtcag	cgccttcgca	cattatgtca	tcgcaggatg	5280	
ctgtcgctca	ccctgtggaa	caccaatatac	tgttataatcg	aagcgtgtgc	5340	
agtgtatttt	ctctgttccc	gcccgcattca	tacccgcagg	ttgtttaccc	5400	
cagtaacccg	gcatgttcat	catcagtaac	ccgtatctgt	agcatectt	5460	
cggtatattt	accccccatt	acagaaatcc	cccttacacg	gaggatctca	5520	
ggaaaaaaacc	gcccattaaac	tgggccgtt	tatcagaage	cagacattaa	5580	
gaaaactcaac	gagctgacg	cggtatgaca	ggcagacatc	tgtgaatcgc	5640	
cgctgtatgg	ctttaccgca	gctgcctcg	gctttcggt	gtatgcggg	5700	
acacatcgacg	ctcccccggaga	cggtcacago	ttgtctgtaa	gcccgcggc	5760	
agccccgtatc	ggcgcgtcag	cgggttgtgg	cggtgtcgg	ggcgcgcgca	5820	
acgttagcgat	agccggatgt	atactggctt	aactatcggt	catcagacgc	5880	
agagtgcacc	atatatgcgg	tgtgaaatac	cgcacagatg	cgtaaggaga	5940	
tcagggcgtc	ttccgcgttcc	tcgctcaactg	actcgctcg	ctcggtcggt	6000	
gagccgttac	agctcactca	aagggggtta	tacgggttac	cacagaatca	6060	
caggaaagaa	catgtgagca	aaaggccacg	aaaaggccag	aaaccgtaaa	6120	
tgtgtggcgtt	tttccatagg	ctccggcccc	ctgacgagca	tcacaaaaat	6180	
gtcagagggt	ggggaaacccg	acaggactat	aaagatacca	ggcggttccc	6240	
ccctcgtcg	ctctcggtt	ccgcctcg	cggttacccg	atacctgtcc	6300	
cttcggggaa	cggtggcgtt	tctcatagct	cacgcgttag	gtatctcgt	6360	
tegttcgtc	caagctggc	tgtgtcaeg	aaccccccgt	tcagccgcac	6420	
tatcccgtaa	ctatcgctt	gagtcacacc	cggtaaagaca	cgacttatcg	6480	
cagccactgg	taacacggatt	agcagagcgc	ggtagttagc	cggtgtetaca	6540	
agtgggtggc	taactacggc	taactacgaa	ggacagttat	tgttatttgc	6600	
agccagttac	cttcggaaaa	agagtggta	gtcttgatc	cggtttccgt	6660	
gtagcggtgg	ttttttttgtt	tgcaagcago	agattacgcg	cagaaaaaaa	6720	
aaagatctttt	gatctttttct	acgggggtct	acgctcatgt	gaacgaaaac	6780	
ggatttttgtt	catgaaacaat	aaaactgtct	gcttacataa	acagtaataac	6840	
atgagccata	ttcaacggga	aacgtcttgc	tctaggccgc	gattaaatc	6900	
gctgatttat	atgggtataa	atgggctcg	gataatgtc	ggcaatcagg	6960	
tatcgatgtt	atgggaaggg	cgatgcgcg	gagttgtttc	tgaaacatgg	7020	
gttgccaaatg	atgttacaga	tgatgttgtc	agactaaact	gggtgcggg	7080	
cttccgacca	tcaagcattt	tatcgctact	cctgtatgt	catgttact	7140	
atccccggga	aaacacgattt	ccaggattata	gaagaatatac	ctgattcagg	7200	
gtttagcgcc	ttggcaatgtt	ctgttgcgg	ttccctgttt	taattgtcc	7260	
tttaacacgc	atcgcgatatt	tgctgtcgat	caggcgcaat	cacgaatgaa	7320	
gtttagcgca	gtgatttttgt	tgacggcggt	atggctggc	ctgttgcac	7380	
gaaaatgcata	aacttttgc	atttcacccg	gattcgtcg	tcactcatgg	7440	
cttggataacc	ttatattttca	cgaggggaaa	ttaataggtt	gtttagatgt	7500	
ggaatcgca	ggatccatcca	ggatcttgc	atcttatgg	actgcctcg	7560	
ccttcattac	agaaaacggct	tttttttttt	ttttgttattt	ataatcttgc	7620	
ttgcagtttc	atttgatgt	cgatgagttt	ttctaaagat	taatttcatga	7680	
atttgatgt	atttagaaaa	ataaaacaaat	aggggttccg	cgccacattt	7740	
gccacactgg	atgttacaaacg	ttatattttt	tttttttttt	ggcttttttt	7800	
caagcttattt	ttaaccaat	aggccggaaat	cggttttttt	cctttttttt	7860	
gaccggatata	gggttggatgt	ttgttccagt	tttggaaacaag	agtcacat	7920	
ggacttccaa	gtcaaaaggcc	gaaaacccat	ctatcaggcc	gatggcccac	7980	
atcacccattt	tcaagtttttt	ttggggatcg	tgccgttata	gcaataatc	8040	
aggggggcccc	cgattttagag	tttgcacgggg	aaaggccggc	aacgtggcga	8100	
gaagaaaacg	aaaggaggcgg	gctgttggc	gctggcaagt	gttagcggtc	8160	
aaccaccaca	cccgccgcgc	ttaatgcgc	gttacaggcc	cggtttccatt	8215	

```

SEQ_ID NO: 9          moltype = DNA  length = 6135
FEATURE           Location/Qualifiers
misc_feature      1..6135
note = Synthetic Polynucleotide
source            1..6135
mol_type = other DNA
organism = synthetic construct

```

```

SEQUENCE: 9
atccggatat agttccctct ttcaacaaa aacccctcaa gacccgttta gaggcccaa 60
ggggtttatgc tagttattgc tcagcggtgg cagcagccaa ctcagttcc tttcggttt 120
tgttagcagc cggtatctcg tgggtgtgt ggtgtgtc gactgtggcc gcaagcttt 180
agccacgacc tgcctgaaag ctccgatact gggtcatacc gccatccgca aacagggtaa 240
tgccggtcac atagctcgct tcgctgtttcc ccagccacgc tgccaccgtc gcaatttctt 300
ccgggtcgcc aatataggccc atcggaaatca tgctttccac atccgcacgc tggccggat 360
cgccaaattt ttccgcgttta atcgggggtgt taatcgcacc cggaccaatg ttgttcacac 420
gaatgccttt cggtgcataat tccaggccca gggtttgcgtt catcagtttc ataccgcctt 480

```

-continued

tgcctcgctgc	ataatgcaca	aacagcggcc	acgaaatttt	ttcatgcacg	ctgctcatgt	540
taatcaccgt	gocaaaaataa	tcgttccca	cgaagtattt	aatcgcttca	cggtgcgcca	600
gaaaacgcacc	ggtcagggtt	gtataatca	cttgggttca	atcgctcagg	ctcatttcat	660
gggtgctcac	gggatttcc	ataccgcat	tgtaatcat	cacatccagt	ttgccaattt	720
ctttaatgtc	gtctcgacc	aggtaatca	catcgcttc	cacggtcaca	tcacccatca	780
cegcaatccgc	ttcgccaccc	actttttaa	tttcttccag	aacgctgttc	gttctttctt	840
ctttgtcgcg	atagttaaacc	accactttcg	cttttccgg	cgcaaaacaga	atcgccattt	900
ctttgcccaag	accggctgtg	ctggggtaa	tcaccaccac	tttacccccc	agatctttat	960
acatggatcc	cgaccat	gctgtccacc	agtcatgcta	gccccatggc	tgccgcgcgg	1020
caccaggcgc	ctgtgtgtat	gatgtatgt	atggctgttgc	ccccatggat	atctctctt	1080
taaagttaaa	aaaaattttt	ttagaggggg	aattgttata	cgctcacaat	tcccttatag	1140
tgagtcgtat	taatttcg	ggatcgat	ctcgatcttc	tacggccgac	gcatcggtgc	1200
cggtcatcacc	gggcacacag	gtgggggtgc	tggccctat	atcgccgaca	tcaccatgtt	1260
ggaagatccg	gtctggccact	tcgggtctat	gagcgttgc	ttcggcgttgc	gtatgggtgc	1320
aggccccctg	ggccggggac	ttgggggcgc	catctcccttgc	catgcaccat	tccttgcggc	1380
ggcgggtgtc	aacggctca	actactact	gggtgttcc	ctaatgcagg	agtcgcataa	1440
ggggagagcgt	cgagatcccg	gacaccatcg	aatggcgca	aaccttgcgc	ggtatggcat	1500
gatagegcocc	ggaagagagt	caatttcagg	tggtagatgt	gaaacccatgt	acgttatacg	1560
atgtcgca	gtatcggttgc	gttcttcgttgc	agaccgttgc	ccgcgttgc	aaccaggcc	1620
gccccatgttgc	tcgcggaaacg	cgggaaaaaa	tggaaagggcgc	gatggcggag	ctgaattaca	1680
ttcccaaccgc	cgtggcacaa	caactggcg	gcaaacatgc	gttgcgtatt	ggcgttgc	1740
cctccactct	ggccctgcac	gcccgttgc	aaattgtcgc	ggcgattaaa	tctcgccgc	1800
atcoaactggg	tgccacgtgt	gtgggtgtc	tggtagaaacg	aagccggcgt	gaagectgt	1860
aagccggcgtt	gcacaatctt	ctcgccaa	ggctcgttgc	gtgcgttattt	aactatccgc	1920
tggatgacca	ggatgecatt	gctgtggaa	ctgcctgcac	taatgttccg	gcgttattt	1980
ttgtatgttgc	tgaccagaca	cccaatcaaca	gtattattt	ctccatgaa	gacggtaacgc	2040
gactgggggt	ggagcatctg	gtcgttgc	gttacccagg	aatcgccgttgc	ttagggggcc	2100
cattaatgttgc	tgtctcgccg	ctgtcgctc	tggctggctgc	gcataaaat	ctcaactcgca	2160
atcaaatttca	gcccgtatcg	gaaeccccgg	ggcactgttgc	tgccatgtcc	ggtttcaac	2220
aaaccatgc	aatgtgtaa	gagggcatcg	ttcccaactgc	gtatgtgttgc	gccaacgatc	2280
agatggcgtt	gggcgtatgc	cgccgtatcg	ccgatccgttgc	gtatgtgttgc	ggtggggata	2340
tctcggtatgt	gggatcgac	gataccggaa	acagctatcg	ttatatcccg	ccgttaacca	2400
ccatcaaaaca	ggatatttcgc	ctgtgggg	aaaccagggt	ggaccgttgc	ctgcaactct	2460
ctcaggggcaca	ggccgttgc	ggcaatcago	tgttgcgcgt	ctcaactgttgc	aaaagaaaaa	2520
ccaccctcgcc	gccaatcaatcg	caaaccgc	ctccccgcgc	gttggccgt	tcattaaatgc	2580
agotggcgtc	acagggttcc	cgactggaaa	cgccggcgttgc	atgcgttgc	aataaatgc	2640
agttatgttgc	ccattttaggc	accgggtat	cgaccgtatgc	ccttggagagc	cttcaaccca	2700
gtcagctct	tccgggtggc	ggggggcatg	actatcg	ccgcacttat	gactgttcc	2760
tttatatgtc	aactcgtag	acagggttgc	cgacgcgttgc	gggttcat	ccgcgttgc	2820
cgcttgcgt	ggagcgtatcg	gtatgttgc	ctgtcgcttgc	cggttatttgc	aatcttgcac	2880
ggccctcgctc	aagccctcg	cactgttgc	gcccccaaa	gttccggcga	gaagcaggcc	2940
attatcgccg	gatggcgcc	cccacgggttgc	cgatgtatcg	tgttgcgttgc	gttggaggacc	3000
cggttgcgttgc	ggccgggggttgc	ccttactgttgc	taicggatgt	aatcccgat	acgcgagccg	3060
acgttgcgttgc	actgtgtcg	ccaaaatcgat	cgccgtatcg	caacaatcat	aatgttcttgc	3120
ggtttccgttgc	tttcgtttaa	atgttgcgttgc	cggttgcgttgc	cgccctgcac	cattatgttgc	3180
cggtatgtc	tcgcggatgt	ctgtgttgc	ccctgtggaa	cacccatc	tgtttaatgc	3240
aagcgttgc	atgttgcgttgc	atgttgcgttgc	tttccgttgc	ggccatccca	taccggccgt	3300
tgttttaccc	cacaacgttgc	cgttacccgg	cgatgttcat	cattatgttgc	ccgtatcg	3360
agatcttct	tcgttgcgtt	cggttcat	accccccgt	acagaaatcc	cccttacacg	3420
gaggcatcg	tgaccatcaa	ggaaaaaaacc	ggcccttacaa	tggcccgctt	tatcagaacg	3480
cagacattaa	cgccgttgc	gaaaactcaatcg	gaggttgcgttgc	ccgtatgttgc	ggcagacatc	3540
tgtgtatgtc	ttcgtatcg	cgctgtatgc	cttaccggcgttgc	gttccgttgc	cggttgcgttgc	3600
gtatgtatgtc	aaacccatcg	acatcgatcg	ctcccgagaa	cggttgcac	ttgttgcgttgc	3660
ggggatgtcc	ggggcagaca	agcccgatcg	ggccgttgc	cggttgcgttgc	cggttgcgttgc	3720
ggccgcagcc	tgaccatcgat	acgttgcgttgc	atgttgcgttgc	aatatgttgc	acgttgcgttgc	3780
catcagatcg	gattgtacttgc	agatgttgc	atataatgttgc	tgttgcgttgc	cgccatcgat	3840
cgttgcgttgc	aaataccatcg	tcaggcgatcg	ttccgttgc	tcgttgcgttgc	actcgatcg	3900
ctcgatgttgc	gggtgttgc	gagcggtatcg	agtcgtatcg	aaggcggtaa	tacgttgcgtt	3960
cacagatca	ggggatatacg	caggaaagaa	catgtgtatcg	aaaggccatcg	aaaaggccatcg	4020
gaacccatcg	aaaggccatcg	tgctgggttgc	tttccatgg	ctccggcccc	ctgttgcgttgc	4080
tcacaaaaat	cgacgtatcg	tcgtatcgat	cggttgcgttgc	ccgttgcgttgc	cgccatcgat	4140
gggttccgttgc	ccttgcgttgc	cccttgcgttgc	cttccgttgc	ccgttgcgttgc	cggttgcgttgc	4200
ataccgttgc	ggccatccca	tttccgttgc	tttccgttgc	ccgttgcgttgc	cggttgcgttgc	4260
gtatgtatgtc	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4320
tcagccgcac	cgcttgcgttgc	atataatgttgc	ctatgttgc	gatgttgcgttgc	aatcccgat	4380
cgacttacatcg	ccacttgcgttgc	cagccactgttgc	taacccatcg	agcgttgcgttgc	gggttgcgttgc	4440
cggttgcgttgc	gaggatgttgc	atgttgcgttgc	taactacatcg	tttccgttgc	tttccgttgc	4500
tgttgcgttgc	gtctgtatcg	agccgttgcgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4560
cggttgcgttgc	ggggatatacg	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4620
cagaaaaaaa	ggatcttcaatcg	aaatcccgat	tttccgttgc	tttccgttgc	tttccgttgc	4680
gaacccatcg	ttacgttgcgttgc	ggatgttgcgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4740
acagatcaatcg	aaagggttgcgttgc	atgttgcgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4800
gattaaatcc	caacatcgat	gtctgtatcg	tttccgttgc	tttccgttgc	tttccgttgc	4860
ggcaatcgatcg	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4920
tgaacatcgatcg	caaaggatgttgc	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	4980
gggttgcgttgc	atttatgttgc	tttccgttgc	tttccgttgc	tttccgttgc	tttccgttgc	5040

-continued

catgggttact caccactgcg atccccggga aaacagcatt ccaggatata gaagaatatac 5100
ctgatttcagg tgaaaatatt gttgtatgcgc tggcagtgtt cctgcggccgg ttgcattcga 5160
ttcctgttgg taattgtctt ttaaacacgc atcgcgtatt tcgttgcgtt caggcgcgaat 5220
cacaatgaa taacgggtt gttgtatgcga tgatgtttaa tgacgagcgt aatggctggc 5280
ctgttgaaaca agtctggaaa gaaatgcata aacttttgcg attcttccacg gattcgtcg 5340
tcactcatgg tgatttctca cttgtataacc ttatTTTGA cgaggggaaa ttaataggtt 5400
gtattgtatgt tggcacgcgt ggaatcgcag accgatatacc ggatcttgcg atccatgttga 5460
actgcgttgc tgagtttttcc ctttcattac agaaaacggct tttttaaaaa tatgttattt 5520
ataatcttgcg tataatataa ttgcaggttt atttgtatgt ctgcgtatgtt ttctaaatgtt 5580
taattcatgtt gcccgtatcat atttgcgtt atttgtatgtt ataaacaaat agggttccg 5640
cgcacatttc cccgaaaatgt gccacactgaa attgttataacg ttaatatttt gttaaaaattc 5700
ggcttaaattt ttgttaaat cagtcattt ttaaaccat aggccggaaaat cggccaaaatc 5760
cctttataatcaa aaaaagata gaccgcgatc gggttgcgtt tggttccagt ttggaaacaatg 5820
atggccactat taaaagcaatc ggactccaaatc gtcaaaaggc gaaaacccgtt ctatccgggc 5880
gatggcccaatc tacgtgttttcc acatccctaa tcaagttttt tggttgcgtt gtgcgtt 5940
gcactaaatc ggaacccctaa agggagcccc cgatttagag cttgcacgggg aaaggccggcg 6000
aacgtggccg gaaaggaaagg gaagaaagcg aaaggagccg ggcgtatggc gctggcaagt 6060
tgatcggtca cgcgtcgctt aaccaccaca cccggccgcgc ttaatgcgcg cgtacaggcc 6120
gcgttccattt cggca 6135

```
SEQ ID NO: 10          moltype = DNA  length = 9371
FEATURE                  Location/Qualifiers
misc_feature             1..9371
note = Synthetic Polynucleotide
source                   1..9371
mol_type = other DNA
organism = synthetic construct
```

SEQUENCE: 10
 ggggatattgt gagcggataa caattccccct ctagaaataa ttttggtttaa cttaagaag 60
 gagatatacc atgggcatga ccgtggccag cccgcgtggct gatccggaca tcgtggccaga 120
 tccgtacccg gtttacccgg atctggccca acgtcgcccg tgcaactggg ttgacgtct 180
 gaacgcctgg gcagtgtcga octatgcaga ttgcggggcg ggtctgaagg acccgcttt 240
 gaccgcggat agaggtaacctt aggtgtctgc aegcaagttt ccgggtcago cactggcc 300
 ggataacatc ttccacccgg ggaccaagaat ttgtgggtatg tacacccgatc cgecgctgca 360
 ttagtcttgc cgtgcggccg tgccgtccgg tttcacccgc gggttcacc aacattatga 420
 tcagggtctgg caaaaagtag cccacgatct ggttgcagc atccccggg gtgcacccga 480
 gattgtatgc gttccagcac tggcgccggg gctgcgggtg cgtagcggg tgcatgcatt 540
 eggtgttcgg gggaaaggat ttgggtttct gatccggctg gtgcacccga ttatggactt 600
 ccactctgggt cggaggatc agccgggttcc ccaagagatc attctggaga aactgaccga 660
 tctgcacacg tatgcgtccg agctgttgc ggttatgcgt gtaaagggtcc tgccgatcc 720
 cgttaattgcg agactggctg cggcgcaaga tggctgcacc gaaaccacccc cggAACAGAC 780
 ggttcacccaa ctggcggttgg ttgttcatgc ttgttgcacc ccaacccccc cgggttagcc 840
 gagcggcggtt accctggccat ttgcggaaat cccggctcag tgggggcggtt ttctggccga 900
 tcaaggcggtc gttgataaca ccgcgaatgt agtgtcgctg taacacggct ctaatcagg 960
 cacctggcgc gtcgcggca aggatgttgc gatgggggtt gttcgatattt aagctggtca 1020
 aaccctggcc ctgttccctgg gtggccgtaa ccgtgtatgc aatatgttgc aegcccccga 1080
 cgatattgtat ctggatgcgc cgaacacggc aagacacctg agcttcgggtc aggggttgc 1140
 tgcgtgtctg gtcgcacatgt tgatcgatc gcaactgttgc ttgttctatg ttggcggtt 1200
 gaaccgtttt cccgggttattt gcacccgggg tgaaccgatt tggaaatggaga acctggagg 1260
 tcgtatccggc cgtagcttcg cgtgtggccct gctgtggactc cagtttcgtca aaaaatgtc 1320
 caaaaggcca gaaaacgcgc ataaatgcgc tgcgtgttgc ctatacggtt caaatatggg 1380
 aacatgttgc ggaacggccgc gtgttgcattt agatattgcg atagaccaag gatttgacc 1440
 gcaaggcgccg acgcttgattt cacacgcggg aaatctccg cgcgaaggag ctgttattat 1500
 tgtaacccggc tcttataacg gtcatccccc tgatataccgc aagcaattttc tegatgggtt 1560
 agaccaaggcg tctgtgtatgg aatggaaatgg cgttgcgtac tccgtatattt gatccggcga 1620
 taaaatctggc gtcataactgtt atcaaaaatgg cgttgcgttcc ategatggaaa cgttgcggcc 1680
 taaaggggca gaaaacatcg ctgaccgggg tgaaggatggat gcaaggcgcg actttgttgc 1740
 cacatatggaa gaatggcggtt aacatgttgc gatgtacgcgat gcaaggctact taaactcgat 1800
 cattggaaaatc agtggaaatgg ataaatcttc tctttactt caatgttgc acacgcggcc 1860
 ggtatgtccg ctggcaaaaatgg tgccacgggtt gtttccaaatgg aacgtcgtag caacggaaa 1920
 acttcaacag ccaggcgatgt cacgaaggac gcgacatctt gaaatgttgc ttccaaaaga 1980
 agctttttat caagaaggatc atcatttgg tttttttttcc cgcacatcttgc aaggaaatgt 2040
 aaacccgttgc acagcaaggatc tggcccttgc tgcacatcagc caaatccgtc tggcaaggaa 2100
 agaagaaaaaa tttagtcatt tgccacttcgaaaatggatc tccgttgcggat agtttcgtca 2160
 atacatgtggat cttcaagatc ctgttacccggc caccgttgc cgcgcacatgg ctgttccaaatgg 2220
 ggttctggcccg ccgcataaaatgg tagagtttgc agccgttgcgtt gaaaatggat ccttacaaatgg 2280
 acaaggatgttgc gcaaaaatggatc taacaatgttgc tgaactgttgc gaaaatgttgc cggccgtgtga 2340
 aatggaaaatc acgcgttgc tggcccttgc gccaatcgatc cgcggccgtt attactcgat 2400
 ttcttcatca cctctgtgtcg atggaaaatggatc agcaaggatc acgttgcggatc ttgttccgg 2460
 agaaggcgatggc acggatgtatc gagaatataa aggaatgttgc tgcacatcactt ttggccggat 2520
 gcaagaaggatc gatacgatca ctgttgcgtt tttccacccgg cagtcagaat ttacgtgtcc 2580
 aaaagacccatc gaaacggccgc ttatcatgttgc cggaccggga acaggcgatc cggccgtttag 2640
 aggctttgttgc caggcgccgc aacgttgcataa agaacaaggatc cgttacttgc gagaaggatc 2700
 ttatataactt ggttgcggatc cacttcatgttgc agatctgttgc ttatcaaggatc agttggaaa 2760
 gcccccaaggatc gaaaggatcata tttacgttgc tttccacccgg tttccatgtc caaatcaggcc 2820
 gaaaacatc gttcagcacttgc taatggaaaca agacggccatc aaatttggatc aacttcttgc 2880

-continued

tcaaggagcg	cacttctata	tttgccgaga	cggaagccaa	atggcaccctg	ccgttgaagc	2940
aacgccttatg	aaaagctatg	ctgacgttca	ccaagttagt	gaagcagacg	ctcgctttatg	3000
gctgcagcag	ctagaagaaa	aaggccgata	cgaaaaagac	gtgtggctg	ggtaaaagct	3060
tgccggccgca	taatgtctaa	gtcaaacaga	aagtaatcg	attgtacacg	gccgcataat	3120
cggaaattaat	acgactcact	ataggggaat	tgtgagcggg	taacaattcc	ccatcttagt	3180
atatttagtta	agtataagaa	ggagatatac	atatggaaag	aaaagaatc	ctgttgaacg	3240
aaggccaaagc	attcatcgca	gctgttaccc	aagaactggg	caaaggaaaga	gaagtcaaaag	3300
atcgccctggc	ggacattaa	agtgtatcg	atctgaccgg	ttccatgtt	catacgaaag	3360
aagaactgg	acacggcgca	aaaatggctt	ggcgtaacag	caatcgctc	attgtcgctc	3420
tgttttggaa	ctctctgtat	gtgtatcgat	gtcgacgt	tcgcacgaaa	gaagaagtc	3480
gtgtatcgct	gtttcatcac	attgtaaaccg	ccacgaaatc	tggtaaaatc	cgtccgacca	3540
ttacgatctt	cccgccggaa	ggaaaaggcg	aaaaacagg	tggaaatttg	aaccatcaac	3600
tgatccgcta	tgcaaggctac	gaaagcgc	gccaacgtat	ttgtgtatcg	gctagctgt	3660
ctctgacccg	ggccctgtaa	gaactgggt	ggcggttgta	acgcacggat	tttgacatgc	3720
tgecgctgtat	tttccgtat	aaagggtatg	aacaggccgt	gttgcacatgaa	ctgcccgtt	3780
ctctgtgtat	tgaagtccg	atcaccatc	cgacatcg	agcccttagt	gatctggAAC	3840
tgaatgttgc	ccggcgtccc	attatctcg	atatggaaact	ggaagtggc	ggtattcaact	3900
ataaacgcacg	tccgttcaat	ggctgttca	ttggcaccga	aatcgccgcg	cgcaatctgg	3960
ccgacgaaa	acgttacat	aaactgaaaa	aagtgcata	agtgtattgt	atcgccccg	4020
attacaacac	ggacccgtgg	aaagatcagg	cactgttgc	actgtataaa	gctgttctgc	4080
actcataacaa	aaaacaaggc	gttgcatttgc	tggatcatca	caccgcacgt	tcacagttt	4140
aacgccttgc	agaacaggaa	gaagaaggcg	gtcgtaaaatc	gaccggcgat	ttggacgttgc	4200
tgatcccgcc	gatctcgcc	gcagaaaccc	atatcttcc	coctgtat	gacaatagca	4260
tctgtttaacc	gaattacttc	taccggaca	aaacgtatg	atagctcgag	tctgtttaaag	4320
aaaccgtgtc	tgcaaaat	gaacgcgc	acatggactc	gtctactatgc	gcagatataat	4380
taacctaaggc	tgctgtccacc	gtgtacgtat	aactagcata	accccttgg	gcctctaaac	4440
gggtttag	gggttttttgc	ctgaaaggag	gaactatata	cggttggcg	aatgggacgc	4500
ggccctgttgc	ggccgttataa	ggccggccgg	ttgtgttgtt	acgcgcacgc	tgaccgcgt	4560
acttgcacgc	gcccttagcgc	ccgccttctt	cgcttcttcc	cttccttcc	tcgcacgtt	4620
cgccggccgtt	ccccgtcaag	ctctaaatcg	ggggctccct	ttagggttcc	gattttatgc	4680
tttacggccat	ctcgccatcc	aaaaatgttgc	ttagggtatg	gttgcacgt	gtggccatc	4740
ggccctgtatag	acgggttttc	ggcccttgc	gttggagtcc	acgttcttta	atagtggtact	4800
cttggttccaa	actggaaacaa	cactcaaccc	tatctcggtc	tatttttttgc	atttataagg	4860
gatttttgcg	atttccggct	attgtttaaa	aatatggatgt	atthaacaaa	aatttaacgc	4920
gaatttttaac	aaatattaaat	cggttataat	ttctggccgc	acgatggcat	gagattatca	4980
aaaaggatct	tacccatgtat	cctttttat	taaaaatgaa	gtttaatataatc	aatctaaatc	5040
atatatgtat	aaacttggtc	tgacgttac	caatgtttaa	tcaatgttgc	acccatctca	5100
gcatctgtc	tatctgttgc	atccatagtt	gcctgactcc	ccgtcgctgt	gataactacg	5160
atacggggat	gotttacccat	tggcccttgc	gtgtcaatgc	taccgcggaa	cccaacgtca	5220
ccggcttccat	atccatcgc	ataaaacccat	ccagccggaa	ggggccggcg	cagaatgtgt	5280
cctgtcaactt	tatccgcctc	catccatgt	attaattgtt	ggccggaaatc	tagatgtat	5340
agttcgccat	ttaatagttt	gcatgttgc	gttgcatttgc	ctacaggcat	cgtgtgtca	5400
cgctcgctgt	tttgtatggc	ttcggatcgc	tcgggttcc	aacgtatca	gcgqatgtaca	5460
tgatcccccata	tgttgtgc	aaaaggcggtt	agcttcttgc	gttcttgcgt	cggtgttgc	5520
agtaatgttt	ccgcacgttgc	atactatcg	gttattggat	cactgtat	ttctttatgc	5580
gtcatgtccat	ccgtatgtat	cttttctgt	actgtgtatg	actcaatccaa	gtcatttgc	5640
gaatatgtat	tgccggccgg	gaggttgc	tgccggccgt	caatacggga	taataccgcg	5700
ccacatcgca	gaaatccat	agtgttgc	attggaaaatc	gttcttgcgg	gcgaaaactc	5760
tcaaggatct	taccgtgtt	gagatccat	tcgatgttac	ccactctgtc	acccaaatcga	5820
tcttcagcat	cttttacttt	caccagcgtt	tctgggtat	caaaaacagg	aaggcaaaat	5880
ggccgcacaaa	agggataat	ggcgcacacgg	aaatgttgc	taactatataat	cttcttttt	5940
caatcatcgat	tgaagatc	atcagggtat	ttgtctatgc	agcggatata	tatttgc	6000
tatttagaaaa	ataaaacaaat	taggtatgtat	ccaaaatccc	ttaaatgtat	ttttctgtcc	6060
actgagcg	agaccccgta	gaaaatgtat	aggatcttgc	tttgcatttgc	ttttttctgc	6120
gcgtatctg	ctgtgttgc	acaaaaaaaat	caccgttacc	agccgttgc	ttgttgc	6180
atcaagatgt	accaactat	tttccggat	taacttgcgt	cagcagatc	ccatccat	6240
atactgttct	tctatgtat	ccgtatgtat	ggccacactt	caagaatct	gtacccatgc	6300
ctacataactt	cgctctgtat	atccgttac	cagtgttgc	tgccgttgc	gataatgtat	6360
gttcttgcgg	gttgcacttgc	agacatgtat	tacccgtata	ggcgacacgg	tcgggttgc	6420
ccgggggttgc	gtgcacatcg	cccacgttgc	agcgaacgc	ctacacgaa	cttgcgtat	6480
tacagcgttgc	gtatgtat	ggccacacgg	ttcccgaa	gagaaaggcg	gacaggatc	6540
cggttaaggcg	cagggtcgga	acaggagatc	gcacgaggga	gttccagg	ggaaacgcct	6600
ggtatcttta	tagtctgtc	gggtttcgcc	acccatgtat	tgacgttgc	ttttttgtat	6660
gttgcgttgc	ggggccggcgc	ctatgtat	acccatgtat	ggcgacacgg	tcgggttgc	6720
ttggcttttt	ttggccctt	gttcacatgt	tctttctgtc	gttccatctt	gattctgttgc	6780
ataaccgtat	taccgttgc	gatgtatgt	ataccgttgc	ccgcacatgt	acgaccgtat	6840
gcagcgatgc	agtgtatgtat	ggccatgtat	ggccatgtat	ggttgcattt	ctccatgtat	6900
atctgttgcgg	tatttacac	cgcatatata	gtgtacttgc	agtatataat	gtctgtatgc	6960
cgcatatgtat	acccatgtat	cactccgtat	tcgtatgtat	acttgcgtat	ggcttgc	7020
cgacacccgc	caacacccgc	tgacccgttgc	tgacccgttgc	gtctgtatgc	ggccatccgt	7080
tacagacatcg	ctgtgtatgc	ctccggat	tgatgtatgc	agagggtttc	accgtatcat	7140
ccgaaacgcgc	cgaggcagat	ggccgtatgtat	tcatgtatgc	ggtgcgttgc	taatgtatgc	7200
atgtctgtat	gttcatccgc	gttccatgtat	tttgcatttgc	ccagaatgtat	taatgtatgc	7260
cttctgtat	agccggccat	gtttaagggg	tttttttgc	tttttgc	tgatgcctcc	7320
gtgtatgtat	ggggccat	gtttaagggg	tttttgc	tttttgc	tgatgcctcc	7380
acgatcatcg	ttactgtat	tgaatcatgtat	ccggatgtat	aaatgtatgc	gggttgc	7440

-continued

ttggccgttat	ggatgcggcg	ggaccagaga	aaaatcaactc	agggtcaatg	ccagcgcttc	7500
gttaatacag	atgtagggt	tccacaggg	agccagcagc	atccctgcgt	gcagatccgg	7560
aacataatcg	tgcaggggc	tgacttccgc	gttccagac	tttacaaac	acggaaacccg	7620
aaagaccattc	atgttgttc	tcaggctcga	gacgtttgc	agcagcgtc	gttccacgtt	7680
cgctcgctga	tcgggtatcc	attctgtcaa	ccagtaaggc	aaccccgcca	gcctagccgg	7740
gtcctaaca	acaggagcac	gatcatgtca	gtcatggccc	gegccccacccg	gaaggagctg	7800
actgggttgc	aggctctcaa	gggcattcggt	cgagatcccg	gtgcactaatg	agtgcgactt	7860
cttacattaa	ttgcgttgc	ctacatggcc	gttcccaatgt	cgggaaacct	gtctgcgcag	7920
ctgcattaaat	gaatcgccca	acgcgcgggg	agaggccgtt	tcgtatattgg	gcccagggtt	7980
gggttttctt	ttcaccagg	agacggccaa	cagctgtatttgc	cccttcacccg	cctggccctg	8040
agagagttgc	agcaacgcgt	ccacgcgttgc	ttgcggccacgg	aggggaaaaat	cctgttgcgt	8100
gggtggtaac	ggcgggatca	aacatgtatgc	gttcttcgttgc	tcgtcgatcc	ccactatccgg	8160
gtatgtccgc	ccaaacgcgc	gccccggactc	ggtatggcc	cgatctggcc	ccagcgccat	8220
ctgatcggtt	gcaaccagg	tcgcgttgcgg	aacgtatggcc	tcatttcgc	tttgcatgtt	8280
ttgtgtgaaaa	ccggacatgg	cattccatgc	gccttcctgttgc	tcggctatgc	gctgttgcgtt	8340
attggcgatgt	agatatttat	gcccacgcgc	cgacgcgcaga	cgccgcggaga	caagaatctaa	8400
tggggccgcgt	aacaggccg	tttgcgttgc	acccaaatgcgt	accagatgttgc	ccacgcggcc	8460
tcgcgttccgc	tcttcgttgc	agaaaataat	actgttgcgttgc	gggtgtctgttgc	caagagacatc	8520
aagaataataa	ggccggacat	tagtgcggc	agcttcacca	gcaatggccat	cctgttgcgt	8580
cagcggatag	ttatgtatca	gccccactgc	gcgttgcgcgc	aaagatgttgc	gcacccggcc	8640
tttacacgttgc	tcgcggccgc	tttcgttctac	catgcacacc	accacgcgttgc	caccagggttgc	8700
atccggcgca	gatttaatcg	ccgcgcacaaat	ttgcgcacggc	gcgtgcagggg	ccagactgg	8760
gggtggcaacgc	ccatcaggca	acgcgttttgc	gccccccatgt	tgttgtgc	ccgggttgcgc	8820
aatgttatttc	agetcggcgc	tcggccgttgc	cacttttcc	cgcggtttcg	cagaaacgtgt	8880
gttgcgttgc	ttcacccacgc	ggggaaacccgt	ctgataagag	acacccgcatt	acttcggcgc	8940
atcgatataac	gttactgttgc	tcacatttcc	caccctgtat	tgacttcttt	ccggggcgttgc	9000
tcatgcata	ccgcggaaagg	ttttgcgcgc	ttcgatgttgc	tccgggtatcc	cgacgcgttgc	9060
cctttatgcga	cttcctgcgt	aggaaaggcgc	ccagatgtatgc	gttggggccgc	tttgacccgg	9120
ccggccggaa	gaatgttgc	tgcaaggaga	ttggccggccaa	cgatcccccgc	gcacccggcc	9180
ctggccacat	accacacgcgc	aaacaacgcgc	tcatgagcc	gaatgttgcgc	gcccgcatttgc	9240
ccccatcggtt	gtatgttgcgc	atataaggcgc	cagcaacccgc	acccgttgcgc	ccgggtatgc	9300
cgggccacgt	gggttgcggc	tagaggatgc	agatcgatct	cgatcccccgc	aaatataatcg	9360
qactctactat	a					9371

```
SEQ ID NO: 11          moltype = DNA  length = 7214
FEATURE                Location/Qualifiers
misc_feature           1..7214
                        note = Synthetic Polynucleotide
source                 1..7214
                        mol_type = other DNA
                        organism = synthetic construct
```

SEQUENCE: 11 Organism - Synthetic Construct
 ggggattgt gagcggataa caattccctt ctagaaataa ttttgtttaa cttaagaag 60
 gagatatacc atgggcagca gccatcacca tcatcaccc acggcaggatc cgatgtataa 120
 agatctggaa ggttaaagtgg ttggtatttc cggcggcage acggcgttgg cgaaggcaat 180
 ggccatcgatc tttgcgaccc aaaaagcggaa agtgtgggtt aatactcgca gcaaaagaaga 240
 agaagcgaac agcggttctgg aagaattaa aaaaatgggtt ggccaaagcga ttgcgggtgaa 300
 aggtgtatgtt accgtggaaa gcgatgtat taacctgggtt cagagcagca ttaaagaattt 360
 tggccaaatctt gatgtgtatc ttacaatgc ggttatggaa aatccgggttgc gcaggccat 420
 aataggccctg agcgattggaa acaaagtgt tgataccac ctgaccgggtt cgtttctggg 480
 cagccgtgaa gcgatataatc acttcgtggaa aaacggatattt aaaaaggccggc tgatatacat 540
 gaggcaggctg catgaaaaaaa ttccgtggcc gctgtttgtt cattatgcag cgagcaaaagg 600
 cggatgtgaaa ctgtatgcacg aaacccttgc cctggaaat tgcacccggaaat gcattctgtt 660
 gaacaacattt ggtccgggttgc gattaacac ccggatataac gcccggaaaaat ttgcgtatcc 720
 gggacacgcgtt gggatgtggaa aagacgtatc tccgatgggc tatatggcgc aacccggaa 780
 aatttgccgcgtt gtggcaggcgtt ggctggcaag cagcgaagcg agctatgtga cccgcattac 840
 cctgtttgcg gatggcggta tgaccatgtt tccgagctttt caggcagggtc gtggctaaaa 900
 gtttgcggcg gcatataatgtt taatgtggaa agaaaatgtt cgtatgtac acggccgcgtt 960
 aatccggaaat tataacgcctt actatagggg aattgtggac ggataacaat tcccccatttt 1020
 agtataatggaa ttaatgtggaa gaaggatgtt tacatatggaa agaaaatggaa atcctgtggaa 1080
 acgaaaggccaa agcattcatc gcagcgtgtt accaagaactt gggcaaaagaa gaagaagtca 1140
 aagatccgcctt ggcggacattt aaaatgtggaa tccgtatgtac cgggttccat tttccatcaga 1200
 aagaagaactt ggaacacgcgtt gccaaaaatgg ttccggcttgc cagcaatcgcc tgcattttgg 1260
 gtctgttttgc gaaactctgtt aatgtgtatc atcgtcgccgc tccgtccacgc aaaaaggaa 1320
 tccgtatgttgc gctgtttcatc cacattggaa ccggccacggaa caatgttaaa atccgtccga 1380
 ccattacgtt ctcccgccg gaagaaaaaaag gcgaaaaaaca ggttggaaattt tggaaaccatc 1440
 aactgtatccgc tcatgcaggc tacggaaatgg acggcgaacg tattgtgtatc cggctatgtt 1500
 gtttctgttgc cggggctgtt gaaatgttgc gctggcggttgc tgaacgcacg gattttggacc 1560
 tgcgtccgcgtt gattttccgc atggaaatgtt atggaaacgc acggcgttgc gatgtccgcgtt 1620
 gtttctgttgc gatgtggatc cccgtatccaccc atccggacatc cggacccctt atgtatgttgc 1680
 aactgtggaaatgtt gtacggcgcc cccgtatatctt cccgtatgttgc actggaaatgtt gggcggttacc 1740
 actataacgcgtt agctccgttc aatgggttgc acatgggcac cggaaatcgcc gcgccaaatcc 1800
 tggccgacgcaaaaatgttgc gataaaatgttgc aaaaatgttgc atcgtatgttgc gatgtccgcgtt 1860
 cccgtatccaccc cccggacccgtt tggaaatgttgc agggcgttgc ggttgcgttgc aatgttgcgtt 1920
 tgcgtatccatc aaaaaaaaaaaatgttgc tggatgttgc tccacccgc gttccacatc 1980
 tttaaacccgtt cggaaatgttgc gaaatgttgc cggggccgttgc tttgttgc tccacccgc gttccacatc 2040

-continued

ggctgattcc	cccgatctcg	ccggcagcaa	ccatatctt	ccaccgctcg	tatgacaata	2100
gcacatcgaa	accgaatcac	tttaccagg	acaacccgtg	tgaatagctc	gagtctggtt	2160
aagaaaccgc	tgctgaaa	tttgaacgc	agcacatgg	ctcgctact	agcgcagctt	2220
aattaaccta	ggctgtgca	accgtgago	aataactagc	ataaccctt	ggggctctta	2280
aacgggttct	gagggtttt	ttgctgaaag	gaggaactat	atccggatgt	gccaatggga	2340
cggccctgt	acggcgtat	taagcggg	gggtgtgggt	tttacgcgca	gcgtgaccgc	2400
tacacttgcc	agegcctag	cgccccgtc	tttcgctt	ttcccttct	ttctcgccac	2460
gttcgcggc	tttccccgtc	aagctctaa	tcgggggtctc	cctttagggt	tccgatttag	2520
tgcttacgg	ccacgtgacc	ccaaaaaaact	tgatttaggt	gatggttcac	gtatgggcc	2580
atcgccctga	tagacgtttt	tttcgcctt	gacgttggag	tccacgttct	ttaatagtgg	2640
actcttgc	aaaactggaa	caacactaa	ccctatctcg	gtctattttt	ttgattata	2700
agggatttt	ccgatttcgg	cctattgggt	aaaaatggaa	ctgatttaac	aaaaatttaa	2760
cgcgaatttt	aacaaaatat	taacgtttac	aatttctggc	ggcacgtat	catgagatta	2820
taaaaaaggaa	tcttacccat	gatcccttta	aattaaatatt	gaagttttaa	atcaactctaa	2880
agtatataatg	agtaaaatgtt	gtctgacat	taccaatgt	taatcgtga	ggcacctatc	2940
tcagcqatct	gtcttatttcg	ttcatccata	gttgcctgac	ccccgtctgt	qtagatact	3000
acgatacggg	aggggcttacc	atctggcccc	agtgtctgaa	tgatacccg	agacccacgc	3060
tcaccggc	tcagatttac	agcaataaa	caggccaggg	aaaggccga	gcgcagaagt	3120
ggtcctgc	ctttatccgc	ctccatccag	tcttattaa	gttgcgggaa	agcttagagta	3180
agtagttcgc	cgatataatg	tttgcgcaad	gttgcgttca	ttgttacagg	categtgtgt	3240
tcacgctgt	cgtttggat	ggcttcatc	agtcgggtt	ccccacgtc	aaggcagat	3300
acatgatccc	ccatgttgt	aaaaaaagcg	gttagcttct	tcggcttccc	gategttg	3360
agaagtaatgt	tggcccgagt	tttacactc	atgggttatgg	cagcactgca	taatttcttt	3420
actgtcatgc	cattccgtaa	atgtttttt	gtgacttgg	agactcaac	caagtccattc	3480
tgagaatagt	gtatggggcg	accgagttgc	tcttgcggg	cgtaataacg	ggataatacc	3540
gcccacata	gcagaactt	aaaagtgtc	atcatggaa	aacgttctc	ggggcgaaaa	3600
cttcgaagga	totttacccgt	gttgcgat	agttcgatgt	aacccactcg	tgcaacccaa	3660
tgatcttc	catctttac	tttccacccg	gttctgggt	gagaaaaaac	aggaaggcaa	3720
aatgcgc	aaaaggaaat	aagggcaca	cggaatgtt	gaataactcat	actttctt	3780
tttcaatcat	gatttgc	tttacccat	tttgcggat	atgagccat	acatatttga	3840
atgtatttag	aaaataaaac	aatatgttgc	tgacccaaat	cccttaacgt	gagttttcg	3900
tccactgac	gtcagacccc	tgaaaaaaa	tcaaggatc	tttttgcgtt	ccctttttc	3960
tgogcgtat	ctgtgtctt	caaacaaaaa	aaccacccgt	accagggtt	gttgcgtt	4020
cggatcaaga	gttaccaact	cttttccga	aggttaactgg	cttcagcaga	gcgcagatac	4080
caaaatctgt	ccttctatgt	tagccgtat	tagccacca	cttcaagaa	actgtgttgc	4140
cgcctacata	cctcgctc	ttatccat	taccatggc	tgctgcgtt	ggcgataat	4200
cgtgtcttac	cggttggac	tcaagacat	agttacccg	taaggccag	cggtcggtt	4260
gaacgggggg	ttcgtgcaca	cagcccgat	tggagcga	gacccatacc	gaactgagat	4320
acctacacg	tgagatgtat	gaaagcgc	cgcttccca	agggagaag	gcggacagg	4380
atccggat	cgccgggtc	ggaacaggag	agcgcac	ggagcttca	gggggaaacg	4440
cctggatct	ttatagttct	gtccgggtt	gcacacttgc	acttgcgtt	cgatttttt	4500
gatgtctgt	aggggggccg	agcctatgg	aaaacgc	caacgcgg	tttttacgg	4560
tccgtgc	tttgcgttcc	tttgcgttcc	tgctgttatcc	cttgatttc	4620	
tggataacc	tattaccgc	tttgcgttcc	tgataccgc	tcggcgc	cgatgttgc	4680
agcgcagoga	gtcagtgc	gagaaaggcg	aaagacgc	gtatgcgtt	tttccctt	4740
cgcacatctgt	cggttattca	caccgcata	atggtgcact	ctcagtacaa	tctgcgttgc	4800
tgcgcatag	ttaagcgat	ataactc	ctatcgctc	gtgacttgg	catggctgc	4860
ccccgacacc	cgccaaacacc	cgtgtacgc	ccctgacggg	tttgcgttgc	ccccgcattc	4920
gettacagac	aagctgtgc	cgttccggg	agtcgtat	gtcagagg	tttccgttca	4980
tcaccgaaac	gcgcgaggca	gtcgggtaa	agtcatca	ctgggtcg	aagcgattca	5040
cagatgttgc	ctgttccatc	cgcgtcc	tcgttgcgtt	tcccaagaa	cgtaatgtc	5100
tggcttgc	taaaggccgc	catgttgc	tttgcgttgc	tttgcgttgc	cactgtatgc	5160
tccgtgttgc	ggggatttct	tttgcgttgc	gtatgtatc	cgatgaaacg	agagaggat	5220
ctcacgatac	gggttactga	tgatgtatc	gcccgttac	tttgcgttgc	tttgcgttgc	5280
caactggccg	tatgtatgc	ggggaccgc	agaaaaatca	ctcagggttca	atgcgcgc	5340
ttcgttgc	cagatgttgc	tttgcgttgc	gggttgcgtt	agcacttgc	gtatgtatgc	5400
cggacataaa	ttgtgcggg	cgtgtactc	cgccgttca	gacttacaa	aacacggaaa	5460
ccgaagacca	ttcatgttgc	tgctcagg	ccatgttgc	tttgcgttgc	tttgcgttgc	5520
gttcgttgc	gtatgttgc	tttgcgttgc	taaccgttac	ggcaaccccg	ccagccatgc	5580
cgggttgc	acgacaggag	cacgtatcg	ctatgtatc	cccgccgc	ccggcaggag	5640
ctgactgtgt	tgaagggttct	caagggtatc	ggtcggat	ccgtgttca	atgtgtatgc	5700
taacttacat	taattgcgtt	tgctgtatc	cccggttcc	agtcggaaa	cctgtgttgc	5760
cagctgcatt	aatgtatcg	ccaaacgc	ggggaggccg	tttgcgttgc	tttgcgttgc	5820
gggtgggtt	tttttccat	gttgcgttgc	caacgttgc	tttgcgttgc	tttgcgttgc	5880
ctgagagatgt	tgcaacgc	ggtccacgc	gggttgcgtt	agcaggccaa	aatctgttt	5940
gtatgtgtt	aacggccgg	tataatgtat	gtatgttgc	gtatgttgc	atcccactac	6000
cgagatgtcc	gcaccaacgc	tgacccgg	ctcggtat	ggtgcgttgc	ccggccagcc	6060
catctgtatcg	ttggcaacca	gtatgtatc	gggaacgtat	cccttattca	gcatttgc	6120
ggtttgcgttgc	aaacccgg	ttggacttca	gttgcgttgc	ccggcgttgc	ccggcgttgc	6180
ttgatttgc	gtgatgtat	ttatgtatc	gtatgtatc	ggcgttgc	ccggcgttgc	6240
taatggcc	gtcaacgc	cgatgttgc	gttgcgttgc	ccggcgttgc	ccggcgttgc	6300
cagtcgtgt	ccgttccat	ggggaaaat	aatactgttgc	tttgcgttgc	tttgcgttgc	6360
atcaagaat	aacggccgg	cattatgtatc	ggcgttgc	ccggcgttgc	ccggcgttgc	6420
atccagccg	tagttaatgtat	tcagccact	gacgcgttgc	ccggcgttgc	ccggcgttgc	6480
cgctttacag	gtttcgacgc	cgcttccgtt	taccatgtatc	accaccacgc	tttgcgttgc	6540
tttgcgttgc	cgatgtatc	aaatgtatc	gttgcgttgc	ccggcgttgc	ccggcgttgc	6600

-continued

ggagggtggca	acgccaatca	gcaacgactg	tttgcggcc	agttgttgtg	ccacgcgg	6660
ggaaatgtaa	ttcagctccg	ccatcgccg	tccacttt	tccgcgg	tcgcaga	6720
gtggcgtggc	tggttaccca	cgcggaa	ggctgtataa	gagacacccg	catactcg	6780
gacatcgat	aacgttactg	gtttcacatt	caccaccc	aattgactt	cttcggcg	6840
ctatcatgcc	ataccgcga	aggtttgcg	ccatcgatg	gtgtccgg	tctcgac	6900
ctcccttatg	cgactctgc	atttagaago	ageccagt	taggttgagg	ccgttgag	6960
ccgcgcgcg	aaggaatgtt	gcatgcaagg	agatggcg	caacagtcc	ccggccac	7020
ggctgtccac	cataccacg	ccgaaaca	cgctcatg	ccgaaatgg	cgagcccg	7080
cttccccatc	ggtgatgtcg	gcatatagg	cgccagca	cgcacctgt	gcccgg	7140
tgcggc	gatgegtccg	gctgtagag	tcgagatcg	tctcgatcc	gctaattaa	7200
tacgactac	tata					7214

SEQ ID NO: 12	moltype = DNA	length = 7959
FEATURE	Location/Qualifiers	
misc_feature	1..7959	note = Synthetic Polynucleotide
source	1..7959	mol_type = other DNA
		organism = synthetic construct

SEQUENCE: 12						
ggggattgt	gagcggataa	caattccct	gtagaaataa	ttttgtttaa	ctttaataag	60
gagatatacc	atgggcat	ccgtgccc	agccgtgcgt	gatccgagca	tcgtgc	120
tcgttacccg	gtttacgcgg	atctggcga	acgtcgcccc	gtgcactgg	ttgagcg	180
gaacgcgttg	ggagtgtcg	cctatcgaga	ttgcgcgg	ggtctaaagg	acccgcgtt	240
gaccgcggat	agaggtaccg	agggtgtcg	agcgaagttt	ccgggtc	caactgcgc	300
ggataaacatc	tttcaccgtt	ggaccaagaa	tggtgttat	tacaccgatc	cgccgcgt	360
tgtgttgc	cgtcgcagcg	tgccgtcagg	tttcacccgc	goggctcacc	aaattatgt	420
tcaggctcttgc	aaaaaaatgt	ccccatgtt	ggttgc	aaacccgg	gtgcacccg	480
gattgtatgt	gttccagcac	tggcgccg	gtgcgcgtt	cgtaggcgg	tgcatgtt	540
cggtgttccg	gaggaatgtt	tgggtttt	gatcccgcgt	gtgaacacga	ttatgactt	600
ccactgttgcgttgc	ccgaaatgttgc	agccgttac	ccaaagatgtt	attctggaga	aactgacccg	660
tctgcacacg	tatgcgtcg	tgctgtcg	gggtatgcgt	ggttgcgttgc	tgccggat	720
cgttaattgc	agactgtgt	cgccgc	tggtctgacc	gaaaccaccc	cgaaacagac	780
ggtccaccaa	ctggcg	tgttcatgt	tctgtttgc	ccaaccaccc	cggttgc	840
gagcgcgggtt	cccccgttgc	tttgc	ccgcgttgc	gttgcgcgtt	ttctgcgc	900
tcaagcgtgc	gttgcataaca	ccgcgttgc	gcaactgttgc	tacaacgcgt	ctaactgtt	960
cacactggcgc	gtcgccgc	aggatgttgc	gttgcgttgc	ttctgttgc	tttgcgttgc	1020
aaccctggcg	ctgttcttgc	gttgcgttgc	ccgtgtatgc	aatatgttgc	agcgcgc	1080
cgttttgcgttgc	ctggcg	cgaaacgcgc	aaagacaccc	agcttcgcgt	agggtgttca	1140
tgcgtgtctgt	gtgcacgt	tgcgtatgt	gtatcgat	tgttttgcgttgc	tttgcgttgc	1200
gaaccgttttgc	ccgggttattc	gcacccgc	tgacccgttgc	tggatgttgc	tttgcgttgc	1260
tgcgtatgttgc	cgatgtgt	cgctgtatgt	cgctgtatgt	tttgcgttgc	tttgcgttgc	1320
aaaaaaatgttgc	gataatgcgttgc	gatgtatgt	ccgtgtatgt	ccatatgttgc	ccatatgttgc	1380
aaacagctgttgc	gaaacgcgc	gttgcgttgc	gttgcgttgc	atgacaaatgttgc	gatgtatgt	1440
gcgcgtgcgc	acgttgcgttgc	cacacgcgc	aaatcttgc	cgcgaaagg	ctgtatgt	1500
tgtatgttgcgttgc	tcttataacgc	gtcatcg	tgataacgc	aaacatgttgc	tcgactgttgc	1560
agaccaacgcgttgc	tctgtgtatgt	aaataaaatgttgc	cggtgtatgt	tttgcgttgc	tttgcgttgc	1620
taaaaatgttgcgttgc	gttgcgttgc	atcaaaaatgttgc	ccgtgtatgt	atcgatgttgc	ccgtgtatgt	1680
taaaggggcgc	gaaaacatgc	ctgacccgc	tgaagcgtat	gcaacgcgc	actttgttgc	1740
cacatatgttgc	aatatgttgc	aaatgttgc	gatgtatgt	gcacgtat	ttaacctgc	1800
cattgttgcgttgc	aatatgttgc	tctttatgt	caatgttgc	acagcgcgc	1860	
ggatatgttgcgttgc	cttgcgttgc	tgcgtatgt	tttgcgttgc	aaacgttgcgt	caagcgttgc	1920
acttcaacacgc	ccaggcgttgc	cacaaacgc	ccgtatgttgc	aaatgttgc	tttgcgttgc	1980
agtttgcgttgc	ccatgttgc	atgttgcgttgc	ccgtgtatgt	tttgcgttgc	tttgcgttgc	2040
aaaccgtgttgc	acacgttgc	tcggccgttgc	tgcgtatgt	ccatatgttgc	tttgcgttgc	2100
atgttgcgttgc	ttatgttgc	tcgcgtatgt	tcgtatgt	aaatgttgc	tttgcgttgc	2160
atacgttgcgttgc	tttgcgtatgt	tcgtatgt	tcgtatgt	tttgcgttgc	tttgcgttgc	2220
ggtctgttgcgttgc	ccgcataatgc	tagatgttgc	agcttgcgttgc	aaatgttgc	tttgcgttgc	2280
acaacgtgttgc	gaaaatgttgc	taaatgttgc	tgaaatgttgc	tttgcgttgc	tttgcgttgc	2340
atgttgcgttgc	acacgttgc	tcggccgttgc	tgcgtatgt	ccatatgttgc	tttgcgttgc	2400
tttgcgtatgttgc	ccatgttgc	tcgtatgt	tcgtatgt	tttgcgttgc	tttgcgttgc	2460
agaaacgttgcgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	2520
gcaagaacgttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	2580
aaaagacccgttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	2640
aggcttgcgttgc	ccatgttgc	aaatgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	2700
tttgcgtatgttgcgttgc	ccatgttgc	tcgtatgt	tcgtatgt	tttgcgttgc	tttgcgttgc	2760
cgcccaaaggcgttgcgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	2820
gaaaacatatacg	gttgcgtatgt	taatgttgc	agcttgcgttgc	aaatgttgc	tttgcgttgc	2880
tcaaggacgttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	2940
aacgttgcgttgc	aaaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3000
gtctgttgcgttgc	ccatgttgc	tcgtatgt	tcgtatgt	tttgcgttgc	tttgcgttgc	3060
tgccgcgttgcgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3120
cgttgcgttgcgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3180
atattgttgcgttgcgttgc	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3240
aagccaaaggcgttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3300
atcgcgttgcgttgc	ggacattaa	aaatgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3360

-continued

aagaactgga	acacggcgca	aaaatggctt	ggcgtaacaq	caatcgctc	attggtcgtc	3420
tgttttggaa	ctctctgat	gtgcgcgatc	gtcgacgt	tcgcacgaaa	gaagaagtcc	3480
gtgatgcgct	gttcatc	attgaacccg	ccacgaacaa	tggtaaaatc	cgtccgacc	3540
ttacgatctt	cccgccggaa	aaaaaaggcg	aaaaacaggt	tgaatttgg	aaccatcaac	3600
tgatccgcta	tgcaggctac	gaaagcga	gccaacgtat	tggtgatccg	gctagctgt	3660
ctctgaccgc	ggccctgtgaa	gaactgggt	ggcggttgta	acgcacggat	tttgac	3720
tgccgctgtat	tttccgcat	aaagggtat	aacagccgat	gtggtatgaa	ctgcgcgtt	3780
ctctggtgat	tgaagtccg	attatctcg	atatgaaact	ggaagtgggc	ggtattcact	3840
tgaatgtt	ggcgctcccg	attatctcg	atatgaaact	ggaagtgggc	ggtattcact	3900
ataacgcgcg	tccgttcaat	ggctgttata	tggcacccaa	aatcgccgcg	cgcaatctgg	3960
ccgacgaaa	acgtttagat	aaactgaaa	aagtccat	agtgttgtt	atcgccggc	4020
attacaacac	ggacccgtgg	aaagatcagg	cactgggtt	actgaataaa	gctgttctgc	4080
actcatacaa	aaaacaaggc	gttgcattt	tggatcatca	caccgcag	tcacatgtt	4140
aacgcttgcg	agaacaggaa	gaagaacggg	gtcgat	gaccggat	tggacgtggc	4200
tgatccgccc	gatctgcgc	gcagaaaccc	atatcttca	cegtcgat	gacaatgc	4260
tcgtgaaacc	gattactt	taccggaca	aaccgtatg	atagctcg	tctgttaaag	4320
aaaccgtgc	tgcgaaattt	gaacgccc	acatggact	gtctactag	gcagettaat	4380
taaacatggc	tgctgcacc	gctgacat	aactagata	accccttggg	gcctcttaac	4440
gggtcttgag	gggtttttt	ctgaaaccc	aggcat	gaagcacacg	gtcacactgc	4500
ttccggtagt	caataaaccg	gtaaaaaccg	aatagatca	agcggat	taacgacc	4560
gcctgaaacc	gacgaccggg	tcgaaattt	tttgcattt	ctgcatttca	tccgttatt	4620
atcaacttatt	caggcgttgc	accaggcgtt	taaggcacc	aataactggc	ttaaaaaaaat	4680
tacgccccgc	ctgcgcact	atcgactt	tgttgatatt	cattaa	tctgcgc	4740
tggaaaggccat	cacagacgc	atgatgaa	tgaatcgcc	gcccgc	caccctgtcg	4800
ccttgcgtat	aatatttgc	catacgaaa	acgggggg	agaagtgtc	catattggc	4860
acgtttaaat	caaaactgtt	gaaactcacc	cagggttgg	ctgagacgaa	aaacatattt	4920
tcaataaacc	cttttaggaa	ataggcagg	tttccacgt	aacacgocac	atcttgcgaa	4980
tatatgttgc	gaaactggcg	gaaatcgct	ttgttattc	tccagagcga	tgaaaacgtt	5040
tcagtttgc	catggaaaac	gggttacaa	gggttacac	tatccat	caccagctca	5100
ccgtctttca	tttgcatac	gaaactccgg	tgagcatttca	tcaggcgggc	aagaatgtga	5160
ataaaggccg	gataaaactt	gtgettattt	ttctttacgg	tctttttttt	ggccgtataa	5220
tccagctgaa	cggtctgg	ataggatcat	tgagcaact	actgaaatgc	ctcaaaatgt	5280
tctttacat	gocatggga	tatacaac	gtgttat	tttccat	5340	
ttagcttct	tagcttgc	aaatctcgat	aactcaaaa	atacgc	ccgg	5400
atttcattat	ggtaaaggat	ggaaatctt	acgtgcggat	caacgttca	ttttcgccaa	5460
aagtggccc	aggggctccc	ggtatcaaca	gggacac	gattttat	ttctgcgaa	5520
tgatcttgc	tcacaggtat	ttatcgccg	caaagtgcgt	cgggtatgc	tgccaactt	5580
ctgatttat	gtatgttgc	gtttttgagg	tgctccat	gtttctgtt	ctatcagct	5640
tcctcttgc	tcagctact	acgggggtgt	gcgttaacggc	aaaagcac	ccggacat	5700
gcgttaggg	agtgtat	ggcttactat	tttgcact	atgggtt	cagtgaatgt	5760
cttcatgtgg	caggagaaaa	aaaggctc	cggtgctca	gcagaat	tgatcag	5820
tatattccgc	ttcctcgctc	actgactc	tacgctcggt	cggtcgact	cgccgagc	5880
aaatggctt	cgaaacggggc	gggat	tggaagatgc	caggaaata	cttaacagg	5940
aagtggagg	ccggccggca	agccgtt	ccataggc	ccccccctg	acaagcat	6000
cgaatctga	cgctcaatc	agtgtgggg	aaacccgaca	ggactataaa	gataccagg	6060
gttccctgt	cggttccct	cgtgcgtt	cgttgc	ccttcgtt	taccgtgt	6120
attccgtgt	tatggccgc	tttgcata	tccacgcgt	actacgtt	ccgggttag	6180
agttcgttcc	aaactgtt	gtatgc	accccgtt	cgtccgacc	gtcgcc	6240
atccgttaac	tatcttgc	atgttca	ggaaagat	gaaaagcac	cactgc	6300
agccactgtt	aattgttta	gaggat	tcttgc	atgcgc	ccgt	6360
ctgaaaggac	aaatgttgc	gactgc	cttcaac	gttac	ccgg	6420
tggtagtca	gagaacat	gaaaaaccc	cgttgc	gggtttt	tttgc	6480
aagagattac	gcccacac	aaacgat	aaagatca	tcttattat	cagataaaat	6540
atttctat	ttcagtgc	tttatctt	caaagtgc	acctgaa	agccccat	6600
gatataatgtt	gtatcttgc	ttgttgc	gccccgc	caccgg	agctgact	6660
gttgaaggct	ctcaaggc	ttgttgc	tccgggt	taatgtat	gtacttac	6720
attaatttgc	tttgcgtc	ttccgc	ccagt	tttgcgt	gccatct	6780
ttaatgtatc	ggccacac	cgggag	cggttgcgt	atttgc	gggg	6840
tttcttcac	cagtgcac	ggcaacac	gattgc	caccgc	ccctg	6900
gttgcacaa	cggttccac	ctgggttgc	ccagcagg	aaaatctt	tttgcgtt	6960
ttaacggccg	gatataat	gatgtt	cgttgc	tttgcgt	ccatct	7020
cgcaccaac	cgccaccc	gactcggt	tggcgc	cat	tgccccc	7080
cgttgcac	cagcatcg	gtgggac	tgcattt	cagcatttgc	atgggtt	7140
aaaaacggca	cattgcac	cattgc	cccg	tatcggt	atttgcgt	7200
gagtggat	ttatgttgc	ccagc	acacc	atgttgc	accgc	7260
cgcctaac	cgcgttgc	ttgttgc	atgcgc	ccgttccac	cccac	7320
taccgttcc	atggggaaa	ataat	atgttgc	ttgttgc	atgttgc	7380
ataacgcgg	aacattatgt	caggc	ccac	tttgcgt	tcatcc	7440
gatagttat	gatcagccca	ctgac	cgccg	gatgttgc	accgc	7500
aggcttcgac	ccgcgttgc	tataccat	acacc	atgttgc	ccgc	7560
cgcgagat	aatcgccgc	acaatttgc	acggcgc	caggcc	ctggagg	7620
caacgc	cagcaac	tggttgc	ccagt	ttgttgc	tgccac	7680
aattcagtc	cgccatcg	tttcc	tttgcgt	tttgcgt	tttgcgt	7740
cgttgcac	cacgcgg	acggcttac	tttcc	tttgcgt	tttgcgt	7800
ataacgttac	ttgtttcaca	ttcaccac	tgaatttgc	cttcc	ccgg	7860
ccatcc	aaagggttttgc	cgccat	tttcc	tttgcgt	tttgcgt	7920

-continued

tgcgactcct gcattaggaa attataacga ctcactata	7959
SEQ ID NO: 13	moltype = DNA length = 5802
FEATURE	Location/Qualifiers
misc_feature	1..5802
	note = Synthetic Polynucleotide
source	1..5802
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 13	
ggggaaatgt gagcgatata caattccct gttagaaataa ttttgtttaa cttaataag 60	
gagatatacc atggcagca gccatcaca tcatacaccac agccaggatc cgatgtataa 120	
agatctggaa gttaaaatgtgg ttgttattac cggcagcage accggcttgg gcaaagaat 180	
ggcgatttgtt ttcggaccc aaaaggcga aagtgggtt aactatccga gcaaagaaga 240	
agaagcgaac acgcgttgg aaaaattaa aaaatgggtt ggcgaagcga ttgcggtaa 300	
agggtatgtg accgttgaaa gcatgttatc taacctgggtt cagagcaga tttaaaggat 360	
tggcaactg gatgtatga ttaacaatgc gggtatggaa aatccggtaa gcagccatga 420	
aatggactcg acgcgttgg acaaaggat tgataccaaat ctgacccgtt cgtttctgg 480	
cagccgttggaa cgtttaaat acttctgttgg aaacgatatt aaacgcaccc tgattaacat 540	
gagcagcgtt catggaaaaa ttccgttggc gctgtttgtt cattatcgat cggcaagg 600	
cggtatgaaa ctgtatggcc aaacccgttgc ccttggatat gcacccaaag gcattcg 660	
gaacaacattt ggtccgggtt cgatataaccc cccgatataa gggaaaaat ttgcggatcc 720	
ggaacacgat gggatgtgg aaagoatgtat tccgatgggg tatattggc aacccggaa 780	
aatttcggcg gtggcagcgtt ggcttggaa cggcgaaggc acgtatgttgc cccgcattac 840	
cctgtttgtt gatgggggtt tgaccatgtt ccggatgtt caggcaggcgtt gtggctaaa 900	
gcttgcggcc gataatgtt taatgtcgaa agaaatgtt cgtattgttac acggcccat 960	
aatcgaaat tatacgactc actataggatg aatttgcgttgc ggataacat tccccatctt 1020	
agttatgttataa ttaatgttataa gaaggagata tacatatgttga agaaaaaagaa atccctgttgg 1080	
acgaagccaa acgttccatc gcacgtgttcc accaagaact gggcaaaaagaa gaagaagtca 1140	
aagatcgctt ggccggatcc aaaatgtttttt tcgtatgttgc cgggttctat gttcatatcg 1200	
agaagaaatgg gaaacacggc gcaaaaaatgg ctggcgatgtt cagcaatcgc tgcattgttgc 1260	
gtctgttttgc gaaatctgttgc atgttgcgtt atcgtcgcgc cgttgcaccc aaagaagaag 1320	
tccgtatgttgc gtcgtttcatc cacatgttgc ccccccacggaa caatgttgc atccgtccgc 1380	
ccattacatgtt cttccggccgc gaagaaaaaag gcggaaaaaaca ggttgaattt tggaccatc 1440	
aactgtatgttgc ctatgcggcc tacggatgttgc acggcgatgttgc ttttgcgttgc 1500	
gctctctgttgc acggccgttgc gaaatgttgc cggccgttgc tgaacgcaccc gattttgc 1560	
tgttgcggccgtt gattttgcgttgc atggatgttgc agtgcacccgc ggttgcgttgc taaactgcgc 1620	
gttctctgttgc gattgttgcgttgc atccggatcc cggatgttgc cgttgcaccc 1680	
aactgtatgttgc tgcgtccgttgc cccgtatatttcc cccatgttgc acggatgttgc ggcgttatttgc 1740	
actatgtatgttgc acgtccgttgc atggatgttgc acggatgttgc ttttgcgttgc 1800	
tggccggccgtt gaaatgttgc acggatgttgc acgtatgttgc ttttgcgttgc 1860	
ccgatttacaa caccggatcc tggaaagatc acggactgttgc ggaactgttgc 1920	
tgcacttataa caaaaaaaaacccggcgttgc ttgttgcgttgc tccacacccgc gtttgcacccgt 1980	
ttaaacgttgc cggatgttgc acggatgttgc ttttgcgttgc 2040	
gggttgcgttgc gccgtatgttgc cccgtatatttgc cccatgttgc acggatgttgc ttttgcgttgc 2100	
gcacgttgcgttgc acggatgttgc ttcttgcgttgc acggatgttgc ttttgcgttgc 2160	
aagaaacccgc tgcgttgcgttgc ttttgcgttgc acggatgttgc ttttgcgttgc 2220	
attatgtatgttgc acggatgttgc acggatgttgc ttttgcgttgc 2280	
aacgggttttgc ggggggttttgc ttgttgcgttgc cccatgttgc acggatgttgc ttttgcgttgc 2340	
tgcttccgttgc atgtatgttgc cccgtatatttgc acggatgttgc ttttgcgttgc 2400	
cctgcgttgc acggatgttgc gggatgttgc ttttgcgttgc 2460	
attatgtatgttgc acggatgttgc ttttgcgttgc 2520	
aattatgtatgttgc acggatgttgc ttttgcgttgc 2580	
acatgttgcgttgc acggatgttgc ttttgcgttgc 2640	
tcgcgttgc tataatatttgc gccatgttgc acggatgttgc ttttgcgttgc 2700	
gcccgttgc acggatgttgc ttttgcgttgc 2760	
tttgcgttgc acggatgttgc ttttgcgttgc 2820	
gaatataatgttgc acggatgttgc ttttgcgttgc 2880	
gtttcgttgc acggatgttgc ttttgcgttgc 2940	
tcacccgttgc tataatatttgc gccatgttgc acggatgttgc ttttgcgttgc 3000	
tgtatgttgc acggatgttgc ttttgcgttgc 3060	
atatccatgttgc acggatgttgc ttttgcgttgc 3120	
tgttcttgcgttgc acggatgttgc ttttgcgttgc 3180	
atttttagttgc acggatgttgc ttttgcgttgc 3240	
ctttagttgc acggatgttgc ttttgcgttgc 3300	
caaaaatgttgc acggatgttgc ttttgcgttgc 3360	
aagtgtatgttgc acggatgttgc ttttgcgttgc 3420	
ttactgtatgttgc acggatgttgc ttttgcgttgc 3480	
ctgtccgttgc acggatgttgc ttttgcgttgc 3540	
tcacccgttgc acggatgttgc ttttgcgttgc 3600	
gtgttgcgttgc acggatgttgc ttttgcgttgc 3660	
ggatataatgttgc acggatgttgc ttttgcgttgc 3720	
cggtttccgttgc acggatgttgc ttttgcgttgc 3780	
ggggaaatgttgc acggatgttgc ttttgcgttgc 3840	
tcacggatgttgc acggatgttgc ttttgcgttgc 3900	
ggcggtttccgttgc acggatgttgc ttttgcgttgc 3960	

-continued

gtcattccgc	tgttatggcc	gctgttgtct	cattccacgc	ctgacactca	gttccggta	4020
ggcagtccgc	tccaaagtcgg	actgtatgca	cgaaacccccc	gttcgtccg	accgtgcgc	4080
cttataccgg	aactatcgtc	tttagtccaa	cccgaaaaga	catgaaaag	caccactggc	4140
agcagccact	ggttaattgtat	tttagagggt	tagtcttga	gtcatgccc	ggtaaggct	4200
aaactgaaag	gacaagtttt	ggtaactgcg	ctcttccaag	ccagttactt	cggttcaag	4260
agtggtagc	tcaaaaaacc	ttcgaaaaac	cgccctgc	ggcggtttt	tcgttttcag	4320
agcaagagat	tacgcgcaga	ccaaaacat	ctcaagaaga	tcatcttatt	aatcagataa	4380
aatatttcta	gatttcagt	caattttat	cttcaaaatgt	agcacctgaa	gtcagcccc	4440
tacgatataa	gtttaattc	tcatgttagt	catgcccgc	gcccacccg	aggagctgac	4500
tgggttgaa	gttcaagg	gcatggctcg	agatccccgt	gcttaatgag	tgagctact	4560
taaaaaaaaa	gctgttgcgt	caactgcgt	ttttccagtcg	ggaaacctgt	cgtgcacgt	4620
gcattatgaa	atcgcccaac	gcgcggggag	aggccgttgc	cgatattggc	gccagggtgg	4680
ttttttttt	caccagttag	acgggcaaca	gctgattgc	cttcacccgc	tgccctgag	4740
agaggttcg	caagcggtc	acgtctgggt	gccccagcag	gcaaaaaatcc	tgtttgatgg	4800
tgggttaatataa	cgggatataa	catgactgt	tttcggatcc	gtcgtatccc	actaccgaga	4860
tgtccgacc	aacgcgcage	ccggacttcg	taatggcgcg	cattgcgc	agcgcacat	4920
gatcgttgc	aaccagcatc	gcagtggaa	cgatgcctc	attcagatt	tgcatggtt	4980
gttggaaaacc	ggacatggc	ctccatgco	cttcccggtt	cgctatggc	tgaatttgat	5040
tgccgatgt	atattatgc	cagecgcc	gacgcagaca	cgccgagaca	gaacttaatg	5100
ggcccgctaa	cagcgcatt	tgctgttgc	ccaaatgcac	cagatgtcc	acgcccacgt	5160
gcgtaccgtc	ttcatggag	aaaataatac	tgttgcgtgg	tgttgcgtca	gagacatcaa	5220
gaaaaaatcgc	cggaacatca	gttcggcag	cttccacacg	aatggcatcc	tggtcatcca	5280
gcggatgtt	aatgtacgc	ccactgcac	gttgcgcgag	aatgtgtc	accgcgcgtt	5340
taacgggttc	gacgcgcgtt	cgtttacca	tcgacacacc	cacgcgttgc	cccagtgtat	5400
cgccgcgaga	ttaatcgcc	gcpacaattt	gegacggcgc	gtgcaggccc	agactggagg	5460
tggcaaccc	aatcagcaac	gactgtttgc	ccggccagtttgc	ttgtgcaccc	cggttgggaa	5520
tgttaatccat	ctccgcacat	gcccgttcc	ctttttccgc	cggttttgc	gaaacgtggc	5580
tggcctgggtt	caccacgcgg	gaaacggctt	gataagagac	acggccat	tctgcacat	5640
cgataaacgt	tactgtttc	acattccaca	ccctgaatttgc	actctcttcc	gggcgcatac	5700
atgccatacc	gcgaaaagggtt	ttgcgcatt	cgatgggtc	cgggatctcg	acgctctccc	5760
ttatgcgact	ctgcattat	gaaattaata	cgactcacta	ta		5802

SEQ ID NO: 14 moltype = AA length = 406
 FEATURE Location/Qualifiers
 REGION 1..406
 note = Synthetic Polypeptide
 source 1..406
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 14
 MTVPSPALDP SIVPDPYPVY ADLAQRRPVH WVERLNAAWV LTYADCAAGL KDPRLTADRG 60
 TEVLAAKFPQ QPLPPDNIFH RWTKNVVMT DPPLHDALRR SVRAGFTRAA HQHYDQLQK 120
 VAHDLVASIC AGATEIDAVP ALAELPVS AVHAFGVPEE DLGFLIPRVN TIMTYHSGPK 180
 DQPVTQEIIK EKLTLHHTYA SELQGMGRK VLPDTVIARL AAAQDGLTET TPEQTVHQLA 240
 LVPIALFAPT TPGLSLSGTL AFARNPROVQE RFLADQACVD NTANEVLRYN ASNQPTWRVA 300
 AKDVEMGVR IEAGQTLALF LGSANRDANM FERPNDFLDL RPNSARHLSF GQGVHACLAA 360
 QLISLQLKWF YVALLNRFPY IRTAGEPIWN ENLEFRSLRS LPLSLR 406

SEQ ID NO: 15 moltype = AA length = 572
 FEATURE Location/Qualifiers
 REGION 1..572
 note = Synthetic Polypeptide
 source 1..572
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 15
 AHNTPLLVLY GSNNMGTAEQT ARDLADIAMS KGFAPQVATL DSHAGNLPRE GAVLIVTASY 60
 NGHPPDNAKQ FVDWLQASA DEVKGVRYSV FGCGDKNWAT TYQKVPAFID ETLAAKGAEN 120
 IADRGEADAS DDFEGTYEEW REHMWSDVAE YFNLDIENSE DNKSTLSSLQF VDSAADMPLA 180
 KMHGAFADAS VASKELQOOG SARSHRLIEI ELPKEASYQE GDHGLGVIPRN YEGIVNRVTA 240
 RFGLDASQQI RLEAEBEKLA HPLAKTVSV EELLQYVELQ DPVTRTOLRA MAAKTVCPPH 300
 KVELEALLEK QAYKEQVLA RLTMLLELEK YPACEMKFSE FIAALLPSIRP RYYSISSSPR 360
 VDEKQASITV SVSGEAWSG YGEYKGIAASN YLAELQEGDT ITCFISTPQS EFTLPKDPE 420
 PLIMVGPBTG VAPFRGFVQA RKQLKEQGQS LGEAHLYFGC RSPHEDYLQ EELENAQSEG 480
 IITLHTAFSR MPNQPKTYVQ HVMEQDGKKL IELLDQGAHF YICGDGSQMA PAVEATLMKS 540
 YADVHQVSEA DARLWLQOLE EKGRYAKDVW AG 572

SEQ ID NO: 16 moltype = AA length = 25
 FEATURE Location/Qualifiers
 REGION 1..25
 note = Synthetic Polypeptide
 source 1..25
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 16
 KIPLGGIPSP STEQSAKKVR KKAEN 25

-continued

```

SEQ ID NO: 17      moltype = DNA  length = 26
FEATURE           Location/Qualifiers
misc_feature      1..26
source            note = Synthetic Polynucleotide
                  1..26
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 17
ataccatggt gaccgtcccc tcgcccg                                     26

SEQ ID NO: 18      moltype = DNA  length = 30
FEATURE           Location/Qualifiers
misc_feature      1..30
source            note = Synthetic Polynucleotide
                  1..30
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 18
atcaagcttc ccagcccaaca cgtcttttgc                                     30

SEQ ID NO: 19      moltype = DNA  length = 39
FEATURE           Location/Qualifiers
misc_feature      1..39
source            note = Synthetic Polynucleotide
                  1..39
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 19
caggatccga tgtataaaga tctggaaggt aaagtggtg                                     39

SEQ ID NO: 20      moltype = DNA  length = 30
FEATURE           Location/Qualifiers
misc_feature      1..30
source            note = Synthetic Polynucleotide
                  1..30
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 20
caaagctttt agccacgacc tgcctgaaag                                     30

SEQ ID NO: 21      moltype = DNA  length = 27
FEATURE           Location/Qualifiers
misc_feature      1..27
source            note = Synthetic Polynucleotide
                  1..27
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 21
actcatatga tggaagaaaa agaaaatc                                     27

SEQ ID NO: 22      moltype = DNA  length = 27
FEATURE           Location/Qualifiers
misc_feature      1..27
source            note = Synthetic Polynucleotide
                  1..27
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 22
actaagcttc tattcatacg gtttgtc                                     27

SEQ ID NO: 23      moltype = DNA  length = 26
FEATURE           Location/Qualifiers
misc_feature      1..26
source            note = Synthetic Polynucleotide
                  1..26
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 23
ctacatatgg tgactttcga agtcgc                                     26

SEQ ID NO: 24      moltype = DNA  length = 28
FEATURE           Location/Qualifiers
misc_feature      1..28
source            note = Synthetic Polynucleotide
                  1..28

```

-continued

```

mol_type = other DNA
organism = synthetic construct
SEQUENCE: 24
ctcaagttc tcatgggggt aaaagttg 28

SEQ ID NO: 25      moltype = DNA length = 30
FEATURE           Location/Qualifiers
misc_feature      1..30
note = Synthetic Polynucleotide
source            1..30
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 25
actccatatgg tgactttcgaa gtcgcctcg 30

SEQ ID NO: 26      moltype = DNA length = 31
FEATURE           Location/Qualifiers
misc_feature      1..31
note = Synthetic Polynucleotide
source            1..31
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 26
actaaggcttc tcatgggggt aaaagttggg g 31

SEQ ID NO: 27      moltype = DNA length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
note = Synthetic Polynucleotide
source            1..70
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 27
acatccttat agccactctg tagtattaaat taaaacttctt taagtttgc attccgggaa 60
tcggtcgacc 70

SEQ ID NO: 28      moltype = DNA length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
note = Synthetic Polynucleotide
source            1..70
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 28
aatatttcaca gggatcactg taattaaat aaatgaagga ttatgtaatg tgtaggctgg 60
agctgcttcg 70

SEQ ID NO: 29      moltype = DNA length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
note = Synthetic Polynucleotide
source            1..70
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 29
tacaaccggg ggaggcattt tgcttcccc gctaacaatg gcgacatatt gtgtaggctg 60
gagctgttcc 70

SEQ ID NO: 30      moltype = DNA length = 67
FEATURE           Location/Qualifiers
misc_feature      1..67
note = Synthetic Polynucleotide
source            1..67
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 30
attcggtgca ccatgttgcata tgcgcacatgt ctatcaggc ctacaaaaca tatgtatc 60
ctccctta 67

SEQ ID NO: 31      moltype = DNA length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
note = Synthetic Polynucleotide
source            1..70
mol_type = other DNA
organism = synthetic construct

```

-continued

```

SEQUENCE: 31
ggcctcccaa atcgaaaaaa ctttttatt gataacaaaa aggcaacact gtgtaggctg 60
gagctgttc 70

SEQ ID NO: 32      moltype = DNA  length = 69
FEATURE
misc_feature       Location/Qualifiers
1..69
note = Synthetic Polynucleotide
source             1..69
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 32
gccagtaata atccagtgcg ggatgattca catcatccgg cacctttca catatgaata 60
tcctcccta 69

SEQ ID NO: 33      moltype = DNA  length = 70
FEATURE
misc_feature       Location/Qualifiers
1..70
note = Synthetic Polynucleotide
source             1..70
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 33
tcaggatctg aacgggcagc tgacggctcg cgtggcttaa gaggttatt gtgtaggctg 60
gagctgttc 70

SEQ ID NO: 34      moltype = DNA  length = 69
FEATURE
misc_feature       Location/Qualifiers
1..69
note = Synthetic Polynucleotide
source             1..69
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 34
caaacctgatg aaaaggtgcc ggatgatgtg aatcatccgg cactggatta catatgaata 60
tcctcccta 69

SEQ ID NO: 35      moltype = DNA  length = 26
FEATURE
misc_feature       Location/Qualifiers
1..26
note = Synthetic Polynucleotide
source             1..26
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 35
ataccatggt gaccgtcccc tcgccc 26

SEQ ID NO: 36      moltype = DNA  length = 30
FEATURE
misc_feature       Location/Qualifiers
1..30
note = Synthetic Polynucleotide
source             1..30
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 36
atcaagcttc ccagccacaca cgttttgc 30

SEQ ID NO: 37      moltype = DNA  length = 39
FEATURE
misc_feature       Location/Qualifiers
1..39
note = Synthetic Polynucleotide
source             1..39
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 37
caggatccga tgtataaaga tctggaaaggtaaaatgggt 39

SEQ ID NO: 38      moltype = DNA  length = 30
FEATURE
misc_feature       Location/Qualifiers
1..30
note = Synthetic Polynucleotide
source             1..30
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 38
caaagctttt agccacgacc tgccctgaaaag 30

```

-continued

```

SEQ ID NO: 39      moltype = DNA  length = 27
FEATURE           Location/Qualifiers
misc_feature      1..27
source            note = Synthetic Polynucleotide
                  1..27
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 39
actcatatga tggaagaaaa agaaaatc                                         27

SEQ ID NO: 40      moltype = DNA  length = 27
FEATURE           Location/Qualifiers
misc_feature      1..27
source            note = Synthetic Polynucleotide
                  1..27
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 40
actaaagcttc tattcatacg gtttgtc                                         27

SEQ ID NO: 41      moltype = DNA  length = 32
FEATURE           Location/Qualifiers
misc_feature      1..32
source            note = Synthetic Polynucleotide
                  1..32
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 41
actggatccg atggaaaact ttaaacatct cc                                         32

SEQ ID NO: 42      moltype = DNA  length = 33
FEATURE           Location/Qualifiers
misc_feature      1..33
source            note = Synthetic Polynucleotide
                  1..33
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 42
actgaattcg aaacttcttt aagttttgcg gtg                                         33

SEQ ID NO: 43      moltype = DNA  length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
source            note = Synthetic Polynucleotide
                  1..70
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 43
tacaaccggg ggaggcattt tgcttcccc gctaacaatg gcgacatatt gtgtaggctg 60
gagctgcttc                                         70

SEQ ID NO: 44      moltype = DNA  length = 67
FEATURE           Location/Qualifiers
misc_feature      1..67
source            note = Synthetic Polynucleotide
                  1..67
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 44
attcggtgca cgatgcctga tgcgccacgt cttatcaggc ctacaaaaca tatgaatatc 60
ctcctta                                         67

SEQ ID NO: 45      moltype = DNA  length = 70
FEATURE           Location/Qualifiers
misc_feature      1..70
source            note = Synthetic Polynucleotide
                  1..70
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 45
ggcctcccaa atcggggggc ctttttatt gataacaaaa aggcaacact gtgtaggctg 60
gagctgcttc                                         70

SEQ ID NO: 46      moltype = DNA  length = 69
FEATURE           Location/Qualifiers

```

-continued

```

misc_feature      1..69
                  note = Synthetic Polynucleotide
source           1..69
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 46
gccagtaata atccagtgcg ggatgattca catcatccgg cacctttca catatgaata 60
tcctcctta                                69

SEQ ID NO: 47      moltype = DNA length = 70
FEATURE          Location/Qualifiers
misc_feature     1..70
                  note = Synthetic Polynucleotide
source           1..70
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 47
tcaggatctg aacgggcagc tgacggctcg cgtggctaa gaggttatt gtgtaggctg 60
gagctgcttc                                70

SEQ ID NO: 48      moltype = DNA length = 69
FEATURE          Location/Qualifiers
misc_feature     1..69
                  note = Synthetic Polynucleotide
source           1..69
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 48
caaacctgatg aaaaggtgcc ggatgatgtg aatcatccgg cactggattt cataatgaata 60
tcctcctta                                69


SEQ ID NO: 49      moltype = DNA length = 59
FEATURE          Location/Qualifiers
misc_feature     1..59
                  note = Synthetic Polynucleotide
source           1..59
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 49
ggatcactgt aattaaaata aatgaaggat tatgtaatgg tgtaggctgg agctgcttc 59

SEQ ID NO: 50      moltype = DNA length = 58
FEATURE          Location/Qualifiers
misc_feature     1..58
                  note = Synthetic Polynucleotide
source           1..58
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 50
gtggctaaca tccttatagc cactctgttag tattaattac atatgaatat cctcctta 58

```


1-39. (canceled)

40. A method for producing a compound of Formula (I) or Formula (IV):



-continued

(IV)



wherein:

X¹ is halogen or C₁₋₆ alkyl;
 each X² and X³ is, independently, hydrogen, halogen, or
 C₁₋₆ alkyl;
 each Y¹, Y², and Y³ is, independently, hydrogen, halogen
 or C₁₋₆ alkyl;
 Y is NO₂;

2-amino-3-(7-bromo-1-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(6-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
2-amino-3-(7-fluoro-2-methyl-4-nitro-1H-indol-3-yl)propanoic acid;
2-amino-3-(5-chloro-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(6-chloro-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(7-chloro-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(5-bromo-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(6-bromo-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(7-bromo-2-methyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(6-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(7-fluoro-1,2-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(5-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(6-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(7-chloro-1,2-dimethyl-4-nitro-1H-indol-3-yl) propanoic acid;
2-amino-3-(5-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
2-amino-3-(6-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid;
2-amino-3-(7-bromo-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid; or
2-amino-3-(5-methoxy-1,2-dimethyl-4-nitro-1H-indol-3-yl)propanoic acid.

50. The method of claim 40, wherein the step of growing the bacterial cell culture comprises introducing one or more

antibiotic into the bacterial cell culture, optionally wherein the one or more antibiotic is selected from ampicillin and kanamycin.

51. The method of claim 40, wherein the step of growing the bacterial cell culture comprises introducing one or more inducer into the bacterial cell culture, optionally wherein the one or more inducer is Isopropyl β -D-1-thiogalactopyranoside (IPTG).

52. The method of claim 40, wherein the step of growing the bacterial cell is performed at a temperature below 37° C.

53. The method of claim 40, wherein the bacterial cell culture is grown for up to 25 hours.

54. The method of claim 40, wherein the step of isolating the one or more compounds of Formula (I) or Formula (IV) comprises lysing the recombinant bacterial cell.

55. The method of claim 54, wherein the step of isolating further comprises performing high-pressure liquid chromatography (HPLC) on the bacterial cell lysate, or performing a liquid extraction method on the bacterial lysate.

56. The method of claim 40, wherein:

(a) the NOS enzyme is a bacterial NOS enzyme, optionally wherein the NOS enzyme is a *Bacillus subtilis* enzyme or wherein the NOS enzyme is encoded by the sequence set forth in SEQ ID NO: 3; and/or

(b) the GDH enzyme is a bacterial GDH enzyme, optionally wherein the bacterial GDH enzyme is a *Bacillus megaterium* GDH enzyme.

57. The method of claim 40, wherein an isolated nucleic acid engineered to express the NOS enzyme and an isolated nucleic acid engineered to express the GDH enzyme are located on the same plasmid.

58. The method of claim 57, wherein the isolated nucleic acid engineered to express the fusion protein is located on a plasmid that does not contain an isolated nucleic acid engineered to express the NOS enzyme or an isolated nucleic acid engineered to express the GDH enzyme.

59. The method of claim 40, wherein the bacterial cell is a Gram-negative bacterial cell, optionally wherein the bacterial cell is an *E. coli* cell.

* * * * *